text
"Trial Id: Breast Cancer Index (BCI) Registry Recruitment Status: Active, not recruiting Trail description: The purpose of the Breast Cancer Index (BCI) Registry study is to conduct a large scale, population-based prospective registry to evaluate long-term clinical outcome, clinical impact, medication adherence and quality of life in hormone receptor positive (HR+) early-stage breast cancer patients receiving BCI testing as part of routine clinical care to inform extended endocrine therapy. Inclusion Criteria: Early stage (I, II or III) female breast cancer patients, who have completed 4-7 years of primary adjuvant endocrine therapy
Patient was diagnosed with invasive breast carcinoma (ductal, lobular, or mixed ductal/lobular).
The primary tumor was hormone receptor positive (HR+), i.e. estrogen receptor-positive and/or progesterone receptor-positive.
The primary tumor was HER2 negative or positive and node-negative or node-positive with 1-3 positive lymph nodes.
Subject has pre-treatment breast tumor tissue [formalin fixed and paraffin embedded (FFPE)] from a previous breast-conserving surgery, mastectomy or core needle biopsy available for testing by the Sponsor. Exclusion Criteria: Patient has distant metastatic disease (M1).
Patient was diagnosed with metaplastic breast cancer, carcinosarcoma, sarcoma, neuroendocrine carcinoma, adenoid cystic carcinoma, or phyllodes tumor. "
"[INST] Provide inclusion criteria for trial id: NCT04875351 [/INST] Early stage (I, II or III) female breast cancer patients, who have completed 4-7 years of primary adjuvant endocrine therapy
Patient was diagnosed with invasive breast carcinoma (ductal, lobular, or mixed ductal/lobular).
The primary tumor was hormone receptor positive (HR+), i.e. estrogen receptor-positive and/or progesterone receptor-positive.
The primary tumor was HER2 negative or positive and node-negative or node-positive with 1-3 positive lymph nodes.
Subject has pre-treatment breast tumor tissue [formalin fixed and paraffin embedded (FFPE)] from a previous breast-conserving surgery, mastectomy or core needle biopsy available for testing by the Sponsor. "
"[INST] Provide exclusion criteria for trial id: NCT04875351 [/INST] Patient has distant metastatic disease (M1).
Patient was diagnosed with metaplastic breast cancer, carcinosarcoma, sarcoma, neuroendocrine carcinoma, adenoid cystic carcinoma, or phyllodes tumor. "
"[INST] Provide description for trial id: NCT04875351 [/INST] The purpose of the Breast Cancer Index (BCI) Registry study is to conduct a large scale, population-based prospective registry to evaluate long-term clinical outcome, clinical impact, medication adherence and quality of life in hormone receptor positive (HR+) early-stage breast cancer patients receiving BCI testing as part of routine clinical care to inform extended endocrine therapy. "
[INST] Provide title for trial id: NCT04875351 [/INST] Breast Cancer Index (BCI) Registry
"[INST] Provide the recruitment status for trial id: NCT04875351 [/INST] Active, not recruiting "
[INST] Provide the medical condition for trial id: NCT04875351 [/INST] Breast Cancer
"Trial Id: Breast Cancer Risk Assessment in Women Aged 40-49 Recruitment Status: Completed Trail description: In a randomized controlled trial, the investigators will test the effect of a novel strategy for breast cancer risk assessment and risk-based management of women in their 40s seen in primary care. The investigators anticipate that this approach will lead to more optimal use of mammography screening and breast cancer prevention interventions in women in their 40s and as a result will improve care of these women. Inclusion Criteria: women
aged 40-49 years
read and speak English
scheduled for a routine visit or physical examination with a non-resident PCP in the next 4-12 weeks at HealthCare Associates (HCA, BIDMC's outpatient primary care practice). Exclusion Criteria: women scheduled for acute care
women who had or will have a mammogram within 6 months of their PCP visit
women with a history of breast cancer or a BRCA mutation
women already receiving screening breast MRIs
women who have been referred to genetic counseling
women who have taken or are taking tamoxifen or aromatase inhibitors for breast cancer prevention
women with a history of an abnormal mammogram in the past two years
women with a history of breast enlargement or reduction. "
"[INST] Provide inclusion criteria for trial id: NCT03180086 [/INST] women
aged 40-49 years
read and speak English
scheduled for a routine visit or physical examination with a non-resident PCP in the next 4-12 weeks at HealthCare Associates (HCA, BIDMC's outpatient primary care practice). "
"[INST] Provide exclusion criteria for trial id: NCT03180086 [/INST] women scheduled for acute care
women who had or will have a mammogram within 6 months of their PCP visit
women with a history of breast cancer or a BRCA mutation
women already receiving screening breast MRIs
women who have been referred to genetic counseling
women who have taken or are taking tamoxifen or aromatase inhibitors for breast cancer prevention
women with a history of an abnormal mammogram in the past two years
women with a history of breast enlargement or reduction. "
"[INST] Provide description for trial id: NCT03180086 [/INST] In a randomized controlled trial, the investigators will test the effect of a novel strategy for breast cancer risk assessment and risk-based management of women in their 40s seen in primary care. The investigators anticipate that this approach will lead to more optimal use of mammography screening and breast cancer prevention interventions in women in their 40s and as a result will improve care of these women. "
[INST] Provide title for trial id: NCT03180086 [/INST] Breast Cancer Risk Assessment in Women Aged 40-49
[INST] Provide the recruitment status for trial id: NCT03180086 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT03180086 [/INST] Breast Cancer
"Trial Id: Diagnosis Value of SEMA4C in Breast Cancer Recruitment Status: Not yet recruiting Trail description: Breast cancer remains the most common cancer in women worldwide. Early diagnosis can greatly improve the prognosis. To date, imaging examination is still the most important diagnostic and grading tool for breast cancer. Semaphorin4C (SEMA4C) has previously been identified as a highly expressed protein by breast cancer-associated lymphatic endothelial cells (LECs). The study is undertaken to evaluate the diagnostic efficiency of SEMA4C. Inclusion Criteria: Receiving no treatment before diagnosis
Establishing Diagnosis according to biopsy or surgery Exclusion Criteria: Patients who are not mentally capable of giving written informed consent
Clinical data missing
Serum samples doesn't qualified
Patients with a diagnosis of other severe acute or chronic medical conditions that may interfere with the interpretation of the study results "
"[INST] Provide inclusion criteria for trial id: NCT03662633 [/INST] Receiving no treatment before diagnosis
Establishing Diagnosis according to biopsy or surgery "
"[INST] Provide exclusion criteria for trial id: NCT03662633 [/INST] Patients who are not mentally capable of giving written informed consent
Clinical data missing
Serum samples doesn't qualified
Patients with a diagnosis of other severe acute or chronic medical conditions that may interfere with the interpretation of the study results "
"[INST] Provide description for trial id: NCT03662633 [/INST] Breast cancer remains the most common cancer in women worldwide. Early diagnosis can greatly improve the prognosis. To date, imaging examination is still the most important diagnostic and grading tool for breast cancer. Semaphorin4C (SEMA4C) has previously been identified as a highly expressed protein by breast cancer-associated lymphatic endothelial cells (LECs). The study is undertaken to evaluate the diagnostic efficiency of SEMA4C. "
[INST] Provide title for trial id: NCT03662633 [/INST] Diagnosis Value of SEMA4C in Breast Cancer
[INST] Provide the recruitment status for trial id: NCT03662633 [/INST] Not yet recruiting
[INST] Provide the medical condition for trial id: NCT03662633 [/INST] Breast Neoplasm Female
"Trial Id: A Multicenter Study of Clinical Epidemiology of Breast Cancer in Shaanxi Province of China Recruitment Status: Unknown status Trail description: The purpose of the study is to study the epidemic features and diagnosis of female breast cancer, especially the diagnosis and treatment of breast cancer.The disease-free survival (DFS) and the total survival time(OS) of the breast cancer patients will also be studied. Inclusion Criteria: Female patients;
The hospitalized patients who are confirmed of the primary breast cancer histologically;
The date of the inpatients are within the month we chosen;
Patients who are within the month we chosen have been received or under receiving the relevant treatment including surgical treatment, chemotherapy and radiotherapy. Exclusion Criteria: Male breast cancer patients;
Patients with breast cancer who are not under the chosen time;
Non hospitalized patients. "
"[INST] Provide inclusion criteria for trial id: NCT02493569 [/INST] Female patients;
The hospitalized patients who are confirmed of the primary breast cancer histologically;
The date of the inpatients are within the month we chosen;
Patients who are within the month we chosen have been received or under receiving the relevant treatment including surgical treatment, chemotherapy and radiotherapy. "
"[INST] Provide exclusion criteria for trial id: NCT02493569 [/INST] Male breast cancer patients;
Patients with breast cancer who are not under the chosen time;
Non hospitalized patients. "
"[INST] Provide description for trial id: NCT02493569 [/INST] The purpose of the study is to study the epidemic features and diagnosis of female breast cancer, especially the diagnosis and treatment of breast cancer.The disease-free survival (DFS) and the total survival time(OS) of the breast cancer patients will also be studied. "
[INST] Provide title for trial id: NCT02493569 [/INST] A Multicenter Study of Clinical Epidemiology of Breast Cancer in Shaanxi Province of China
[INST] Provide the recruitment status for trial id: NCT02493569 [/INST] Unknown status
[INST] Provide the medical condition for trial id: NCT02493569 [/INST] Breast Cancer
"Trial Id: Role of Sorcin and Annexin A3 in Breast Cancer Patients Recruitment Status: Unknown status Trail description: Breast cancer (BC) is the most common female malignancy worldwide and the second leading cause of cancer death in women. One in eight women in the United States will develop the illness in their lifetimes. In Egypt, 37.7% of total cancer cases among women is breast cancer. A locally advanced disease is very common and total mastectomy is the most commonly performed surgery. Screening methods and adjuvant therapy following surgery led to a remarkable decrease in mortality.
Reliable prognostic and predictive markers are needed to guide the selection of the most appropriate adjuvant therapies for individual patients with breast cancer. In fact, a shift from defining the cancer patients who should receive chemotherapy on the basis of their prognostic characteristics to defining the patients who are likely to benefit most from this modality of adjuvant treatment is currently taking place. Understanding the molecular mechanisms underlying the spread of cancer cells to distant organs, therefore, is a prerequisite for the development of novel cancer therapies. Inclusion Criteria: breast cancer patients before surgery who are admitted to the South Egypt Cancer Institute, Surgery Department, Assiut University Exclusion Criteria: • Patients with malignancies elsewhere in the body.
Patients with chronic cardiac diseases.
Getting neoadjuvant chemotherapy.
Renal disease.
Neurodegenerative disease. "
"[INST] Provide inclusion criteria for trial id: NCT03598660 [/INST] breast cancer patients before surgery who are admitted to the South Egypt Cancer Institute, Surgery Department, Assiut University "
"[INST] Provide exclusion criteria for trial id: NCT03598660 [/INST] • Patients with malignancies elsewhere in the body.
Patients with chronic cardiac diseases.
Getting neoadjuvant chemotherapy.
Renal disease.
Neurodegenerative disease. "
"[INST] Provide description for trial id: NCT03598660 [/INST] Breast cancer (BC) is the most common female malignancy worldwide and the second leading cause of cancer death in women. One in eight women in the United States will develop the illness in their lifetimes. In Egypt, 37.7% of total cancer cases among women is breast cancer. A locally advanced disease is very common and total mastectomy is the most commonly performed surgery. Screening methods and adjuvant therapy following surgery led to a remarkable decrease in mortality.
Reliable prognostic and predictive markers are needed to guide the selection of the most appropriate adjuvant therapies for individual patients with breast cancer. In fact, a shift from defining the cancer patients who should receive chemotherapy on the basis of their prognostic characteristics to defining the patients who are likely to benefit most from this modality of adjuvant treatment is currently taking place. Understanding the molecular mechanisms underlying the spread of cancer cells to distant organs, therefore, is a prerequisite for the development of novel cancer therapies. "
[INST] Provide title for trial id: NCT03598660 [/INST] Role of Sorcin and Annexin A3 in Breast Cancer Patients
[INST] Provide the recruitment status for trial id: NCT03598660 [/INST] Unknown status
[INST] Provide the medical condition for trial id: NCT03598660 [/INST] Breast Cancer
"Trial Id: Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases Recruitment Status: Recruiting Trail description: Bone metastases represent a frequent complication of some solid tumours, particularly prostate, breast and lung carcinomas. Bone metastases can cause pain and give rise to the so-called ""Skeletal-related Events"" (SRE) such as pathological fractures and nerve compression. Despite advances in cancer treatment in general, treatment options for bone metastases remain inadequate and generally palliative. It is therefore necessary to identify patients at ""high risk"" of developing metastases at an early stage of neoplastic disease in order to counteract it. Therefore, the identification of changes in the expression of proteins that could be variously involved in the progression of breast cancer is of primary importance since they could act as prognostic factors and therefore address the therapeutic strategy. The aim of the investigators is to clarify the role of de-regulation of post-translational events (such as SUMOylation) in the progression of breast cancer. Inclusion Criteria: Adult women (≥ 18 years) candidates for excisional surgery and bone consolidation due to osteolytic bone metastases from breast cancer.
Female
Ability to understand the experimental study and willingness to sign the written consent Exclusion Criteria: - Retraction of written consent "
"[INST] Provide inclusion criteria for trial id: NCT04167605 [/INST] Adult women (≥ 18 years) candidates for excisional surgery and bone consolidation due to osteolytic bone metastases from breast cancer.
Female
Ability to understand the experimental study and willingness to sign the written consent "
[INST] Provide exclusion criteria for trial id: NCT04167605 [/INST] - Retraction of written consent
"[INST] Provide description for trial id: NCT04167605 [/INST] Bone metastases represent a frequent complication of some solid tumours, particularly prostate, breast and lung carcinomas. Bone metastases can cause pain and give rise to the so-called ""Skeletal-related Events"" (SRE) such as pathological fractures and nerve compression. Despite advances in cancer treatment in general, treatment options for bone metastases remain inadequate and generally palliative. It is therefore necessary to identify patients at ""high risk"" of developing metastases at an early stage of neoplastic disease in order to counteract it. Therefore, the identification of changes in the expression of proteins that could be variously involved in the progression of breast cancer is of primary importance since they could act as prognostic factors and therefore address the therapeutic strategy. The aim of the investigators is to clarify the role of de-regulation of post-translational events (such as SUMOylation) in the progression of breast cancer. "
[INST] Provide title for trial id: NCT04167605 [/INST] Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases
[INST] Provide the recruitment status for trial id: NCT04167605 [/INST] Recruiting
"[INST] Provide the medical condition for trial id: NCT04167605 [/INST] Breast Cancer Metastatic, Bone Metastases "
"Trial Id: Can MicroRNA's Predict Multicentricity in Breast Cancer? Recruitment Status: Completed Trail description: The aim of this study is to determine if microRNA's have role in predicting multicentricity in breast cancer. If a specific microRNA will be found to be related with multicentricity, it will help us to make appropriate decisions on the treatment of patients with multicentric breast cancer. Inclusion Criteria: Having breast cancer
Having no other malignancy
Female patient Exclusion Criteria: Having other malignancy
Under 18 years old
Male patient "
"[INST] Provide inclusion criteria for trial id: NCT04516330 [/INST] Having breast cancer
Having no other malignancy
Female patient "
"[INST] Provide exclusion criteria for trial id: NCT04516330 [/INST] Having other malignancy
Under 18 years old
Male patient "
"[INST] Provide description for trial id: NCT04516330 [/INST] The aim of this study is to determine if microRNA's have role in predicting multicentricity in breast cancer. If a specific microRNA will be found to be related with multicentricity, it will help us to make appropriate decisions on the treatment of patients with multicentric breast cancer. "
[INST] Provide title for trial id: NCT04516330 [/INST] Can MicroRNA's Predict Multicentricity in Breast Cancer?
[INST] Provide the recruitment status for trial id: NCT04516330 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT04516330 [/INST] Multicentric Breast Cancer
"Trial Id: A Study to Identify Breast Cancer (IDBC) Recruitment Status: Unknown status Trail description: Detecting cancer as early as possible is key to achieving positive outcomes in response to diagnosis and treatment. The current project is aimed at validating a novel blood-based breast cancer identification test (Syantra DX Breast Cancer) that has been developed by Syantra Inc. Syantra DX Breast Cancer measures gene expression signatures in whole blood, and has been retrospectively demonstrated in 780 samples. The test uses proprietary algorithms to analyse gene expression characteristics from a novel multi-biomarker panel, and then classify a sample as positive or negative for breast cancer. Based upon test performance in a retrospective environment, a prospective validation study is being proposed.
The primary objective of this study is to validate Syantra DX Breast Cancer methodology and biomarker panel using prospective samples, well categorized by diagnostic imaging scores, pathology outcomes, and subject characteristics. Inclusion Criteria: None Exclusion Criteria: None "
[INST] Provide inclusion criteria for trial id: NCT04495244 [/INST] None
[INST] Provide exclusion criteria for trial id: NCT04495244 [/INST] None
"[INST] Provide description for trial id: NCT04495244 [/INST] Detecting cancer as early as possible is key to achieving positive outcomes in response to diagnosis and treatment. The current project is aimed at validating a novel blood-based breast cancer identification test (Syantra DX Breast Cancer) that has been developed by Syantra Inc. Syantra DX Breast Cancer measures gene expression signatures in whole blood, and has been retrospectively demonstrated in 780 samples. The test uses proprietary algorithms to analyse gene expression characteristics from a novel multi-biomarker panel, and then classify a sample as positive or negative for breast cancer. Based upon test performance in a retrospective environment, a prospective validation study is being proposed.
The primary objective of this study is to validate Syantra DX Breast Cancer methodology and biomarker panel using prospective samples, well categorized by diagnostic imaging scores, pathology outcomes, and subject characteristics. "
[INST] Provide title for trial id: NCT04495244 [/INST] A Study to Identify Breast Cancer (IDBC)
[INST] Provide the recruitment status for trial id: NCT04495244 [/INST] Unknown status
[INST] Provide the medical condition for trial id: NCT04495244 [/INST] Breast Cancer Female
"Trial Id: The Effect of Breast Cancer Prevention Journey Program Recruitment Status: Not yet recruiting Trail description: The aim of this quasi-experimental study is to determine the effect of the ""Breast Cancer Prevention Journey Program"" on health beliefs about breast cancer in women over 40 years of age who have never had a mammogram before. The research aims to answer the following basic questions:
-Do women who participated in the ""Breast Cancer Prevention Journey Program"" have different health beliefs about breast cancer than women who did not participate in the program? The researchers will compare the program with routine care to see if the ""Breast Cancer Prevention Journey Program"" works. The study will be conducted in a quasi-experimental design with a pre-test post-test control group.
Participants in the experimental group will first participate in the ""The fight against breast cancer"" training structured according to the Health Belief Model. One week after the training, the participants in the experimental group will be taken to mammography screening with free shuttles.
Participants in the control group will not receive any additional intervention. This group will only receive routine intervention within the scope of the breast cancer screening program conducted by the Ministry of Health. Inclusion Criteria: Being a woman between the ages of 40-69
Having never had a mammogram before Exclusion Criteria: Being diagnosed with breast cancer
Having had a breast operation "
"[INST] Provide inclusion criteria for trial id: NCT06395896 [/INST] Being a woman between the ages of 40-69
Having never had a mammogram before "
"[INST] Provide exclusion criteria for trial id: NCT06395896 [/INST] Being diagnosed with breast cancer
Having had a breast operation "
"[INST] Provide description for trial id: NCT06395896 [/INST] The aim of this quasi-experimental study is to determine the effect of the ""Breast Cancer Prevention Journey Program"" on health beliefs about breast cancer in women over 40 years of age who have never had a mammogram before. The research aims to answer the following basic questions:
-Do women who participated in the ""Breast Cancer Prevention Journey Program"" have different health beliefs about breast cancer than women who did not participate in the program? The researchers will compare the program with routine care to see if the ""Breast Cancer Prevention Journey Program"" works. The study will be conducted in a quasi-experimental design with a pre-test post-test control group.
Participants in the experimental group will first participate in the ""The fight against breast cancer"" training structured according to the Health Belief Model. One week after the training, the participants in the experimental group will be taken to mammography screening with free shuttles.
Participants in the control group will not receive any additional intervention. This group will only receive routine intervention within the scope of the breast cancer screening program conducted by the Ministry of Health. "
[INST] Provide title for trial id: NCT06395896 [/INST] The Effect of Breast Cancer Prevention Journey Program
[INST] Provide the recruitment status for trial id: NCT06395896 [/INST] Not yet recruiting
[INST] Provide the medical condition for trial id: NCT06395896 [/INST] Breast Cancer Female
"Trial Id: Blood Test for Early Detection of Breast Cancer Using Todos Medical -Breast 1(TM-B1) Assay Recruitment Status: Unknown status Trail description: Blood samples from a total of 200 women in two cohorts will be collected and analyzed by TM-B1 assay, which is based on TBIA (Total Biochemical Infrared Analysis) to confirm the presence of cancer. These two cohorts will yield 75 healthy women with no pathological findings, 75 women diagnosed as having benign breast tumor and 50 women diagnosed as having breast cancer. Inclusion Criteria: Screening Population:
Subject signed the informed consent.
Subject is aged 25 years and older.
Subject is presenting for routine screening or diagnostic XRM and / or breast US.
Breast Cancer Population
Subject signed the informed consent form.
Subject is aged 25 years and older.
Subject was diagnosed with a malignant breast tumor, and has not yet started treatment. Exclusion Criteria: All Subjects:
Subject has been diagnosed with any type of malignancy apart from breast cancer.
Subject has been previously treated for breast cancer.
Subject underwent any surgery within the previous year (apart from benign nevus removal).
Subject was treated for benign tumor within the previous year (e.g. polyps or cysts).
Subject has an active infection or inflammation from any type of infection (bacterial or viral) as determined clinically at screening.
Subject is currently taking medications related directly to, or that can affect, the immune system such as steroids.
Subject has any type of active autoimmune disease such as lupus or rheumatoid arthritis.
Diagnostic drugs (e.g. contrast materials) were injected or given orally to subject within the last 7 days prior to sample collection for TM-B1 analysis.
Subject has been taking any investigational drug which influence her health status within 30 days prior to sample collection for TM-B1 analysis.
Subject is not feeling well at the time of blood collection for TM-B1 analysis due to suspected bacterial or viral infection or subject has symptoms such as high fever, diarrhea, headache, vomiting, dizziness etc.
Subject is pregnant, lactating, or undergoing fertility treatment.
Subject has participated in this study, in another cohort, and the TM-B1 test was performed.
Breast Cancer Population only:
The subject's tumor has been surgically removed before sample collection for TM-B1 analysis. "
"[INST] Provide inclusion criteria for trial id: NCT03343691 [/INST] Screening Population:
Subject signed the informed consent.
Subject is aged 25 years and older.
Subject is presenting for routine screening or diagnostic XRM and / or breast US.
Breast Cancer Population
Subject signed the informed consent form.
Subject is aged 25 years and older.
Subject was diagnosed with a malignant breast tumor, and has not yet started treatment. "
"[INST] Provide exclusion criteria for trial id: NCT03343691 [/INST] All Subjects:
Subject has been diagnosed with any type of malignancy apart from breast cancer.
Subject has been previously treated for breast cancer.
Subject underwent any surgery within the previous year (apart from benign nevus removal).
Subject was treated for benign tumor within the previous year (e.g. polyps or cysts).
Subject has an active infection or inflammation from any type of infection (bacterial or viral) as determined clinically at screening.
Subject is currently taking medications related directly to, or that can affect, the immune system such as steroids.
Subject has any type of active autoimmune disease such as lupus or rheumatoid arthritis.
Diagnostic drugs (e.g. contrast materials) were injected or given orally to subject within the last 7 days prior to sample collection for TM-B1 analysis.
Subject has been taking any investigational drug which influence her health status within 30 days prior to sample collection for TM-B1 analysis.
Subject is not feeling well at the time of blood collection for TM-B1 analysis due to suspected bacterial or viral infection or subject has symptoms such as high fever, diarrhea, headache, vomiting, dizziness etc.
Subject is pregnant, lactating, or undergoing fertility treatment.
Subject has participated in this study, in another cohort, and the TM-B1 test was performed.
Breast Cancer Population only:
The subject's tumor has been surgically removed before sample collection for TM-B1 analysis. "
"[INST] Provide description for trial id: NCT03343691 [/INST] Blood samples from a total of 200 women in two cohorts will be collected and analyzed by TM-B1 assay, which is based on TBIA (Total Biochemical Infrared Analysis) to confirm the presence of cancer. These two cohorts will yield 75 healthy women with no pathological findings, 75 women diagnosed as having benign breast tumor and 50 women diagnosed as having breast cancer. "
[INST] Provide title for trial id: NCT03343691 [/INST] Blood Test for Early Detection of Breast Cancer Using Todos Medical -Breast 1(TM-B1) Assay
[INST] Provide the recruitment status for trial id: NCT03343691 [/INST] Unknown status
[INST] Provide the medical condition for trial id: NCT03343691 [/INST] Breast Cancer
"Trial Id: FH-Risk 2.0: Updating Breast Cancer Risk Estimates Recruitment Status: Completed Trail description: In the UK women with a strong family history of breast cancer are eligible for breast cancer risk estimation via Family History Risk and Prevention Clinics (FHRPCs). Here breast cancer risk is calculated using popular risk prediction models like the Tyrer-Cuzick, CanRisk or Gail models. These models combine breast cancer risk factors to calculate a risk estimate for women. Risk factors include, family history, hormonal and reproductive factors, and risk factors related to health behaviours, for example, smoking, exercise and alcohol intake.
Recently, risk estimation for breast cancer has become more accurate with the inclusion of mammographic density and Single Nucleotide Polymorphisms (SNPs) into popular risk prediction models. The addition of these new risk factors could alter the risk estimates that women in FHRPCs have been provided. How much these new risk factors alter a previously given risk estimate is unknown. It is also unknown how women will react to a revised risk estimate, especially if it changes their previous estimate and their access to preventive management options.
This research aims to explore this gap in the literature. Inclusion Criteria: previously given informed consent to participate in the original FH-Risk study,
have an up to date clear mammogram,
aged between 25 and 60,
have not developed breast cancer and,
have the capacity to consent. Exclusion Criteria: women who have received a diagnosis of breast cancer,
women who have not had a clear mammogram,
women who took part in the original FH-Risk study but did not consent for their data to be used in future research and,
women who lack the capacity to consent. "
"[INST] Provide inclusion criteria for trial id: NCT05082740 [/INST] previously given informed consent to participate in the original FH-Risk study,
have an up to date clear mammogram,
aged between 25 and 60,
have not developed breast cancer and,
have the capacity to consent. "
"[INST] Provide exclusion criteria for trial id: NCT05082740 [/INST] women who have received a diagnosis of breast cancer,
women who have not had a clear mammogram,
women who took part in the original FH-Risk study but did not consent for their data to be used in future research and,
women who lack the capacity to consent. "
"[INST] Provide description for trial id: NCT05082740 [/INST] In the UK women with a strong family history of breast cancer are eligible for breast cancer risk estimation via Family History Risk and Prevention Clinics (FHRPCs). Here breast cancer risk is calculated using popular risk prediction models like the Tyrer-Cuzick, CanRisk or Gail models. These models combine breast cancer risk factors to calculate a risk estimate for women. Risk factors include, family history, hormonal and reproductive factors, and risk factors related to health behaviours, for example, smoking, exercise and alcohol intake.
Recently, risk estimation for breast cancer has become more accurate with the inclusion of mammographic density and Single Nucleotide Polymorphisms (SNPs) into popular risk prediction models. The addition of these new risk factors could alter the risk estimates that women in FHRPCs have been provided. How much these new risk factors alter a previously given risk estimate is unknown. It is also unknown how women will react to a revised risk estimate, especially if it changes their previous estimate and their access to preventive management options.
This research aims to explore this gap in the literature. "
[INST] Provide title for trial id: NCT05082740 [/INST] FH-Risk 2.0: Updating Breast Cancer Risk Estimates
[INST] Provide the recruitment status for trial id: NCT05082740 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT05082740 [/INST] Breast Cancer Risk
"Trial Id: Genetic and Non-Genetic Breast Cancer Risk Prediction Evaluation in Indonesian Samples Recruitment Status: Completed Trail description: Breast cancer is the most common cancer and cause of cancer- related deaths among women, accounting for 1.67 million (25.2%) new cases and 521,907 (14.7%) deaths worldwide. The prevalence and survival rates of breast cancer differ per country. In Indonesia, majority of patients (70.9%) go to the clinic with advanced stages of breast cancer. Five-year survival rate is 51.07%. One of the most important determinants of survival is education level and stage of breast cancer.
Current screening methods include mammography and radiology assessments, both of which have disadvantages specifically in Asian population. Mammography is less useful in Asian population because the population has denser breast, resulting to failure to diagnose cases of breast cancer in this population in 37-70% of cases. Moreover, screening methods provide binary answers, and therefore does not inform risk profile of the patients.
The investigators aim to implement PRS into the breast cancer screening process while observing the differences of genetic and non-genetic risk factor in patients with breast cancer and patients without any medical/family history of breast cancer in Indonesian population. Inclusion Criteria: For case group
Had been diagnosed with primary breast cancer or tested positive for high penetrance genes (e.g. BRCA 1/2)
Menarche age >12 years old
Premenopausal
For control group
Premenopausal
Menarche age >12 years old
Asymptomatic
Consented for the study and follow up Exclusion Criteria: For case group:
First degree family history of breast or ovarian cancer
For control group:
Family history of breast or ovarian cancer
First-degree relationship with the cases "
"[INST] Provide inclusion criteria for trial id: NCT05570266 [/INST] For case group
Had been diagnosed with primary breast cancer or tested positive for high penetrance genes (e.g. BRCA 1/2)
Menarche age >12 years old
Premenopausal
For control group
Premenopausal
Menarche age >12 years old
Asymptomatic
Consented for the study and follow up "
"[INST] Provide exclusion criteria for trial id: NCT05570266 [/INST] For case group:
First degree family history of breast or ovarian cancer
For control group:
Family history of breast or ovarian cancer
First-degree relationship with the cases "
"[INST] Provide description for trial id: NCT05570266 [/INST] Breast cancer is the most common cancer and cause of cancer- related deaths among women, accounting for 1.67 million (25.2%) new cases and 521,907 (14.7%) deaths worldwide. The prevalence and survival rates of breast cancer differ per country. In Indonesia, majority of patients (70.9%) go to the clinic with advanced stages of breast cancer. Five-year survival rate is 51.07%. One of the most important determinants of survival is education level and stage of breast cancer.
Current screening methods include mammography and radiology assessments, both of which have disadvantages specifically in Asian population. Mammography is less useful in Asian population because the population has denser breast, resulting to failure to diagnose cases of breast cancer in this population in 37-70% of cases. Moreover, screening methods provide binary answers, and therefore does not inform risk profile of the patients.
The investigators aim to implement PRS into the breast cancer screening process while observing the differences of genetic and non-genetic risk factor in patients with breast cancer and patients without any medical/family history of breast cancer in Indonesian population. "
[INST] Provide title for trial id: NCT05570266 [/INST] Genetic and Non-Genetic Breast Cancer Risk Prediction Evaluation in Indonesian Samples
[INST] Provide the recruitment status for trial id: NCT05570266 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT05570266 [/INST] Breast Cancer
"Trial Id: What is the Best Interval to Screen Women 45-49 and 70-74 for Breast Cancer? Recruitment Status: Recruiting Trail description: Italian, multicenter, study aimed at defining the best interval for screening women 45-49 and 70-74 years for Breast Cancer (BC). This research project includes (1) a controlled, prospective randomized non-inferiority trial to determine the optimal screening interval for women aged 45-49, with and without high mammographic density, (2) a retrospective data collection, with the same purpose, on screening performed by women aged 70-74, and (3) a qualitative research to define the best communication strategy. Inclusion Criteria: Women invited for their first or second mammography (45 or 46 y/o) presenting for screening;
Willingness and ability to comply with scheduled visits;
Written informed consent obtained prior to performing any protocol-related procedures. Exclusion Criteria: Pregnancy status;
Personal history of prior breast carcinoma, either invasive or ductal carcinoma in situ (DCIS) diagnosis;
Ascertained heredo-familial risk according to the standard family history used in screening programs;
Participation in another clinical trial on BC screening;
Inability to provide signed informed consent. "
"[INST] Provide inclusion criteria for trial id: NCT04590560 [/INST] Women invited for their first or second mammography (45 or 46 y/o) presenting for screening;
Willingness and ability to comply with scheduled visits;
Written informed consent obtained prior to performing any protocol-related procedures. "
"[INST] Provide exclusion criteria for trial id: NCT04590560 [/INST] Pregnancy status;
Personal history of prior breast carcinoma, either invasive or ductal carcinoma in situ (DCIS) diagnosis;
Ascertained heredo-familial risk according to the standard family history used in screening programs;
Participation in another clinical trial on BC screening;
Inability to provide signed informed consent. "
"[INST] Provide description for trial id: NCT04590560 [/INST] Italian, multicenter, study aimed at defining the best interval for screening women 45-49 and 70-74 years for Breast Cancer (BC). This research project includes (1) a controlled, prospective randomized non-inferiority trial to determine the optimal screening interval for women aged 45-49, with and without high mammographic density, (2) a retrospective data collection, with the same purpose, on screening performed by women aged 70-74, and (3) a qualitative research to define the best communication strategy. "
[INST] Provide title for trial id: NCT04590560 [/INST] What is the Best Interval to Screen Women 45-49 and 70-74 for Breast Cancer?
[INST] Provide the recruitment status for trial id: NCT04590560 [/INST] Recruiting
[INST] Provide the medical condition for trial id: NCT04590560 [/INST] Breast Cancer
"Trial Id: Weight Loss and Breast Cancer Recruitment Status: Not yet recruiting Trail description: Obesity is an important risk factor for postmenopausal breast cancer. A large meta-analysis concluded that obesity is associated with a 20% to 40% increased risk for receptor-positive postmenopausal breast cancer. The International Agency for Research on Cancer working group on obesity and cancer risk drew similar conclusions. Obesity seems to have the opposite effect among premenopausal women, with most studies suggesting that higher BMI is associated with a reduced risk of premenopausal breast cancer.
Determining whether deliberate weight loss is associated with a reduced risk of breast cancer is difficult in part because sustained weight loss is difficult to achieve and few studies have sufficient statistical power to address this question. Bariatric surgery is one of the few weight loss interventions in which significant weight loss is maintained. A limited number of previous studies have suggested a reduced risk of cancer following bariatric surgery. Recently, it showed that bariatric surgery is associated with a lower risk of several types of cancer, including an approximately 40 % reduction in the risk of postmenopausal breast cancer. However, whether bariatric surgery affects breast cancer risk in premenopausal women and whether this association is altered by estrogen receptor (ER) status has not been addressed.
The aim of this study is to examine the relationship between weight loss after laparoscopic sleeve gastrectomy (LSG) and breast cancer. Inclusion Criteria: 40 years and older (age as of 2022, not the age of operation)
LSG was applied in our clinic due to morbid obesity.
Patients whose mamagrofi images are available in the hospital system Exclusion Criteria: Patients who underwent abdominal surgery again after LSG
Patients whose mamagrophy image is not in the system
Patients with suspicious findings as a result of mammography and who did not undergo additional imaging or biopsy
Patients out of follow-up after the operation "
"[INST] Provide inclusion criteria for trial id: NCT05654571 [/INST] 40 years and older (age as of 2022, not the age of operation)
LSG was applied in our clinic due to morbid obesity.
Patients whose mamagrofi images are available in the hospital system "
"[INST] Provide exclusion criteria for trial id: NCT05654571 [/INST] Patients who underwent abdominal surgery again after LSG
Patients whose mamagrophy image is not in the system
Patients with suspicious findings as a result of mammography and who did not undergo additional imaging or biopsy
Patients out of follow-up after the operation "
"[INST] Provide description for trial id: NCT05654571 [/INST] Obesity is an important risk factor for postmenopausal breast cancer. A large meta-analysis concluded that obesity is associated with a 20% to 40% increased risk for receptor-positive postmenopausal breast cancer. The International Agency for Research on Cancer working group on obesity and cancer risk drew similar conclusions. Obesity seems to have the opposite effect among premenopausal women, with most studies suggesting that higher BMI is associated with a reduced risk of premenopausal breast cancer.
Determining whether deliberate weight loss is associated with a reduced risk of breast cancer is difficult in part because sustained weight loss is difficult to achieve and few studies have sufficient statistical power to address this question. Bariatric surgery is one of the few weight loss interventions in which significant weight loss is maintained. A limited number of previous studies have suggested a reduced risk of cancer following bariatric surgery. Recently, it showed that bariatric surgery is associated with a lower risk of several types of cancer, including an approximately 40 % reduction in the risk of postmenopausal breast cancer. However, whether bariatric surgery affects breast cancer risk in premenopausal women and whether this association is altered by estrogen receptor (ER) status has not been addressed.
The aim of this study is to examine the relationship between weight loss after laparoscopic sleeve gastrectomy (LSG) and breast cancer. "
[INST] Provide title for trial id: NCT05654571 [/INST] Weight Loss and Breast Cancer
[INST] Provide the recruitment status for trial id: NCT05654571 [/INST] Not yet recruiting
"[INST] Provide the medical condition for trial id: NCT05654571 [/INST] Breast Cancer, Obesity, Morbid "
"Trial Id: Breast Cancer Prevention Education Recruitment Status: Completed Trail description: We will develop and evaluate a community-based approach for disseminating comparative effective reviews (CERs) about breast cancer prevention to African American women. The specific aims of our research, as shown below, will target this population because of persistent disparities in breast cancer morbidity and mortality among this population. Our primary aims are:
To evaluate uptake of a community-based strategy for disseminating CERs about breast cancer prevention to African American women based on sociodemographic characteristics, beliefs about medical research, and medical history. We predict that participation in a community forum will be higher among women with greater socioeconomic resources, those who have a family history of breast cancer, and women who have more positive beliefs about research.
To evaluate the impact of evidential versus non-evidential content about breast cancer prevention on psychological and behavioral outcomes that include: knowledge of breast cancer risk factors and prevention strategies, communication with individuals in their social and medical network, and distrust of medical research. We predict that women who receive evidential content that is specific for African American women will report greater knowledge about breast cancer risk factors and prevention strategies, will be more likely to discuss breast cancer prevention strategies with individuals in their social and medical network, and will report greater reductions in distrust of medical research compared to those who receive non-evidential content. Inclusion Criteria: African American women
Ages 35-70
No personal history of cancer
Resident of Philadelphia metropolitan area Exclusion Criteria: Non-African American
Male
Under 35 or over 70 years of age
Personal history of cancer
Not a resident of Philadelphia Metropolitan Area "
"[INST] Provide inclusion criteria for trial id: NCT01299623 [/INST] African American women
Ages 35-70
No personal history of cancer
Resident of Philadelphia metropolitan area "
"[INST] Provide exclusion criteria for trial id: NCT01299623 [/INST] Non-African American
Male
Under 35 or over 70 years of age
Personal history of cancer
Not a resident of Philadelphia Metropolitan Area "
"[INST] Provide description for trial id: NCT01299623 [/INST] We will develop and evaluate a community-based approach for disseminating comparative effective reviews (CERs) about breast cancer prevention to African American women. The specific aims of our research, as shown below, will target this population because of persistent disparities in breast cancer morbidity and mortality among this population. Our primary aims are:
To evaluate uptake of a community-based strategy for disseminating CERs about breast cancer prevention to African American women based on sociodemographic characteristics, beliefs about medical research, and medical history. We predict that participation in a community forum will be higher among women with greater socioeconomic resources, those who have a family history of breast cancer, and women who have more positive beliefs about research.
To evaluate the impact of evidential versus non-evidential content about breast cancer prevention on psychological and behavioral outcomes that include: knowledge of breast cancer risk factors and prevention strategies, communication with individuals in their social and medical network, and distrust of medical research. We predict that women who receive evidential content that is specific for African American women will report greater knowledge about breast cancer risk factors and prevention strategies, will be more likely to discuss breast cancer prevention strategies with individuals in their social and medical network, and will report greater reductions in distrust of medical research compared to those who receive non-evidential content. "
[INST] Provide title for trial id: NCT01299623 [/INST] Breast Cancer Prevention Education
[INST] Provide the recruitment status for trial id: NCT01299623 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT01299623 [/INST] Breast Cancer Prevention
"Trial Id: Ethnic Predisposition, Risk Factors & Breast Cancer Presentation. Recruitment Status: Completed Trail description: Breast cancer, a leading cause of mortality among females, has been the center of research for many decades. Work is in progress to further advance the research worldwide and in our region. This study is conducted to look into regional ethical predilection, clinical presentation/stage, pathological subtypes & risk factors of BC among patients of Karachi, with the aim of proposing a ground to policy making regarding protocol setting for screening and management of BC for our region. Inclusion Criteria: female sex, age ≥ 20 years, patients with availability of complete clinical details, biopsy proven breast cancer, no previous history of breast cancer treatment from other centers, males, all regional ethnicities(residents of Karachi, Sindh) and all stages of breast cancer Exclusion Criteria: previously treated breast cancer patients, female ≤19 years, male/transgender, females coming for treatment for other provinces/foreigners. "
"[INST] Provide inclusion criteria for trial id: NCT05458570 [/INST] female sex, age ≥ 20 years, patients with availability of complete clinical details, biopsy proven breast cancer, no previous history of breast cancer treatment from other centers, males, all regional ethnicities(residents of Karachi, Sindh) and all stages of breast cancer "
"[INST] Provide exclusion criteria for trial id: NCT05458570 [/INST] previously treated breast cancer patients, female ≤19 years, male/transgender, females coming for treatment for other provinces/foreigners. "
"[INST] Provide description for trial id: NCT05458570 [/INST] Breast cancer, a leading cause of mortality among females, has been the center of research for many decades. Work is in progress to further advance the research worldwide and in our region. This study is conducted to look into regional ethical predilection, clinical presentation/stage, pathological subtypes & risk factors of BC among patients of Karachi, with the aim of proposing a ground to policy making regarding protocol setting for screening and management of BC for our region. "
"[INST] Provide title for trial id: NCT05458570 [/INST] Ethnic Predisposition, Risk Factors & Breast Cancer Presentation. "
[INST] Provide the recruitment status for trial id: NCT05458570 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT05458570 [/INST] Breast Cancer
"Trial Id: Breast Cancer Survivors: Main Physical and Psychosocial Problems After Completion of Treatment Recruitment Status: Unknown status Trail description: Breast cancer directly affects women physically, psychologically and socially in the process of diagnosis, treatment and post-treatment. Despite the improvement in conventional breast cancer treatments that led to longer disease-free survival, many patients still suffer from physical, psychological, social and spiritual problems after treatment. The neglect of physical and psychosocial problems faced by patients who are between 1 and 2 years after the end of treatment negatively impacts the quality of life of this population. Inclusion Criteria: Breast cancer
Adult women (age ≥ 20 years old and less than 60 years old)
Patient who has been treated by surgery, with or without adjuvant chemotherapy
Clinical Stages I, II and III
Patients considered cured, without history of recurrences
Patients who completed treatment within a minimum of 1 year and are currently being undergoing outpatient follow-up Exclusion Criteria: Initial diagnosis of another type of cancer, other than breast cancer
Bilateral breast cancer
Patient unable to fill out the QoL questionnaire
Patient with disease recurrence
Patient with metastatic breast cancer "
"[INST] Provide inclusion criteria for trial id: NCT04834570 [/INST] Breast cancer
Adult women (age ≥ 20 years old and less than 60 years old)
Patient who has been treated by surgery, with or without adjuvant chemotherapy
Clinical Stages I, II and III
Patients considered cured, without history of recurrences
Patients who completed treatment within a minimum of 1 year and are currently being undergoing outpatient follow-up "
"[INST] Provide exclusion criteria for trial id: NCT04834570 [/INST] Initial diagnosis of another type of cancer, other than breast cancer
Bilateral breast cancer
Patient unable to fill out the QoL questionnaire
Patient with disease recurrence
Patient with metastatic breast cancer "
"[INST] Provide description for trial id: NCT04834570 [/INST] Breast cancer directly affects women physically, psychologically and socially in the process of diagnosis, treatment and post-treatment. Despite the improvement in conventional breast cancer treatments that led to longer disease-free survival, many patients still suffer from physical, psychological, social and spiritual problems after treatment. The neglect of physical and psychosocial problems faced by patients who are between 1 and 2 years after the end of treatment negatively impacts the quality of life of this population. "
[INST] Provide title for trial id: NCT04834570 [/INST] Breast Cancer Survivors: Main Physical and Psychosocial Problems After Completion of Treatment
[INST] Provide the recruitment status for trial id: NCT04834570 [/INST] Unknown status
[INST] Provide the medical condition for trial id: NCT04834570 [/INST] Breast Cancer
"Trial Id: No Axillary Surgery for Early Breast Cancer. Recruitment Status: Completed Trail description: After breast cancer (BC) screening was introduced for all Swedish women in 1989-90 the number of early invasive BC, clin N0 rose dramatically. For these BC it was known that only 10 % or less was N+ after axillary dissection and the morbidity for axillary surgery was substantial. Omitting axillary dissection in a randomized trial was ruled out because of anticipated few events. A national cohort was decided for invasive unifocal BC, histological grade 1 or 2, T=max 10mm, free margins, clin node neg. No axillary dissection should be undertaken. This was before the Sentinel Node era. Adjuvant treatment could be given according to regional guidelines for early breast cancer. Not uniform concerning postoperative radiotherapy and antihormonal treatment. Follow-up was clinical the first 5 years with mammography and then by hospital records and national Death register. Primary aim: Number of axillary recurrence and BC specific survival. Inclusion Criteria: Invasive breast cancer, unifocal
T=max 10mm
Clinical node negative and clinical M0
Histological grade 1 or 2
Both screening / clinical detected accepted
Radical operation = free margins in breast specimen
Partial mastectomy and mastectomy accepted
Fit to understand inclusion criteria Exclusion Criteria: Previous breast cancer diagnosis, including carcinoma in situ
Previous ipsilateral axillary dissection
Non radical operation = no free margins
Multifocal cancer
Previous treatment for other cancer.
Unable to understand information (informed consent)
Bilateral breast cancer at diagnosis "
"[INST] Provide inclusion criteria for trial id: NCT03669705 [/INST] Invasive breast cancer, unifocal
T=max 10mm
Clinical node negative and clinical M0
Histological grade 1 or 2
Both screening / clinical detected accepted
Radical operation = free margins in breast specimen
Partial mastectomy and mastectomy accepted
Fit to understand inclusion criteria "
"[INST] Provide exclusion criteria for trial id: NCT03669705 [/INST] Previous breast cancer diagnosis, including carcinoma in situ
Previous ipsilateral axillary dissection
Non radical operation = no free margins
Multifocal cancer
Previous treatment for other cancer.
Unable to understand information (informed consent)
Bilateral breast cancer at diagnosis "
"[INST] Provide description for trial id: NCT03669705 [/INST] After breast cancer (BC) screening was introduced for all Swedish women in 1989-90 the number of early invasive BC, clin N0 rose dramatically. For these BC it was known that only 10 % or less was N+ after axillary dissection and the morbidity for axillary surgery was substantial. Omitting axillary dissection in a randomized trial was ruled out because of anticipated few events. A national cohort was decided for invasive unifocal BC, histological grade 1 or 2, T=max 10mm, free margins, clin node neg. No axillary dissection should be undertaken. This was before the Sentinel Node era. Adjuvant treatment could be given according to regional guidelines for early breast cancer. Not uniform concerning postoperative radiotherapy and antihormonal treatment. Follow-up was clinical the first 5 years with mammography and then by hospital records and national Death register. Primary aim: Number of axillary recurrence and BC specific survival. "
[INST] Provide title for trial id: NCT03669705 [/INST] No Axillary Surgery for Early Breast Cancer.
[INST] Provide the recruitment status for trial id: NCT03669705 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT03669705 [/INST] Breast Cancer Invasive
"Trial Id: Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy Recruitment Status: Recruiting Trail description: This multicenter clinical study aims to build an intelligent and accurate diagnosis and dynamic prediction and early warning model of cardiotoxicity due to anthracycline-based breast cancer chemotherapy, clarify the value of the early warning model in guiding the targeted prevention of myocardial protection, providing an important theoretical basis for reducing the mortality rate of breast cancer and improving the prognosis. Inclusion Criteria: Age ≥18 years
Histologically or cytopathological confirmed stage I-III HER2+ breast cancer, scheduled to receive consecutive anthracycline chemotherapy or subsequent sequential trastuzumab targeted therapy
LVEF≥53% before chemotherapy Exclusion Criteria: life expectancy ≤12 months
Participating in other ongoing oncology clinical trials
Prior treatment with anthracyclines or chest radiation therapy
Pregnant or lactating women
Ultrasound images of the heart are of very poor quality "
"[INST] Provide inclusion criteria for trial id: NCT06282796 [/INST] Age ≥18 years
Histologically or cytopathological confirmed stage I-III HER2+ breast cancer, scheduled to receive consecutive anthracycline chemotherapy or subsequent sequential trastuzumab targeted therapy
LVEF≥53% before chemotherapy "
"[INST] Provide exclusion criteria for trial id: NCT06282796 [/INST] life expectancy ≤12 months
Participating in other ongoing oncology clinical trials
Prior treatment with anthracyclines or chest radiation therapy
Pregnant or lactating women
Ultrasound images of the heart are of very poor quality "
"[INST] Provide description for trial id: NCT06282796 [/INST] This multicenter clinical study aims to build an intelligent and accurate diagnosis and dynamic prediction and early warning model of cardiotoxicity due to anthracycline-based breast cancer chemotherapy, clarify the value of the early warning model in guiding the targeted prevention of myocardial protection, providing an important theoretical basis for reducing the mortality rate of breast cancer and improving the prognosis. "
[INST] Provide title for trial id: NCT06282796 [/INST] Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy
[INST] Provide the recruitment status for trial id: NCT06282796 [/INST] Recruiting
[INST] Provide the medical condition for trial id: NCT06282796 [/INST] Breast Cancer
"Trial Id: Increasing African Immigrant Women's Participation in Breast Cancer Screening Recruitment Status: Completed Trail description: New York City (NYC) is home to a large and diverse immigrant population. Many of these groups face significant barriers to preventive health care, including lack of insurance, poor health care access and language difficulties. Most African immigrant women are likely to live below the poverty line and have low health literacy, are less likely to have health insurance and visit a doctor, particularly for primary/preventive care. Without access to primary care, many preventive services, such as breast cancer screenings go unattended. The barriers and facilitators to breast cancer screening for other minority groups from underserved populations, such as African Americans and Latina women have been studied. Less is known about these for African immigrant women and how to most effectively engage their participation in regular screening. Data of over 2,000 African-born immigrants living in NYC show that 77% report not having health insurance; 75% do not have a primary care physician; and 57% have less than a high school education. As for cancer screening, when corrected for age, 44% have never had a mammogram. Through the study team's unique collaboration with the African Services Committee and the African Advisory Council of the Bronx, two non-governmental community-based service organizations, the study team is poised to have a significant impact on these immigrant women, who have emigrated from more than 20 countries in Africa. This is a population with great need for increased breast cancer knowledge, access to breast cancer screening, and basic medical care. The Health Belief Model (HBM) provides a framework for addressing cultural health barriers by positing that making a decision to engage in a health behavior is determined by weighing perceived threats versus benefits. The long term goal of the proposed project is to conduct a randomized clinical trial that tests the adapted intervention to increase breast cancer screening rates for African-born immigrants. In the short term, the study team plans to pursue the following specific aims: (1) Identify barriers and facilitators to breast cancer screening among African-born immigrants and (2) Culturally adapt and pilot test the Witness Project breast cancer education program for African-born women. Thus, the study team will culturally adapt an effective, innovative intervention to address this significant health disparity in African-born immigrant communities. Inclusion Criteria: None Exclusion Criteria: None "
[INST] Provide inclusion criteria for trial id: NCT04450264 [/INST] None
[INST] Provide exclusion criteria for trial id: NCT04450264 [/INST] None
"[INST] Provide description for trial id: NCT04450264 [/INST] New York City (NYC) is home to a large and diverse immigrant population. Many of these groups face significant barriers to preventive health care, including lack of insurance, poor health care access and language difficulties. Most African immigrant women are likely to live below the poverty line and have low health literacy, are less likely to have health insurance and visit a doctor, particularly for primary/preventive care. Without access to primary care, many preventive services, such as breast cancer screenings go unattended. The barriers and facilitators to breast cancer screening for other minority groups from underserved populations, such as African Americans and Latina women have been studied. Less is known about these for African immigrant women and how to most effectively engage their participation in regular screening. Data of over 2,000 African-born immigrants living in NYC show that 77% report not having health insurance; 75% do not have a primary care physician; and 57% have less than a high school education. As for cancer screening, when corrected for age, 44% have never had a mammogram. Through the study team's unique collaboration with the African Services Committee and the African Advisory Council of the Bronx, two non-governmental community-based service organizations, the study team is poised to have a significant impact on these immigrant women, who have emigrated from more than 20 countries in Africa. This is a population with great need for increased breast cancer knowledge, access to breast cancer screening, and basic medical care. The Health Belief Model (HBM) provides a framework for addressing cultural health barriers by positing that making a decision to engage in a health behavior is determined by weighing perceived threats versus benefits. The long term goal of the proposed project is to conduct a randomized clinical trial that tests the adapted intervention to increase breast cancer screening rates for African-born immigrants. In the short term, the study team plans to pursue the following specific aims: (1) Identify barriers and facilitators to breast cancer screening among African-born immigrants and (2) Culturally adapt and pilot test the Witness Project breast cancer education program for African-born women. Thus, the study team will culturally adapt an effective, innovative intervention to address this significant health disparity in African-born immigrant communities. "
[INST] Provide title for trial id: NCT04450264 [/INST] Increasing African Immigrant Women's Participation in Breast Cancer Screening
[INST] Provide the recruitment status for trial id: NCT04450264 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT04450264 [/INST] Breast Cancer
"Trial Id: A Study to Evaluate the Accuracy of a Breast Cancer Locator (BCL) in Patients With Palpable Cancers Recruitment Status: Completed Trail description: In this study, the investigators will enroll women with palpable cancers to assess the accuracy of the Breast Cancer Locator (BCL) and the concomitant procedure as a vehicle to optimize and validate the approach in such surgical cases. This approach of adopting palpable cancer patients before initiating an evaluative trial of the BCL in non-palpable breast cancer cases ensures that the BCL does not substantially alter or modify the standard-of-care procedure. Inclusion Criteria: Age greater than or equal to 18 years
Histologic diagnosis of palpable invasive breast cancer or ductal carcinoma in situ
Patient desire to undergo breast surgery
Ability to voluntarily provide informed consent to participate prior to any study-related assessments/procedures being conducted
The cancer enhances on breast MRI imaging. Exclusion Criteria: Absolute contraindication to MRI, including presence of implanted electrical device (pacemaker or neurostimulator), aneurysm clip, or metallic foreign body in or near eyes
Severe claustrophobia
Contraindication to use of gadolinium-based intravenous contrast, including life-threatening allergy or compromised renal function (creatinine > 2.0)
History of median sternotomy
Pregnancy. Patient attestation that they are not pregnant will be acceptable as per standard policy for MRIs at DHMC. "
"[INST] Provide inclusion criteria for trial id: NCT02550210 [/INST] Age greater than or equal to 18 years
Histologic diagnosis of palpable invasive breast cancer or ductal carcinoma in situ
Patient desire to undergo breast surgery
Ability to voluntarily provide informed consent to participate prior to any study-related assessments/procedures being conducted
The cancer enhances on breast MRI imaging. "
"[INST] Provide exclusion criteria for trial id: NCT02550210 [/INST] Absolute contraindication to MRI, including presence of implanted electrical device (pacemaker or neurostimulator), aneurysm clip, or metallic foreign body in or near eyes
Severe claustrophobia
Contraindication to use of gadolinium-based intravenous contrast, including life-threatening allergy or compromised renal function (creatinine > 2.0)
History of median sternotomy
Pregnancy. Patient attestation that they are not pregnant will be acceptable as per standard policy for MRIs at DHMC. "
"[INST] Provide description for trial id: NCT02550210 [/INST] In this study, the investigators will enroll women with palpable cancers to assess the accuracy of the Breast Cancer Locator (BCL) and the concomitant procedure as a vehicle to optimize and validate the approach in such surgical cases. This approach of adopting palpable cancer patients before initiating an evaluative trial of the BCL in non-palpable breast cancer cases ensures that the BCL does not substantially alter or modify the standard-of-care procedure. "
[INST] Provide title for trial id: NCT02550210 [/INST] A Study to Evaluate the Accuracy of a Breast Cancer Locator (BCL) in Patients With Palpable Cancers
[INST] Provide the recruitment status for trial id: NCT02550210 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT02550210 [/INST] Breast Cancer
"Trial Id: The HIFUB Study (HIFU in Breast Cancer) Recruitment Status: Unknown status Trail description: High Intensity Focused Ultrasound (HIFU) is a new method of treating solid tumours by thermally ablating them. It has been used in a number of different types of cancers but there is little information on its use in invasive breast cancer (IBC). The investigators aim to assess the efficacy and safety of HIFU in the treatment of IBC.
In this study, fifteen otherwise healthy women diagnosed with small, early stage IBC will be treated with HIFU prior to conventional surgical treatment. The effects of HIFU on the resected tumour will be analysed pathologically and correlated with radiological findings. Immune response and participant experience will also be evaluated Inclusion Criteria: Participant is willing and able to give informed consent for participation in the trial.
Female, aged 18 years or above.
Histologically confirmed breast cancer (invasive ductal cancer) by core biopsy, which is suitable for surgical resection.
Participants must have one non-metastatic, clinically palpable, invasive breast cancer measuring ≤2cm in its largest dimension, which can be visualised using diagnostic ultrasound.
All participants must have an adequate biopsy determination of oestrogen, progesterone, HER2 receptor status on pre-operative biopsy.
Adequate ECG, haematological, renal and hepatic function, as indicated, as would be required for imaging and surgery.
In the Investigator's opinion, is able and willing to comply with all trial requirements. Exclusion Criteria: Female participant who is pregnant.
Significant renal or hepatic impairment.
An inadequate biopsy determination of oestrogen, progesterone, HER2 receptor status on pre-operative biopsy.
Unable to visualize lesion or tumour boundaries clearly on ultrasound.
Subjects with tumours lying less than 5mm to overlying skin or less than 5mm to the underlying muscle on the diagnostic scan.
Any uncontrolled illness or any other medical problem that would preclude surgery.
The presence of any contraindication for magnetic resonance imaging, e.g. the presence of a heart pacemaker, a metallic foreign body (metal sliver) in the eye, or an aneurysm clip in the brain or severe claustrophobia. "
"[INST] Provide inclusion criteria for trial id: NCT05350059 [/INST] Participant is willing and able to give informed consent for participation in the trial.
Female, aged 18 years or above.
Histologically confirmed breast cancer (invasive ductal cancer) by core biopsy, which is suitable for surgical resection.
Participants must have one non-metastatic, clinically palpable, invasive breast cancer measuring ≤2cm in its largest dimension, which can be visualised using diagnostic ultrasound.
All participants must have an adequate biopsy determination of oestrogen, progesterone, HER2 receptor status on pre-operative biopsy.
Adequate ECG, haematological, renal and hepatic function, as indicated, as would be required for imaging and surgery.
In the Investigator's opinion, is able and willing to comply with all trial requirements. "
"[INST] Provide exclusion criteria for trial id: NCT05350059 [/INST] Female participant who is pregnant.
Significant renal or hepatic impairment.
An inadequate biopsy determination of oestrogen, progesterone, HER2 receptor status on pre-operative biopsy.
Unable to visualize lesion or tumour boundaries clearly on ultrasound.
Subjects with tumours lying less than 5mm to overlying skin or less than 5mm to the underlying muscle on the diagnostic scan.
Any uncontrolled illness or any other medical problem that would preclude surgery.
The presence of any contraindication for magnetic resonance imaging, e.g. the presence of a heart pacemaker, a metallic foreign body (metal sliver) in the eye, or an aneurysm clip in the brain or severe claustrophobia. "
"[INST] Provide description for trial id: NCT05350059 [/INST] High Intensity Focused Ultrasound (HIFU) is a new method of treating solid tumours by thermally ablating them. It has been used in a number of different types of cancers but there is little information on its use in invasive breast cancer (IBC). The investigators aim to assess the efficacy and safety of HIFU in the treatment of IBC.
In this study, fifteen otherwise healthy women diagnosed with small, early stage IBC will be treated with HIFU prior to conventional surgical treatment. The effects of HIFU on the resected tumour will be analysed pathologically and correlated with radiological findings. Immune response and participant experience will also be evaluated "
[INST] Provide title for trial id: NCT05350059 [/INST] The HIFUB Study (HIFU in Breast Cancer)
[INST] Provide the recruitment status for trial id: NCT05350059 [/INST] Unknown status
[INST] Provide the medical condition for trial id: NCT05350059 [/INST] Breast Cancer
"Trial Id: A Pilot Multi-Institutional Study to Evaluate the Accuracy of a Breast Cancer Locator in Patients With Palpable Cancers Recruitment Status: Completed Trail description: The project objective is to determine whether the Breast Cancer Locator (BCL) can safely and effectively localize breast cancers in patients treated at locations distant from the site of BCL manufacture. This information will be transmitted to CairnSurgical, Inc. where the BCL will be fabricated, tested for quality assurance, sterilized and shipped to the patient's surgeon. The surgeon will then utilize the BCL at the time of resection of the palpable breast cancer. Inclusion Criteria: Age > 18 years.
Histologic diagnosis of palpable invasive breast cancer or ductal carcinoma in situ.
Patient desire to undergo breast surgery (lumpectomy or non-skin sparing mastectomy).
Ability to voluntarily provide informed consent to participate prior to any study-related assessments/procedures being conducted.
The cancer enhances on prone breast MRI imaging
The cancer is visible on mammography. Exclusion Criteria: Absolute contraindication to MRI, including presence of implanted electrical device (pacemaker or neurostimulator), aneurysm clip, or metallic foreign body in or near eyes.
Severe claustrophobia.
Contraindication to use of gadolinium-based intravenous contrast, including life- threatening allergy or compromised renal function (creatinine > 2.0).
History of median sternotomy.
Pregnancy. Patient attestation that they are not pregnant will be acceptable.
Patients receiving neoadjuvant chemotherapy. "
"[INST] Provide inclusion criteria for trial id: NCT03573661 [/INST] Age > 18 years.
Histologic diagnosis of palpable invasive breast cancer or ductal carcinoma in situ.
Patient desire to undergo breast surgery (lumpectomy or non-skin sparing mastectomy).
Ability to voluntarily provide informed consent to participate prior to any study-related assessments/procedures being conducted.
The cancer enhances on prone breast MRI imaging
The cancer is visible on mammography. "
"[INST] Provide exclusion criteria for trial id: NCT03573661 [/INST] Absolute contraindication to MRI, including presence of implanted electrical device (pacemaker or neurostimulator), aneurysm clip, or metallic foreign body in or near eyes.
Severe claustrophobia.
Contraindication to use of gadolinium-based intravenous contrast, including life- threatening allergy or compromised renal function (creatinine > 2.0).
History of median sternotomy.
Pregnancy. Patient attestation that they are not pregnant will be acceptable.
Patients receiving neoadjuvant chemotherapy. "
"[INST] Provide description for trial id: NCT03573661 [/INST] The project objective is to determine whether the Breast Cancer Locator (BCL) can safely and effectively localize breast cancers in patients treated at locations distant from the site of BCL manufacture. This information will be transmitted to CairnSurgical, Inc. where the BCL will be fabricated, tested for quality assurance, sterilized and shipped to the patient's surgeon. The surgeon will then utilize the BCL at the time of resection of the palpable breast cancer. "
[INST] Provide title for trial id: NCT03573661 [/INST] A Pilot Multi-Institutional Study to Evaluate the Accuracy of a Breast Cancer Locator in Patients With Palpable Cancers
[INST] Provide the recruitment status for trial id: NCT03573661 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT03573661 [/INST] Palpable Breast Cancer
"Trial Id: Serum Retinoic Acid Induced Protein 14 (RAI14) and Metastasis Associated Cancer Colon -1 (MACC-1) in Breast Cancer Recruitment Status: Not yet recruiting Trail description: Measurement of serum levels of Retinoic acid induced 14 (RAI14) and Metastasis associated cancer colon -1 (MACC-1) as biomarkers for diagnosis of breast cancer.
Study their relationship to disease stages and clinicopathological features of BC.
Compare the diagnostic performance of serum RAI14 and serum MACC-1 with serum Carcinoembryonic antigen (CEA) and Cancer antigen 15-3 (CA15-3) for diagnosis of BC. Inclusion Criteria: None Exclusion Criteria: None "
[INST] Provide inclusion criteria for trial id: NCT06097546 [/INST] None
[INST] Provide exclusion criteria for trial id: NCT06097546 [/INST] None
"[INST] Provide description for trial id: NCT06097546 [/INST] Measurement of serum levels of Retinoic acid induced 14 (RAI14) and Metastasis associated cancer colon -1 (MACC-1) as biomarkers for diagnosis of breast cancer.
Study their relationship to disease stages and clinicopathological features of BC.
Compare the diagnostic performance of serum RAI14 and serum MACC-1 with serum Carcinoembryonic antigen (CEA) and Cancer antigen 15-3 (CA15-3) for diagnosis of BC. "
[INST] Provide title for trial id: NCT06097546 [/INST] Serum Retinoic Acid Induced Protein 14 (RAI14) and Metastasis Associated Cancer Colon -1 (MACC-1) in Breast Cancer
[INST] Provide the recruitment status for trial id: NCT06097546 [/INST] Not yet recruiting
[INST] Provide the medical condition for trial id: NCT06097546 [/INST] Breast Cancer
"Trial Id: Whole Genome Sequencing in Breast Cancer Recruitment Status: Recruiting Trail description: This study aims to conduct whole genome sequencing in breast cancer patients to elucidate individual genetic characteristics and their correlation with breast cancer subtypes. The primary objective is to establish new treatment guidelines aligned with the paradigm shift in precision medicine. The study will include both prospective and retrospective cohorts totaling 1200 participants. Prospective participants must provide consent and be eligible for tissue collection, while retrospective participants must have histologically confirmed breast cancer and available tissue samples from Samsung Medical Center Biobank. The study period spans 3 years for subject enrollment and 5 years for follow-up observations, with an expected completion date of December 31, 2030. Inclusion Criteria: Patients who have consented to both the patient consent form and the consent for the use of human-derived materials.
Patients who are aged 19 years or older at the time of signing the consent form.
Patients capable of providing written consent to participate voluntarily in the study.
Patients eligible for tissue examination and surgical removal to facilitate sample collection.
Patients histologically confirmed with breast cancer or undergoing tissue examination for pathological confirmation due to imaging findings suggestive of breast cancer. Exclusion Criteria: Patients who do not understand or refuse to consent in writing.
Patients for whom obtaining sufficient samples is challenging.
Patients who refuse genetic testing.
[Retrospective study]
Inclusion Criteria:
Patients histologically confirmed with breast cancer.
Patients for whom breast cancer tissues collected between 2012 and 2023 are stored in the Samsung Seoul Hospital Biobank and available for distribution.
Exclusion Criteria:
- Patients for whom sufficient tissue for analysis is not adequately stored. "
"[INST] Provide inclusion criteria for trial id: NCT06334471 [/INST] Patients who have consented to both the patient consent form and the consent for the use of human-derived materials.
Patients who are aged 19 years or older at the time of signing the consent form.
Patients capable of providing written consent to participate voluntarily in the study.
Patients eligible for tissue examination and surgical removal to facilitate sample collection.
Patients histologically confirmed with breast cancer or undergoing tissue examination for pathological confirmation due to imaging findings suggestive of breast cancer. "
"[INST] Provide exclusion criteria for trial id: NCT06334471 [/INST] Patients who do not understand or refuse to consent in writing.
Patients for whom obtaining sufficient samples is challenging.
Patients who refuse genetic testing.
[Retrospective study]
Inclusion Criteria:
Patients histologically confirmed with breast cancer.
Patients for whom breast cancer tissues collected between 2012 and 2023 are stored in the Samsung Seoul Hospital Biobank and available for distribution.
Exclusion Criteria:
- Patients for whom sufficient tissue for analysis is not adequately stored. "
"[INST] Provide description for trial id: NCT06334471 [/INST] This study aims to conduct whole genome sequencing in breast cancer patients to elucidate individual genetic characteristics and their correlation with breast cancer subtypes. The primary objective is to establish new treatment guidelines aligned with the paradigm shift in precision medicine. The study will include both prospective and retrospective cohorts totaling 1200 participants. Prospective participants must provide consent and be eligible for tissue collection, while retrospective participants must have histologically confirmed breast cancer and available tissue samples from Samsung Medical Center Biobank. The study period spans 3 years for subject enrollment and 5 years for follow-up observations, with an expected completion date of December 31, 2030. "
[INST] Provide title for trial id: NCT06334471 [/INST] Whole Genome Sequencing in Breast Cancer
[INST] Provide the recruitment status for trial id: NCT06334471 [/INST] Recruiting
[INST] Provide the medical condition for trial id: NCT06334471 [/INST] Breast Cancer
"Trial Id: Assessment of Periodontal Therapy and Biofilm Management in Breast Cancer Recruitment Status: Completed Trail description: Objective: To evaluate the impact of chemotherapy on periodontal conditions, hematology, and salivary flow in patients with breast cancer and gingivitis, after basic periodontal therapy (BPT).
Methods: They were divided into patients with breast cancer and gingivitis (BC/G =20); and patients without cancer with gingivitis (G=20). Clinical parameters [Plaque Index (PI), bleeding on probing (BOP), Probing Depth (PS), Clinical Attachment Level (CAL)], hematological parameters (complete blood count), and salivary flow were evaluated at baseline, 6, 12 and 24 weeks. Inclusion Criteria: None Exclusion Criteria: None "
[INST] Provide inclusion criteria for trial id: NCT06212908 [/INST] None
[INST] Provide exclusion criteria for trial id: NCT06212908 [/INST] None
"[INST] Provide description for trial id: NCT06212908 [/INST] Objective: To evaluate the impact of chemotherapy on periodontal conditions, hematology, and salivary flow in patients with breast cancer and gingivitis, after basic periodontal therapy (BPT).
Methods: They were divided into patients with breast cancer and gingivitis (BC/G =20); and patients without cancer with gingivitis (G=20). Clinical parameters [Plaque Index (PI), bleeding on probing (BOP), Probing Depth (PS), Clinical Attachment Level (CAL)], hematological parameters (complete blood count), and salivary flow were evaluated at baseline, 6, 12 and 24 weeks. "
[INST] Provide title for trial id: NCT06212908 [/INST] Assessment of Periodontal Therapy and Biofilm Management in Breast Cancer
[INST] Provide the recruitment status for trial id: NCT06212908 [/INST] Completed
"[INST] Provide the medical condition for trial id: NCT06212908 [/INST] Breast Cancer, Gingivitis, Periodontal "
"Trial Id: Clinical Evaluation of OSNA Breast Cancer System to Extensive Frozen Section Histopathology Recruitment Status: Completed Trail description: The study will determine the sensitivity, specificity, negative predictive value and positive predictive value of the OSNA Breast Cancer System by comparing its performance to an extensive intraoperative frozen section protocol for Sentinel Lymph Nodes removed during standard Sentinel Lymph Node biopsy procedures from breast cancer subjects. Inclusion Criteria: Male or female;
18 years of age or older;
Diagnosed pre-surgically with T1 or T2 breast cancer without clinical evidence of axillary lymph node involvement and scheduled for surgery including sentinel lymph node dissection;
Subjects (or the subjects' legal representatives) who have read, understood to the best of their ability and signed the informed consent form. Exclusion Criteria: Subjects diagnosed pre-surgically with large or locally advanced (T3 & T4) breast cancer;
Pregnant subjects, confirmed by interview with either subject or treating physician;
Subjects diagnosed with inflammatory breast cancer;
Subjects diagnosed with ductal carcinoma in situ (DCIS) when breast conservation is to be done;
Subjects with clinically suspicious, palpable axillary lymph nodes;
Subjects previously treated for or previously diagnosed with another type of invasive cancer. Subjects with skin cancer (basal cell and squamous cell carcinoma) may be included, except for subjects diagnosed with melanoma; Subjects with non-invasive carcinoma of the Cervix may also be included in this study.
Subjects who have received pre-operative systemic therapy;
Subjects who are incapable of providing written informed consent;
Subjects who have been judged to be an inappropriate candidate by any medical care provider (e.g., surgeon, oncologist or pathologist).
Subjects participating in other clinical studies where the SLN evaluation will be negatively impacted by this study. "
"[INST] Provide inclusion criteria for trial id: NCT01368744 [/INST] Male or female;
18 years of age or older;
Diagnosed pre-surgically with T1 or T2 breast cancer without clinical evidence of axillary lymph node involvement and scheduled for surgery including sentinel lymph node dissection;
Subjects (or the subjects' legal representatives) who have read, understood to the best of their ability and signed the informed consent form. "
"[INST] Provide exclusion criteria for trial id: NCT01368744 [/INST] Subjects diagnosed pre-surgically with large or locally advanced (T3 & T4) breast cancer;
Pregnant subjects, confirmed by interview with either subject or treating physician;
Subjects diagnosed with inflammatory breast cancer;
Subjects diagnosed with ductal carcinoma in situ (DCIS) when breast conservation is to be done;
Subjects with clinically suspicious, palpable axillary lymph nodes;
Subjects previously treated for or previously diagnosed with another type of invasive cancer. Subjects with skin cancer (basal cell and squamous cell carcinoma) may be included, except for subjects diagnosed with melanoma; Subjects with non-invasive carcinoma of the Cervix may also be included in this study.
Subjects who have received pre-operative systemic therapy;
Subjects who are incapable of providing written informed consent;
Subjects who have been judged to be an inappropriate candidate by any medical care provider (e.g., surgeon, oncologist or pathologist).
Subjects participating in other clinical studies where the SLN evaluation will be negatively impacted by this study. "
"[INST] Provide description for trial id: NCT01368744 [/INST] The study will determine the sensitivity, specificity, negative predictive value and positive predictive value of the OSNA Breast Cancer System by comparing its performance to an extensive intraoperative frozen section protocol for Sentinel Lymph Nodes removed during standard Sentinel Lymph Node biopsy procedures from breast cancer subjects. "
[INST] Provide title for trial id: NCT01368744 [/INST] Clinical Evaluation of OSNA Breast Cancer System to Extensive Frozen Section Histopathology
[INST] Provide the recruitment status for trial id: NCT01368744 [/INST] Completed
"[INST] Provide the medical condition for trial id: NCT01368744 [/INST] Breast Neoplasms, Breast Diseases "
"Trial Id: Breast Cancer With Over-expression of erbB2-BRAINSTORM Recruitment Status: Completed Trail description: This retrospective cohort study aims to improve our understanding of the current paradigm for treatment of brain metastases in erbB2+ breast cancer patients in the Asia Pacific region. We aim to identify approximately 300 erbB2+ breast cancer patients with brain metastases diagnosed between 2006-2008 in 6 countries. Medical records will be analyzed to determine the treatment pattern for brain metastases, including anti-erbB2 therapy. Additional objectives are to understand the impact of anti-erbB2 therapy on survival after brain metastases and to investigate the relationship between anti-erbB2 therapy for brain metastases and: 1) the time interval between diagnosis of erb2+ breast cancer and brain metastasis, and 2) the occurrence of brain metastasis as the first site of disease progression. Inclusion Criteria: Female patients diagnosed with erbB2+ breast cancer. ErbB2 positivity will be as determined by respective institutional standards, and will be based on medical history only.
Brain metastasis diagnosis made between January 2006 - December 2008. Exclusion Criteria: Women who have another primary cancer diagnosed between the time of breast cancer diagnosis and brain metastasis..
Patient has leptomeningeal metastases only without parenchymal brain involvement (since this pattern of the disease requires a different treatment approach.) "
"[INST] Provide inclusion criteria for trial id: NCT01064349 [/INST] Female patients diagnosed with erbB2+ breast cancer. ErbB2 positivity will be as determined by respective institutional standards, and will be based on medical history only.
Brain metastasis diagnosis made between January 2006 - December 2008. "
"[INST] Provide exclusion criteria for trial id: NCT01064349 [/INST] Women who have another primary cancer diagnosed between the time of breast cancer diagnosis and brain metastasis..
Patient has leptomeningeal metastases only without parenchymal brain involvement (since this pattern of the disease requires a different treatment approach.) "
"[INST] Provide description for trial id: NCT01064349 [/INST] This retrospective cohort study aims to improve our understanding of the current paradigm for treatment of brain metastases in erbB2+ breast cancer patients in the Asia Pacific region. We aim to identify approximately 300 erbB2+ breast cancer patients with brain metastases diagnosed between 2006-2008 in 6 countries. Medical records will be analyzed to determine the treatment pattern for brain metastases, including anti-erbB2 therapy. Additional objectives are to understand the impact of anti-erbB2 therapy on survival after brain metastases and to investigate the relationship between anti-erbB2 therapy for brain metastases and: 1) the time interval between diagnosis of erb2+ breast cancer and brain metastasis, and 2) the occurrence of brain metastasis as the first site of disease progression. "
[INST] Provide title for trial id: NCT01064349 [/INST] Breast Cancer With Over-expression of erbB2-BRAINSTORM
[INST] Provide the recruitment status for trial id: NCT01064349 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT01064349 [/INST] Cancer
"Trial Id: RCT Comparing 2 Radiotherapy HypoFractionation Schedules In Breast Cancer Patients Recruitment Status: Unknown status Trail description: This is a prospective randomized Phase III trial to assess efficiency of two post mastectomy hypofractionation schedules (40 Gy /15 fx / 3 weeks, 5 days per week VS 28.5 Gy delivered in 5 once-weekly fractions of 5.7 Gy each week) as adjuvant radiotherapy in female patients with breast cancer after mastectomy. Inclusion Criteria: Invasive carcinoma of the breast.
Complete microscopic excision of primary tumour and axillary dissection or SLNB .
Females with locally advanced breast cancer ( T3/T4 or N + or both ) who are candidate for neoadjvant chemotherapy regardless pathological stage after mastectomy.
Patients with pathological stage (T3/ T4, +/- N+) or ( N+, any T) after upfront mastectomy.
Able to comply with follow up.
Written informed consent Exclusion Criteria: Patients do not match with inclusion criteria.
Collagen vascular disease, specifically systemic lupus, or scleroderma.
Pregnancy or lactation at the time of radiotherapy. "
"[INST] Provide inclusion criteria for trial id: NCT04550910 [/INST] Invasive carcinoma of the breast.
Complete microscopic excision of primary tumour and axillary dissection or SLNB .
Females with locally advanced breast cancer ( T3/T4 or N + or both ) who are candidate for neoadjvant chemotherapy regardless pathological stage after mastectomy.
Patients with pathological stage (T3/ T4, +/- N+) or ( N+, any T) after upfront mastectomy.
Able to comply with follow up.
Written informed consent "
"[INST] Provide exclusion criteria for trial id: NCT04550910 [/INST] Patients do not match with inclusion criteria.
Collagen vascular disease, specifically systemic lupus, or scleroderma.
Pregnancy or lactation at the time of radiotherapy. "
"[INST] Provide description for trial id: NCT04550910 [/INST] This is a prospective randomized Phase III trial to assess efficiency of two post mastectomy hypofractionation schedules (40 Gy /15 fx / 3 weeks, 5 days per week VS 28.5 Gy delivered in 5 once-weekly fractions of 5.7 Gy each week) as adjuvant radiotherapy in female patients with breast cancer after mastectomy. "
[INST] Provide title for trial id: NCT04550910 [/INST] RCT Comparing 2 Radiotherapy HypoFractionation Schedules In Breast Cancer Patients
[INST] Provide the recruitment status for trial id: NCT04550910 [/INST] Unknown status
"[INST] Provide the medical condition for trial id: NCT04550910 [/INST] Radiotherapy Side Effect, Locoregional Recurrence "
"Trial Id: Persistent Organic Pollutants and Breast Cancers (POPCASE) Recruitment Status: Recruiting Trail description: Exposure to certain classes of chemical contaminants, including certain persistent organic pollutants (POPs) with a character of endocrine disruptors, could be one of the factors that lead to increase incidence of breast cancer in the Western world .
However, the causal role of POPs in the onset of breast cancer remains nowadays unproven. Preliminary epidemiological studies on the impact of these environmental factors in breast cancer etiology have ignored the critical periods of exposure. Similarly, they have considered a limited number of pollutants (not including possible joint or synergistic effects between individual compounds) and did not distinguish the different breast cancer subtypes may have different etiologies or even of genetic susceptibility factors (POP polymorphism of detoxification enzymes).
Thus, POPCASE study examines the association between the presence of breast cancer and the levels and exposure profiles to a group of POPs measured in adipose tissue (AT) and blood, in particular using spectrometric methods developed by the team LABERCA (Nantes, France). These internal levels of POPs (organochlorine pesticides, dioxins, PCBs, brominated flame retardants) will be measured both quantitatively (tissue concentrations) and qualitative (relative proportions of different pollutants sought). Inclusion Criteria: Women ≥ 18 and <75 years
According to the arm:
Arm A: histologically confirmed diagnosis of invasive breast cancer (only), unilateral or bilateral, outside off recurrence and relapse. Patients who have been supported for a contralateral breast cancer can be included if a period of at least 2-years between the last systemic treatment of inclusion in the study.
Arm B: Any woman operated on for breast plastic surgery (breast lift and breast reduction cure only)
Performance status (WHO) ≤ 1
5. Patient affiliated to a social security scheme, 6. Patient who signed and dated informed consent form 7. Arm A only: unifocal lesion 8. Arm A only: Clinical stage M0 Exclusion Criteria: Patient with uncontrolled infection
Patient pregnant or lactating
Patient with a viral infection (HIV, Hepatitis B, Hepatitis C)
Patient cannot be regularly monitored for psychological reasons, social, family or geographical.
Patient Private of liberty or under a guardianship authority / curatorship.
Arm A only: Patient to benefit from neoadjuvant therapy for breast cancer
Arm A only Patient with metastatic breast cancer
Arm A only Patient diagnosed cancer in situ (intra ductal)
Arm A only Patient with BRCA1 or BRCA2 known
Arm B only: previous breast plastic surgery, regardless of the type of intervention "
"[INST] Provide inclusion criteria for trial id: NCT02890095 [/INST] Women ≥ 18 and <75 years
According to the arm:
Arm A: histologically confirmed diagnosis of invasive breast cancer (only), unilateral or bilateral, outside off recurrence and relapse. Patients who have been supported for a contralateral breast cancer can be included if a period of at least 2-years between the last systemic treatment of inclusion in the study.
Arm B: Any woman operated on for breast plastic surgery (breast lift and breast reduction cure only)
Performance status (WHO) ≤ 1
5. Patient affiliated to a social security scheme, 6. Patient who signed and dated informed consent form 7. Arm A only: unifocal lesion 8. Arm A only: Clinical stage M0 "
"[INST] Provide exclusion criteria for trial id: NCT02890095 [/INST] Patient with uncontrolled infection
Patient pregnant or lactating
Patient with a viral infection (HIV, Hepatitis B, Hepatitis C)
Patient cannot be regularly monitored for psychological reasons, social, family or geographical.
Patient Private of liberty or under a guardianship authority / curatorship.
Arm A only: Patient to benefit from neoadjuvant therapy for breast cancer
Arm A only Patient with metastatic breast cancer
Arm A only Patient diagnosed cancer in situ (intra ductal)
Arm A only Patient with BRCA1 or BRCA2 known
Arm B only: previous breast plastic surgery, regardless of the type of intervention "
"[INST] Provide description for trial id: NCT02890095 [/INST] Exposure to certain classes of chemical contaminants, including certain persistent organic pollutants (POPs) with a character of endocrine disruptors, could be one of the factors that lead to increase incidence of breast cancer in the Western world .
However, the causal role of POPs in the onset of breast cancer remains nowadays unproven. Preliminary epidemiological studies on the impact of these environmental factors in breast cancer etiology have ignored the critical periods of exposure. Similarly, they have considered a limited number of pollutants (not including possible joint or synergistic effects between individual compounds) and did not distinguish the different breast cancer subtypes may have different etiologies or even of genetic susceptibility factors (POP polymorphism of detoxification enzymes).
Thus, POPCASE study examines the association between the presence of breast cancer and the levels and exposure profiles to a group of POPs measured in adipose tissue (AT) and blood, in particular using spectrometric methods developed by the team LABERCA (Nantes, France). These internal levels of POPs (organochlorine pesticides, dioxins, PCBs, brominated flame retardants) will be measured both quantitatively (tissue concentrations) and qualitative (relative proportions of different pollutants sought). "
[INST] Provide title for trial id: NCT02890095 [/INST] Persistent Organic Pollutants and Breast Cancers (POPCASE)
[INST] Provide the recruitment status for trial id: NCT02890095 [/INST] Recruiting
[INST] Provide the medical condition for trial id: NCT02890095 [/INST] Breast Cancer
"Trial Id: Prospective Screening for Breast Cancer-related Lymphedema Recruitment Status: Recruiting Trail description: The primary objectives of this study are twofold: 1) to detect and determine the level of symptoms, functional disability, and changes in quality of life that breast cancer patients experience from changes in their arms during and after treatment for breast cancer by collecting patient reported outcome measures, objective measurements, and clinical information in a prospectively maintained database and 2) to improve breast cancer-related lymphedema outcomes by early detection using objective measurements and symptoms assessments and assess these outcomes by maintaining the data in a database in order to contribute to the literature. The secondary aim of this study is to assess extracellular fluid content in the upper extremity, breast, and/or trunk of patients treated for breast cancer before, during, and after treatment in order to better understand the role of bioimpedance spectroscopy in lymphedema screening. Inclusion Criteria: Confirmed diagnosis of breast cancer
Ability to obtain physical positioning for perometry (e.g. abducting shoulder to 90 degrees) and BIS measurements (e.g. standing without aid) Exclusion Criteria: Evidence of distant metastatic disease that may cause edema,
Previous breast cancer
History of lymphedema
Pregnancy at the time of accrual and/or cardiac implants (contraindications for BIS)
Medical conditions that cause fluid retention or swelling (e.g. axillary cancer recurrence, renal insufficiency, congestive heart failure). "
"[INST] Provide inclusion criteria for trial id: NCT01521741 [/INST] Confirmed diagnosis of breast cancer
Ability to obtain physical positioning for perometry (e.g. abducting shoulder to 90 degrees) and BIS measurements (e.g. standing without aid) "
"[INST] Provide exclusion criteria for trial id: NCT01521741 [/INST] Evidence of distant metastatic disease that may cause edema,
Previous breast cancer
History of lymphedema
Pregnancy at the time of accrual and/or cardiac implants (contraindications for BIS)
Medical conditions that cause fluid retention or swelling (e.g. axillary cancer recurrence, renal insufficiency, congestive heart failure). "
"[INST] Provide description for trial id: NCT01521741 [/INST] The primary objectives of this study are twofold: 1) to detect and determine the level of symptoms, functional disability, and changes in quality of life that breast cancer patients experience from changes in their arms during and after treatment for breast cancer by collecting patient reported outcome measures, objective measurements, and clinical information in a prospectively maintained database and 2) to improve breast cancer-related lymphedema outcomes by early detection using objective measurements and symptoms assessments and assess these outcomes by maintaining the data in a database in order to contribute to the literature. The secondary aim of this study is to assess extracellular fluid content in the upper extremity, breast, and/or trunk of patients treated for breast cancer before, during, and after treatment in order to better understand the role of bioimpedance spectroscopy in lymphedema screening. "
[INST] Provide title for trial id: NCT01521741 [/INST] Prospective Screening for Breast Cancer-related Lymphedema
[INST] Provide the recruitment status for trial id: NCT01521741 [/INST] Recruiting
[INST] Provide the medical condition for trial id: NCT01521741 [/INST] Lymphedema
"Trial Id: Role of Ultrasound-Guided Lymph Node Biopsy in Axillary Staging of Breast Cancer. Recruitment Status: Unknown status Trail description: The purpose of the study is to estimate the diagnostic accuracy of preoperative ultrasound-guided axillary lymph node biopsy for staging in patients with newly diagnosed breast cancer, and also to compare between ultrasound-guided fine needle aspiration cytology and core needle biopsy in their ability to detect metastatic disease in the axillary lymph nodes of patients with breast cancer. Inclusion Criteria: Newly diagnosed patients with operable breast cancer regardless of whether lymph nodes are suspicious or not. Exclusion Criteria: Patients who had previously undergone axillary surgery.
Patients with metastatic disease and not planned for axillary surgery.
Patients with a preoperative diagnosis of a benign lesion or ductal carcinoma in situ.
Patients with severe uncorrectable bleeding diathesis.
Patients refused to sign consent. "
[INST] Provide inclusion criteria for trial id: NCT03681418 [/INST] Newly diagnosed patients with operable breast cancer regardless of whether lymph nodes are suspicious or not.
"[INST] Provide exclusion criteria for trial id: NCT03681418 [/INST] Patients who had previously undergone axillary surgery.
Patients with metastatic disease and not planned for axillary surgery.
Patients with a preoperative diagnosis of a benign lesion or ductal carcinoma in situ.
Patients with severe uncorrectable bleeding diathesis.
Patients refused to sign consent. "
"[INST] Provide description for trial id: NCT03681418 [/INST] The purpose of the study is to estimate the diagnostic accuracy of preoperative ultrasound-guided axillary lymph node biopsy for staging in patients with newly diagnosed breast cancer, and also to compare between ultrasound-guided fine needle aspiration cytology and core needle biopsy in their ability to detect metastatic disease in the axillary lymph nodes of patients with breast cancer. "
[INST] Provide title for trial id: NCT03681418 [/INST] Role of Ultrasound-Guided Lymph Node Biopsy in Axillary Staging of Breast Cancer.
[INST] Provide the recruitment status for trial id: NCT03681418 [/INST] Unknown status
[INST] Provide the medical condition for trial id: NCT03681418 [/INST] Breast Cancer
Trial Id: Avoiding Low-value Treatments in Older Women With Early-stage Breast Cancer: Piloting a Patient Decision Aid Recruitment Status: Completed Trail description: The aim of this study is to learn whether participants find a patient guide to breast cancer treatment decisions acceptable and appropriate for use. Inclusion Criteria: None Exclusion Criteria: None
[INST] Provide inclusion criteria for trial id: NCT05140252 [/INST] None
[INST] Provide exclusion criteria for trial id: NCT05140252 [/INST] None
[INST] Provide description for trial id: NCT05140252 [/INST] The aim of this study is to learn whether participants find a patient guide to breast cancer treatment decisions acceptable and appropriate for use.
[INST] Provide title for trial id: NCT05140252 [/INST] Avoiding Low-value Treatments in Older Women With Early-stage Breast Cancer: Piloting a Patient Decision Aid
[INST] Provide the recruitment status for trial id: NCT05140252 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT05140252 [/INST] Breast Cancer
"Trial Id: Anti-Tumor Immunity Induced by Cryoablation of Invasive Breast Cancers Recruitment Status: Terminated Trail description: This protocol will study the impact of cryoablation on immune response in patients diagnosed with invasive breast cancers smaller than 1.5 cm. It will profile the immune response to cryoablation of invasive breast cancers. The intra-tumoral and systemic immune response to cryoablation will be determined and compared to pre-ablated breast cancer specimens and historical control specimens. Inclusion Criteria: Subjects with an invasive breast cancer 1.5 cm or less
The breast cancer must be of ductal histology, unifocal, estrogen receptor positive and her2/neu negative.
The tumor must be visible by ultrasound and the subject must not have had prior surgical resection of the primary lesion.
A clip marking the breast cancer must have been placed at the time of initial diagnosis or will be placed prior to cryotherapy.
The breast cancer must be amenable to cryoablation (visible by ultrasound and more than 2 mm from skin or chest wall).
Subjects with metastatic disease at diagnosis who elect to have their primary tumor excised are eligible for enrollment.
For subjects with breast implants, the treating physician must document that adequate distance exists between the lesion and the implant to ensure that the ablated lesion with not contact or jeopardize the implant.
Subjects must be able to provide consent. Exclusion Criteria: Subjects with breast cancers of lobular histology, with lymph vascular invasion or extensive intraductal component will be excluded.
Subjects with multi-centric or multi-focal breast cancers
Subjects with breast cancers that have invaded skin or have significant skin tethering (assessed clinically).
Subjects receiving chemotherapy within one year or undergoing neoadjuvant chemotherapy are excluded.
Subjects with metastatic disease at diagnosis will be excluded unless they elect definitive surgical therapy for their primary lesion.
Subjects with breast cancers not amenable to cryoablation (lesions not visible by ultrasound, against the chest wall or within 2 mm of skin) will be excluded.
Subjects diagnosed with another malignancy in the preceding 5 years will be excluded.
Subjects diagnosed with simultaneous bilateral breast cancer.
Subjects receiving immunosuppressive therapy within 6 months including oral steroids will be excluded. "
"[INST] Provide inclusion criteria for trial id: NCT01856036 [/INST] Subjects with an invasive breast cancer 1.5 cm or less
The breast cancer must be of ductal histology, unifocal, estrogen receptor positive and her2/neu negative.
The tumor must be visible by ultrasound and the subject must not have had prior surgical resection of the primary lesion.
A clip marking the breast cancer must have been placed at the time of initial diagnosis or will be placed prior to cryotherapy.
The breast cancer must be amenable to cryoablation (visible by ultrasound and more than 2 mm from skin or chest wall).
Subjects with metastatic disease at diagnosis who elect to have their primary tumor excised are eligible for enrollment.
For subjects with breast implants, the treating physician must document that adequate distance exists between the lesion and the implant to ensure that the ablated lesion with not contact or jeopardize the implant.
Subjects must be able to provide consent. "
"[INST] Provide exclusion criteria for trial id: NCT01856036 [/INST] Subjects with breast cancers of lobular histology, with lymph vascular invasion or extensive intraductal component will be excluded.
Subjects with multi-centric or multi-focal breast cancers
Subjects with breast cancers that have invaded skin or have significant skin tethering (assessed clinically).
Subjects receiving chemotherapy within one year or undergoing neoadjuvant chemotherapy are excluded.
Subjects with metastatic disease at diagnosis will be excluded unless they elect definitive surgical therapy for their primary lesion.
Subjects with breast cancers not amenable to cryoablation (lesions not visible by ultrasound, against the chest wall or within 2 mm of skin) will be excluded.
Subjects diagnosed with another malignancy in the preceding 5 years will be excluded.
Subjects diagnosed with simultaneous bilateral breast cancer.
Subjects receiving immunosuppressive therapy within 6 months including oral steroids will be excluded. "
[INST] Provide description for trial id: NCT01856036 [/INST] This protocol will study the impact of cryoablation on immune response in patients diagnosed with invasive breast cancers smaller than 1.5 cm. It will profile the immune response to cryoablation of invasive breast cancers. The intra-tumoral and systemic immune response to cryoablation will be determined and compared to pre-ablated breast cancer specimens and historical control specimens.
[INST] Provide title for trial id: NCT01856036 [/INST] Anti-Tumor Immunity Induced by Cryoablation of Invasive Breast Cancers
[INST] Provide the recruitment status for trial id: NCT01856036 [/INST] Terminated
[INST] Provide the medical condition for trial id: NCT01856036 [/INST] Breast Cancer
"Trial Id: Cluster Randomized Trial Comparing Interventions to Enhance Genetic Counseling Among Breast Cancer Patients Recruitment Status: Completed Trail description: RATIONALE: Multi-faceted provider education and decision support intervention will increase the rate of appropriate referral of breast cancer patients at increased risk for hereditary breast and ovarian cancer (HBOC) to genetic counseling.
PURPOSE: This cluster randomized controlled trial will compare active and passive interventions to increase the rate of appropriate genetic counseling referrals of newly diagnosed breast cancer patients at increased risk for HBOC to genetic counseling in the community oncology setting. Inclusion Criteria: None Exclusion Criteria: None "
[INST] Provide inclusion criteria for trial id: NCT01789684 [/INST] None
[INST] Provide exclusion criteria for trial id: NCT01789684 [/INST] None
"[INST] Provide description for trial id: NCT01789684 [/INST] RATIONALE: Multi-faceted provider education and decision support intervention will increase the rate of appropriate referral of breast cancer patients at increased risk for hereditary breast and ovarian cancer (HBOC) to genetic counseling.
PURPOSE: This cluster randomized controlled trial will compare active and passive interventions to increase the rate of appropriate genetic counseling referrals of newly diagnosed breast cancer patients at increased risk for HBOC to genetic counseling in the community oncology setting. "
[INST] Provide title for trial id: NCT01789684 [/INST] Cluster Randomized Trial Comparing Interventions to Enhance Genetic Counseling Among Breast Cancer Patients
[INST] Provide the recruitment status for trial id: NCT01789684 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT01789684 [/INST] Breast Cancer
"Trial Id: Benefits of Breast MRI for Predicting of Histopathologic Cell Type of Small Breast Cancer Recruitment Status: Unknown status Trail description: This study examines the additional benefits of magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features. Inclusion Criteria: Patients with invasive ductal carcinoma
Patients undergoing DCE-MRI scan which are assessed according to BI-RADS lexicon
Breast cancer patients with pathological diagnosed invasive ductal carcinoma with hormonal receptor (ER, PR and HER-2) response
Patients who have signed on informed consent form Patients will undergo MRI imaging and the physicians will practice according to practice guidelines. Exclusion Criteria: Patients under 18 years old or during pregnancy
Patients with MRI's contraindications e.g. patients with cardiac pacemaker or are allergic to MRI contrast agent Patients with unstable clinical abnormality and might get unexpected clinical treatment "
"[INST] Provide inclusion criteria for trial id: NCT01597999 [/INST] Patients with invasive ductal carcinoma
Patients undergoing DCE-MRI scan which are assessed according to BI-RADS lexicon
Breast cancer patients with pathological diagnosed invasive ductal carcinoma with hormonal receptor (ER, PR and HER-2) response
Patients who have signed on informed consent form Patients will undergo MRI imaging and the physicians will practice according to practice guidelines. "
"[INST] Provide exclusion criteria for trial id: NCT01597999 [/INST] Patients under 18 years old or during pregnancy
Patients with MRI's contraindications e.g. patients with cardiac pacemaker or are allergic to MRI contrast agent Patients with unstable clinical abnormality and might get unexpected clinical treatment "
[INST] Provide description for trial id: NCT01597999 [/INST] This study examines the additional benefits of magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features.
[INST] Provide title for trial id: NCT01597999 [/INST] Benefits of Breast MRI for Predicting of Histopathologic Cell Type of Small Breast Cancer
[INST] Provide the recruitment status for trial id: NCT01597999 [/INST] Unknown status
[INST] Provide the medical condition for trial id: NCT01597999 [/INST] Invasive Breast Cancer
"Trial Id: The Effect of a Patient Decision Aids for Breast Cancer Screening Recruitment Status: Unknown status Trail description: Breast cancer is one of the most common cancers in Chile. National efforts focus on early detection, offering universal access to breast cancer screening through mammography to women at risk age. However, 30% of women do not undertake the exam due to a lack of knowledge and anxiety when facing the decision. The aim of this study is to develop and evaluate the effectiveness of a decision aid (DA) for women facing breast cancer screening decision in the country. Methods: following the Medical Research Council guidelines for the development and implementation of a complex intervention in public health, the investigators have: 1) culturally adapted the German DA for mammography; 2) conducted focus groups with experts to further develop the DA; 3) pilot-tested the online DA with 20 women in primary care centres.
A total of 3,269 women aged 50 to 69 years old are invited to join the study. The intervention group accesses a webpage, answers a set of questionnaires at baseline, and then the DA (developed according to the IPDAS recommendations). The Control group accesses a webpage, answers a set of questionnaires at baseline, and then receives standardised information given by the healthcare system. Both groups complete the questionnaires two weeks later. The primary outcome measure is an adapted and validated version of Informed Choice. Additionally, decisional conflict, anxiety, and screening undertake rate are measured. Multiple lineal regression analysis will be conducted. Inclusion Criteria: Women from 50 to 69 years old
Attend the primary care centres
Fluent in Spanish Exclusion Criteria: Women with a personal history of breast cancer
Have a current mammogram (as recommended by the Chilean Ministry of Health)
Not having the capacity to consent. "
"[INST] Provide inclusion criteria for trial id: NCT04948983 [/INST] Women from 50 to 69 years old
Attend the primary care centres
Fluent in Spanish "
"[INST] Provide exclusion criteria for trial id: NCT04948983 [/INST] Women with a personal history of breast cancer
Have a current mammogram (as recommended by the Chilean Ministry of Health)
Not having the capacity to consent. "
"[INST] Provide description for trial id: NCT04948983 [/INST] Breast cancer is one of the most common cancers in Chile. National efforts focus on early detection, offering universal access to breast cancer screening through mammography to women at risk age. However, 30% of women do not undertake the exam due to a lack of knowledge and anxiety when facing the decision. The aim of this study is to develop and evaluate the effectiveness of a decision aid (DA) for women facing breast cancer screening decision in the country. Methods: following the Medical Research Council guidelines for the development and implementation of a complex intervention in public health, the investigators have: 1) culturally adapted the German DA for mammography; 2) conducted focus groups with experts to further develop the DA; 3) pilot-tested the online DA with 20 women in primary care centres.
A total of 3,269 women aged 50 to 69 years old are invited to join the study. The intervention group accesses a webpage, answers a set of questionnaires at baseline, and then the DA (developed according to the IPDAS recommendations). The Control group accesses a webpage, answers a set of questionnaires at baseline, and then receives standardised information given by the healthcare system. Both groups complete the questionnaires two weeks later. The primary outcome measure is an adapted and validated version of Informed Choice. Additionally, decisional conflict, anxiety, and screening undertake rate are measured. Multiple lineal regression analysis will be conducted. "
[INST] Provide title for trial id: NCT04948983 [/INST] The Effect of a Patient Decision Aids for Breast Cancer Screening
[INST] Provide the recruitment status for trial id: NCT04948983 [/INST] Unknown status
"[INST] Provide the medical condition for trial id: NCT04948983 [/INST] Breast Cancer, Mammary Cancer, Breast Tumor, Mammary Tumor "
"Trial Id: Case-Control-Study on the Breast Cancer Risk of Mirena® Compared With Copper IUDs Recruitment Status: Completed Trail description: The objective of this study is to determine the breast cancer risk of Mirena® users compared to copper intrauterine device (IUD) users in a community-based case-control study. Inclusion Criteria: cases: women with a breast cancer who are younger than 50 years of age at cancer diagnosis
controls: women without a breast cancer diagnosis who are younger than 50 years at the time of the interview Exclusion Criteria: women who are not willing to participate "
"[INST] Provide inclusion criteria for trial id: NCT00461253 [/INST] cases: women with a breast cancer who are younger than 50 years of age at cancer diagnosis
controls: women without a breast cancer diagnosis who are younger than 50 years at the time of the interview "
[INST] Provide exclusion criteria for trial id: NCT00461253 [/INST] women who are not willing to participate
[INST] Provide description for trial id: NCT00461253 [/INST] The objective of this study is to determine the breast cancer risk of Mirena® users compared to copper intrauterine device (IUD) users in a community-based case-control study.
[INST] Provide title for trial id: NCT00461253 [/INST] Case-Control-Study on the Breast Cancer Risk of Mirena® Compared With Copper IUDs
[INST] Provide the recruitment status for trial id: NCT00461253 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT00461253 [/INST] Breast Cancer
"Trial Id: Clinical Pilot Study for Personalized Risk-based Breast Cancer Screening Recruitment Status: Recruiting Trail description: The study aims to evaluate the impact of implementing population-based genetics testing strategy for breast cancer precision prevention using the polygenic risk score and monogenic pathogenic variant (MPV) testing in the Norwegian healthcare setting. Inclusion Criteria: Women referred for clinical mammography in the Vestre Viken Breast Centre
Breast density BI-RADS a or d
40-50 y.o. Exclusion Criteria: Prior history of breast cancer or premalignant breast disease
Prior genetic counselling/testing "
"[INST] Provide inclusion criteria for trial id: NCT05731453 [/INST] Women referred for clinical mammography in the Vestre Viken Breast Centre
Breast density BI-RADS a or d
40-50 y.o. "
"[INST] Provide exclusion criteria for trial id: NCT05731453 [/INST] Prior history of breast cancer or premalignant breast disease
Prior genetic counselling/testing "
[INST] Provide description for trial id: NCT05731453 [/INST] The study aims to evaluate the impact of implementing population-based genetics testing strategy for breast cancer precision prevention using the polygenic risk score and monogenic pathogenic variant (MPV) testing in the Norwegian healthcare setting.
[INST] Provide title for trial id: NCT05731453 [/INST] Clinical Pilot Study for Personalized Risk-based Breast Cancer Screening
[INST] Provide the recruitment status for trial id: NCT05731453 [/INST] Recruiting
[INST] Provide the medical condition for trial id: NCT05731453 [/INST] Breast Cancer
"Trial Id: Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging Recruitment Status: Withdrawn Trail description: The investigators have developed imaging protocols to monitor and predict breast cancer response to neoadjuvant chemotherapy, both prior to and as early as possible during the course of treatment.
The efficacy and practicality of conventional imaging approaches in the neoadjuvant chemotherapy setting varies and identifies the need for alternate functional imaging strategies. Diffuse optical spectroscopic imaging is an experimental imaging method that allows patients to be followed from baseline through treatment and surgery with a cost-effective, bedside, handheld scanning probe. The researcher evaluates a harmonized diffuse optical spectroscopic imaging technology platform that has been standardized for neoadjuvant chemotherapy monitoring. Diffuse optical spectroscopic imaging is an academic research platform that is non-invasive. Studies will be performed in five clinical sites on approximately 60 neoadjuvant chemotherapy patients. Inclusion Criteria: Female, 18 years of age or older, non pregnant or nursing.
Diagnosis of breast cancer and will be receiving chemo therapy treatments Exclusion Criteria: 18 years of age or younger, pregnant or nursing.
Previous treatment including chemo therapy, radiation, surgery, and hormone therapy.
Previous diagnosis with other form of cancer. "
"[INST] Provide inclusion criteria for trial id: NCT01257932 [/INST] Female, 18 years of age or older, non pregnant or nursing.
Diagnosis of breast cancer and will be receiving chemo therapy treatments "
"[INST] Provide exclusion criteria for trial id: NCT01257932 [/INST] 18 years of age or younger, pregnant or nursing.
Previous treatment including chemo therapy, radiation, surgery, and hormone therapy.
Previous diagnosis with other form of cancer. "
"[INST] Provide description for trial id: NCT01257932 [/INST] The investigators have developed imaging protocols to monitor and predict breast cancer response to neoadjuvant chemotherapy, both prior to and as early as possible during the course of treatment.
The efficacy and practicality of conventional imaging approaches in the neoadjuvant chemotherapy setting varies and identifies the need for alternate functional imaging strategies. Diffuse optical spectroscopic imaging is an experimental imaging method that allows patients to be followed from baseline through treatment and surgery with a cost-effective, bedside, handheld scanning probe. The researcher evaluates a harmonized diffuse optical spectroscopic imaging technology platform that has been standardized for neoadjuvant chemotherapy monitoring. Diffuse optical spectroscopic imaging is an academic research platform that is non-invasive. Studies will be performed in five clinical sites on approximately 60 neoadjuvant chemotherapy patients. "
[INST] Provide title for trial id: NCT01257932 [/INST] Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging
[INST] Provide the recruitment status for trial id: NCT01257932 [/INST] Withdrawn
[INST] Provide the medical condition for trial id: NCT01257932 [/INST] Breast Cancer
"Trial Id: Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer Recruitment Status: Not yet recruiting Trail description: To analyze the metabolic activity of Hormone Receptor Positive (HR+)/Her 2 Negative (Her2-) Breast cancer. Inclusion Criteria: Have hormone receptor (HR) positive [estrogen receptor( ER)+/progesterone receptor (PR)+, ER+/PR- or ER-/PR+)/Her2 negative breast cancer previously diagnosed by biopsy.
Have early stage, clinical or anatomic stage I, II or III breast cancer (cT1cN0, cT1cN1, cT2N0, cT2N1, cT3N0)
Candidates for intended curative primary resection who have not had neoadjuvant therapy (endocrine/hormonal therapy, chemotherapy with or without immunotherapy).
Willing to undergo mandatory intraoperative small excisional and core biopsies (4-6 passes) of tumor and normal tissue for research purposes at the time of proposed surgical resection. Exclusion Criteria: Is currently enrolled, or will enroll in, a different clinical study in which investigational therapeutic procedures are performed or investigational therapies are administered while participating in this study.
Has triple negative (ER-/PR-/Her2-) or HER2+ breast cancer.
Concomitant active malignancy
Is of child-bearing potential who has not had a recent negative pregnancy test done outside of this clinical trial (i.e., as part of standard preparation for diagnosis and treatment for her cancer) "
"[INST] Provide inclusion criteria for trial id: NCT05736367 [/INST] Have hormone receptor (HR) positive [estrogen receptor( ER)+/progesterone receptor (PR)+, ER+/PR- or ER-/PR+)/Her2 negative breast cancer previously diagnosed by biopsy.
Have early stage, clinical or anatomic stage I, II or III breast cancer (cT1cN0, cT1cN1, cT2N0, cT2N1, cT3N0)
Candidates for intended curative primary resection who have not had neoadjuvant therapy (endocrine/hormonal therapy, chemotherapy with or without immunotherapy).
Willing to undergo mandatory intraoperative small excisional and core biopsies (4-6 passes) of tumor and normal tissue for research purposes at the time of proposed surgical resection. "
"[INST] Provide exclusion criteria for trial id: NCT05736367 [/INST] Is currently enrolled, or will enroll in, a different clinical study in which investigational therapeutic procedures are performed or investigational therapies are administered while participating in this study.
Has triple negative (ER-/PR-/Her2-) or HER2+ breast cancer.
Concomitant active malignancy
Is of child-bearing potential who has not had a recent negative pregnancy test done outside of this clinical trial (i.e., as part of standard preparation for diagnosis and treatment for her cancer) "
[INST] Provide description for trial id: NCT05736367 [/INST] To analyze the metabolic activity of Hormone Receptor Positive (HR+)/Her 2 Negative (Her2-) Breast cancer.
[INST] Provide title for trial id: NCT05736367 [/INST] Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer
[INST] Provide the recruitment status for trial id: NCT05736367 [/INST] Not yet recruiting
[INST] Provide the medical condition for trial id: NCT05736367 [/INST] Breast Cancer
"Trial Id: Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis Recruitment Status: Completed Trail description: This is a Prospective Clinical Trial without drugs, to determine the HER2 status in the metastasis of patients with primary breast cancer HER2. 32 Sites have been taking part in this Clinical Trial. Inclusion Criteria: Patients who have given their written informed consent to participate in the study.
Women over 18 years.
Breast cancer locally recurrent or metastatic at first relapse or after successive progressions.
Patient has to have available a sample of the primary tumor in paraffin.
Patients who are planning for the next 6 weeks, the biopsy (fine needle aspiration / drainage of fluid cavities, open biopsy, core biopsy) of locally recurrent or metastatic lesion [local relapse in the chest wall, nodal , cutaneous or subcutaneous metastases, peripheral lymph nodes and other soft tissues accessible, bone metastases, visceral metastases (lung, liver, brain, etc..) or pleural effusion / ascites / pericardial / cerebrospinal] according to clinical practice center. Exclusion Criteria: Patients with cognitive impairment that might impede a proper understanding of the written informed consent, according to medical criteria.
Ipsilateral breast local relapses or contralateral breast away.
Patients diagnosed with a second neoplasm, with the exception of cervical carcinoma in situ and non-melanoma skin carcinoma treated properly. "
"[INST] Provide inclusion criteria for trial id: NCT01377363 [/INST] Patients who have given their written informed consent to participate in the study.
Women over 18 years.
Breast cancer locally recurrent or metastatic at first relapse or after successive progressions.
Patient has to have available a sample of the primary tumor in paraffin.
Patients who are planning for the next 6 weeks, the biopsy (fine needle aspiration / drainage of fluid cavities, open biopsy, core biopsy) of locally recurrent or metastatic lesion [local relapse in the chest wall, nodal , cutaneous or subcutaneous metastases, peripheral lymph nodes and other soft tissues accessible, bone metastases, visceral metastases (lung, liver, brain, etc..) or pleural effusion / ascites / pericardial / cerebrospinal] according to clinical practice center. "
"[INST] Provide exclusion criteria for trial id: NCT01377363 [/INST] Patients with cognitive impairment that might impede a proper understanding of the written informed consent, according to medical criteria.
Ipsilateral breast local relapses or contralateral breast away.
Patients diagnosed with a second neoplasm, with the exception of cervical carcinoma in situ and non-melanoma skin carcinoma treated properly. "
"[INST] Provide description for trial id: NCT01377363 [/INST] This is a Prospective Clinical Trial without drugs, to determine the HER2 status in the metastasis of patients with primary breast cancer HER2. 32 Sites have been taking part in this Clinical Trial. "
[INST] Provide title for trial id: NCT01377363 [/INST] Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis
[INST] Provide the recruitment status for trial id: NCT01377363 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT01377363 [/INST] Breast Cancer
"Trial Id: PROSPR/PCIPS Project 3: Communication of Personalized Breast Cancer Risk Recruitment Status: Completed Trail description: In order to better communicate personal risk of breast cancer to women who have not yet initiated breast cancer screening (mammography), The Annenberg School of Communication at the University of Pennsylvania has created a personal breast cancer screening decision aid tool. This tool will be pilot tested, and then implemented and tested in nine primary care and OB/GYN practices within the University of Pennsylvania Health System. Inclusion Criteria: Women ages 39-48
Patient of one of the nine primary care or OB/GYN practices that are participating in the study
Must have had an appointment at one of these locations in the past 24 months
Must have an appointment during the study period
Woman has not yet initiated breast cancer screening (no prior mammogram)
No history of breast cancer Exclusion Criteria: Prior diagnosis of breast cancer
Major comorbidity that substantially affects their 10 year mortality
Non-English speaker "
"[INST] Provide inclusion criteria for trial id: NCT01879189 [/INST] Women ages 39-48
Patient of one of the nine primary care or OB/GYN practices that are participating in the study
Must have had an appointment at one of these locations in the past 24 months
Must have an appointment during the study period
Woman has not yet initiated breast cancer screening (no prior mammogram)
No history of breast cancer "
"[INST] Provide exclusion criteria for trial id: NCT01879189 [/INST] Prior diagnosis of breast cancer
Major comorbidity that substantially affects their 10 year mortality
Non-English speaker "
"[INST] Provide description for trial id: NCT01879189 [/INST] In order to better communicate personal risk of breast cancer to women who have not yet initiated breast cancer screening (mammography), The Annenberg School of Communication at the University of Pennsylvania has created a personal breast cancer screening decision aid tool. This tool will be pilot tested, and then implemented and tested in nine primary care and OB/GYN practices within the University of Pennsylvania Health System. "
[INST] Provide title for trial id: NCT01879189 [/INST] PROSPR/PCIPS Project 3: Communication of Personalized Breast Cancer Risk
[INST] Provide the recruitment status for trial id: NCT01879189 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT01879189 [/INST] Breast Cancer
"Trial Id: Detection of Circulating Tumor Cells in Breast Cancer Patients Using a Novel Microfluidic and Raman Spectrum Device Recruitment Status: Unknown status Trail description: Circulating tumor cells (CTCs) in peripheral blood originate from breast cancer (primary and metastatic lesions) shedding. Utilization of CTCs as novel and noninvasive tests for diagnosis confirmation, therapy selection, and cancer surveillance is a rapidly growing area of interest. In this project, the investigators will explore a novel detection technology of circulating tumor cells in breast cancer using novel Microfluidic and Raman Spectrum Device. The primary objective is to demonstrate that the CTC assay counts technology can distinguish between healthy subjects and malignant breast cancer subjects. The secondary objective is to demonstrate that the CTCs detection technology can evaluate the efficacy of chemotherapy and neoadjuvant chemotherapy, as well as dynamic treatment monitoring and prognosis evaluation. Inclusion Criteria: All subjects need to sign the informed consent form.
Age of at least 20 and at most 70 years.
Cancer group subjects with pathology report confirmed to be malignant.
Chemotherapy is necessary before or after surgery.
Control group need to have mammogram /ultrasound results category1-3.
Patients must be available for and compliant to treatment and follow-up. Exclusion Criteria: Not willing to sign the informed consent form.
Pregnant or lactating patients.
Prior or concomitant secondary malignancy.
Any other serious medical pathology, such as congestive heart failure.
Other condition which may affect the CTC results.
Males. "
"[INST] Provide inclusion criteria for trial id: NCT04239105 [/INST] All subjects need to sign the informed consent form.
Age of at least 20 and at most 70 years.
Cancer group subjects with pathology report confirmed to be malignant.
Chemotherapy is necessary before or after surgery.
Control group need to have mammogram /ultrasound results category1-3.
Patients must be available for and compliant to treatment and follow-up. "
"[INST] Provide exclusion criteria for trial id: NCT04239105 [/INST] Not willing to sign the informed consent form.
Pregnant or lactating patients.
Prior or concomitant secondary malignancy.
Any other serious medical pathology, such as congestive heart failure.
Other condition which may affect the CTC results.
Males. "
"[INST] Provide description for trial id: NCT04239105 [/INST] Circulating tumor cells (CTCs) in peripheral blood originate from breast cancer (primary and metastatic lesions) shedding. Utilization of CTCs as novel and noninvasive tests for diagnosis confirmation, therapy selection, and cancer surveillance is a rapidly growing area of interest. In this project, the investigators will explore a novel detection technology of circulating tumor cells in breast cancer using novel Microfluidic and Raman Spectrum Device. The primary objective is to demonstrate that the CTC assay counts technology can distinguish between healthy subjects and malignant breast cancer subjects. The secondary objective is to demonstrate that the CTCs detection technology can evaluate the efficacy of chemotherapy and neoadjuvant chemotherapy, as well as dynamic treatment monitoring and prognosis evaluation. "
[INST] Provide title for trial id: NCT04239105 [/INST] Detection of Circulating Tumor Cells in Breast Cancer Patients Using a Novel Microfluidic and Raman Spectrum Device
[INST] Provide the recruitment status for trial id: NCT04239105 [/INST] Unknown status
"[INST] Provide the medical condition for trial id: NCT04239105 [/INST] Breast Neoplasms, Circulating Tumor Cells "
"Trial Id: Mobile Application Support for Women With Breast Cancer Undergoing Chemotherapy Recruitment Status: Recruiting Trail description: Mobile phones have become an essential tool for everyday life. The convenience and easy accessibility of the data and information received through mobile phones have made mobile applications as the latest trend to provide education for patients in medical centers. In Taiwan, breast cancer incidence has been the highest among all cancers and the fourth leading cause of cancer deaths in women. Women with breast cancer who are undergoing chemotherapy suffer from a number of symptoms throughout the chemotherapy treatment that detrimentally affects their quality of life. Thus, providing social support and nursing care aids for these vulnerable women is imperative to help them face their breast cancer challenges. This study will develop a Mobile device application providing medical care information and social support for breast cancer women during their chemotherapy treatment to help them receive individually tailored information related to chemotherapy and support from healthcare professionals and peers. This study will use a mixed-methods design to develop a Mobile device application based on breast cancer literature and the clinical experiences of breast cancer patients to fulfill the needs women may experience during the chemotherapy treatment. Women with breast cancer will be invited to help refine the Mobile device application's content based on their experiences and feedback about the mobile application. Upon completing the mobile application development, women with breast cancer patients will be recruited to participate in a randomized controlled trial to examine the effectiveness of the mobile application. The results of this study will provide a foundation to deliver a remote, personalized, and continuous health care model to improve the self-efficacy, social support, and quality of life of women with breast cancer, and ultimately enhancing the overall quality of care and patient satisfaction with the medical care participants receive. Inclusion Criteria: at least 20 years of age.
diagnosed with breast cancer for the first time.
treated with chemotherapy at the study sites.
able to access the internet with a mobile phone.
Fluent in spoken and written Chinese . Exclusion Criteria: patients with cognitive dysfunction.
diagnosed mental health problems.
having with other cancers. "
"[INST] Provide inclusion criteria for trial id: NCT05072197 [/INST] at least 20 years of age.
diagnosed with breast cancer for the first time.
treated with chemotherapy at the study sites.
able to access the internet with a mobile phone.
Fluent in spoken and written Chinese . "
"[INST] Provide exclusion criteria for trial id: NCT05072197 [/INST] patients with cognitive dysfunction.
diagnosed mental health problems.
having with other cancers. "
"[INST] Provide description for trial id: NCT05072197 [/INST] Mobile phones have become an essential tool for everyday life. The convenience and easy accessibility of the data and information received through mobile phones have made mobile applications as the latest trend to provide education for patients in medical centers. In Taiwan, breast cancer incidence has been the highest among all cancers and the fourth leading cause of cancer deaths in women. Women with breast cancer who are undergoing chemotherapy suffer from a number of symptoms throughout the chemotherapy treatment that detrimentally affects their quality of life. Thus, providing social support and nursing care aids for these vulnerable women is imperative to help them face their breast cancer challenges. This study will develop a Mobile device application providing medical care information and social support for breast cancer women during their chemotherapy treatment to help them receive individually tailored information related to chemotherapy and support from healthcare professionals and peers. This study will use a mixed-methods design to develop a Mobile device application based on breast cancer literature and the clinical experiences of breast cancer patients to fulfill the needs women may experience during the chemotherapy treatment. Women with breast cancer will be invited to help refine the Mobile device application's content based on their experiences and feedback about the mobile application. Upon completing the mobile application development, women with breast cancer patients will be recruited to participate in a randomized controlled trial to examine the effectiveness of the mobile application. The results of this study will provide a foundation to deliver a remote, personalized, and continuous health care model to improve the self-efficacy, social support, and quality of life of women with breast cancer, and ultimately enhancing the overall quality of care and patient satisfaction with the medical care participants receive. "
[INST] Provide title for trial id: NCT05072197 [/INST] Mobile Application Support for Women With Breast Cancer Undergoing Chemotherapy
[INST] Provide the recruitment status for trial id: NCT05072197 [/INST] Recruiting
[INST] Provide the medical condition for trial id: NCT05072197 [/INST] Breast Neoplasms
"Trial Id: Breast Cancer Proteomics and Molecular Heterogeneity Recruitment Status: Recruiting Trail description: Primary objective:
The primary objective is to define the proteomic and molecular characteristics of primary and recurrent/ metastatic breast tumours with special focus on the expression of S100 protein and the estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2) genes
Secondary objective:
To expand our understanding of the complex molecular pathways dictating the progression of breast cancer and their response to different treatment regimes.
To relate proteomic findings to survival data
To identify potential serum markers of breast cancer progression Inclusion Criteria: None Exclusion Criteria: None "
[INST] Provide inclusion criteria for trial id: NCT01840293 [/INST] None
[INST] Provide exclusion criteria for trial id: NCT01840293 [/INST] None
"[INST] Provide description for trial id: NCT01840293 [/INST] Primary objective:
The primary objective is to define the proteomic and molecular characteristics of primary and recurrent/ metastatic breast tumours with special focus on the expression of S100 protein and the estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2) genes
Secondary objective:
To expand our understanding of the complex molecular pathways dictating the progression of breast cancer and their response to different treatment regimes.
To relate proteomic findings to survival data
To identify potential serum markers of breast cancer progression "
[INST] Provide title for trial id: NCT01840293 [/INST] Breast Cancer Proteomics and Molecular Heterogeneity
[INST] Provide the recruitment status for trial id: NCT01840293 [/INST] Recruiting
"[INST] Provide the medical condition for trial id: NCT01840293 [/INST] Primary Breast Cancer, Recurrent/Metastatic Breast Cancer "
"Trial Id: Circulating Cancer Cells/Macrophage HYbrid Cells in Patients With Breast Cancer. Recruitment Status: Completed Trail description: Pilot, prospective, monocentric study aimed at evaluating the rate of patients with circulating cancer cell/macrophage hybrid cells in the peripheral blood.
The study will be conducted on a population of patients with breast cancer (regardless of stage of the disease and the immunohistochemical subtype).
For each included patient, blood samples will be taken and tumor specimens will be collected for the study.
At the end of the blood collection, the patient will have completed his participation in the study. Inclusion Criteria: Patient with breast cancer of any stage (stage I, II, III or IV) and any immunohistochemical subtype (triple-negative, HR+/HER2-negative or HER2-positive).
Patient not yet initiated on specific treatment for the stage of breast cancer at inclusion.
Available tumor sample (archived tumor block) : initial tumor or metastasis depending on the stage of the disease and availability.
Age ≥ 18 years old.
Patient affiliated to a Social Health Insurance in France.
Patient having signed informed consent prior to inclusion in the study and prior to any specific study procedure. Exclusion Criteria: Associated pathology(ies) that may prevent the proper conduct of the procedure under consideration.
Pregnant or breastfeeding woman.
Any psychological, family, geographical or sociological condition that prevents compliance with the medical follow-up and/or procedures of the study protocol.
Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship protection of justice).
Patient who has presented another solid tumor (except breast or cervix carcinoma in situ) within 5 years. "
"[INST] Provide inclusion criteria for trial id: NCT04818125 [/INST] Patient with breast cancer of any stage (stage I, II, III or IV) and any immunohistochemical subtype (triple-negative, HR+/HER2-negative or HER2-positive).
Patient not yet initiated on specific treatment for the stage of breast cancer at inclusion.
Available tumor sample (archived tumor block) : initial tumor or metastasis depending on the stage of the disease and availability.
Age ≥ 18 years old.
Patient affiliated to a Social Health Insurance in France.
Patient having signed informed consent prior to inclusion in the study and prior to any specific study procedure. "
"[INST] Provide exclusion criteria for trial id: NCT04818125 [/INST] Associated pathology(ies) that may prevent the proper conduct of the procedure under consideration.
Pregnant or breastfeeding woman.
Any psychological, family, geographical or sociological condition that prevents compliance with the medical follow-up and/or procedures of the study protocol.
Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship protection of justice).
Patient who has presented another solid tumor (except breast or cervix carcinoma in situ) within 5 years. "
"[INST] Provide description for trial id: NCT04818125 [/INST] Pilot, prospective, monocentric study aimed at evaluating the rate of patients with circulating cancer cell/macrophage hybrid cells in the peripheral blood.
The study will be conducted on a population of patients with breast cancer (regardless of stage of the disease and the immunohistochemical subtype).
For each included patient, blood samples will be taken and tumor specimens will be collected for the study.
At the end of the blood collection, the patient will have completed his participation in the study. "
[INST] Provide title for trial id: NCT04818125 [/INST] Circulating Cancer Cells/Macrophage HYbrid Cells in Patients With Breast Cancer.
[INST] Provide the recruitment status for trial id: NCT04818125 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT04818125 [/INST] Breast Cancer
"Trial Id: Blood Glycan Biomarkers in Women With Stage IV Breast Cancer Recruitment Status: Completed Trail description: RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur and identify biomarkers related to cancer.
PURPOSE: This research study is looking at blood glycan biomarkers in women with stage IV breast cancer. Inclusion Criteria: None Exclusion Criteria: None "
[INST] Provide inclusion criteria for trial id: NCT00897962 [/INST] None
[INST] Provide exclusion criteria for trial id: NCT00897962 [/INST] None
"[INST] Provide description for trial id: NCT00897962 [/INST] RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur and identify biomarkers related to cancer.
PURPOSE: This research study is looking at blood glycan biomarkers in women with stage IV breast cancer. "
[INST] Provide title for trial id: NCT00897962 [/INST] Blood Glycan Biomarkers in Women With Stage IV Breast Cancer
[INST] Provide the recruitment status for trial id: NCT00897962 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT00897962 [/INST] Breast Cancer
"Trial Id: Evaluation of Patients With Breast Cancer Using DCE-MRI, MRS, and Proteomics Recruitment Status: Completed Trail description: RATIONALE: Diagnostic procedures, such as dynamic contrast-enhanced magnetic resonance imaging(DCE-MRI), magnetic resonance spectroscopy (MRS), and tissue proteomics, may help doctors find and diagnose breast cancer and plan the best treatment.
PURPOSE: This clinical trial is studying MRI and MRS with or without tissue proteomics analysis to see how well they work in evaluating healthy women and women who are undergoing surgery for breast cancer. Inclusion Criteria: None Exclusion Criteria: None "
[INST] Provide inclusion criteria for trial id: NCT00656604 [/INST] None
[INST] Provide exclusion criteria for trial id: NCT00656604 [/INST] None
"[INST] Provide description for trial id: NCT00656604 [/INST] RATIONALE: Diagnostic procedures, such as dynamic contrast-enhanced magnetic resonance imaging(DCE-MRI), magnetic resonance spectroscopy (MRS), and tissue proteomics, may help doctors find and diagnose breast cancer and plan the best treatment.
PURPOSE: This clinical trial is studying MRI and MRS with or without tissue proteomics analysis to see how well they work in evaluating healthy women and women who are undergoing surgery for breast cancer. "
"[INST] Provide title for trial id: NCT00656604 [/INST] Evaluation of Patients With Breast Cancer Using DCE-MRI, MRS, and Proteomics "
[INST] Provide the recruitment status for trial id: NCT00656604 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT00656604 [/INST] Breast Cancer
"Trial Id: Awareness Scale Related To Physiotherapy After Breast Cancer: A Scale Development Study Recruitment Status: Recruiting Trail description: In this study, the aim is to develop a scale that assesses the awareness levels of particularly short and/or long-term effects, especially related to physiotherapy, in individuals diagnosed with high incidence and survival rates of breast cancer. Inclusion Criteria: Be over 18 years old
Be woman
Being diagnosed with breast cancer (individuals diagnosed with breast cancer who will start, start or have completed breast cancer treatment)
Being able to read and understand the Turkish language Exclusion Criteria: Having a cognitive impairment that interferes with answering questions
Be man "
"[INST] Provide inclusion criteria for trial id: NCT05992441 [/INST] Be over 18 years old
Be woman
Being diagnosed with breast cancer (individuals diagnosed with breast cancer who will start, start or have completed breast cancer treatment)
Being able to read and understand the Turkish language "
"[INST] Provide exclusion criteria for trial id: NCT05992441 [/INST] Having a cognitive impairment that interferes with answering questions
Be man "
"[INST] Provide description for trial id: NCT05992441 [/INST] In this study, the aim is to develop a scale that assesses the awareness levels of particularly short and/or long-term effects, especially related to physiotherapy, in individuals diagnosed with high incidence and survival rates of breast cancer. "
[INST] Provide title for trial id: NCT05992441 [/INST] Awareness Scale Related To Physiotherapy After Breast Cancer: A Scale Development Study
[INST] Provide the recruitment status for trial id: NCT05992441 [/INST] Recruiting
[INST] Provide the medical condition for trial id: NCT05992441 [/INST] Breast Cancer
"Trial Id: Big Data and Text-mining Technologies Applied for Breast Cancer Medical Data Analysis Recruitment Status: Unknown status Trail description: Primary purpose :
To develop a method to automatically extract and structure the information included in numerous medical records from breast cancer patients.
Secondary purpose :
With this procedure we can analyze the content of ten thousand anonymized textual medical records.
This information should enable us to explore many subjects, such as:
The impact of certain therapeutic procedures
The characteristics of sub-groups of patients
Pregnancy associated breast cancers
Risk factors Inclusion Criteria: Majority (age > 18)
Malignant breast tumors
signed informed consent Exclusion Criteria: Benign breast pathology
Patients not initially treated at the Hôpitaux Universitaires de Strasbourg "
"[INST] Provide inclusion criteria for trial id: NCT02810093 [/INST] Majority (age > 18)
Malignant breast tumors
signed informed consent "
"[INST] Provide exclusion criteria for trial id: NCT02810093 [/INST] Benign breast pathology
Patients not initially treated at the Hôpitaux Universitaires de Strasbourg "
"[INST] Provide description for trial id: NCT02810093 [/INST] Primary purpose :
To develop a method to automatically extract and structure the information included in numerous medical records from breast cancer patients.
Secondary purpose :
With this procedure we can analyze the content of ten thousand anonymized textual medical records.
This information should enable us to explore many subjects, such as:
The impact of certain therapeutic procedures
The characteristics of sub-groups of patients
Pregnancy associated breast cancers
Risk factors "
[INST] Provide title for trial id: NCT02810093 [/INST] Big Data and Text-mining Technologies Applied for Breast Cancer Medical Data Analysis
[INST] Provide the recruitment status for trial id: NCT02810093 [/INST] Unknown status
[INST] Provide the medical condition for trial id: NCT02810093 [/INST] Breast Cancer
"Trial Id: Prognostic and Predictive Factors for Small Breast Tumors Recruitment Status: Completed Trail description: Because of mammography screening increasingly more women are diagnosed with centimeter or subcentimeter node-negative breast cancer (i.e., T1abN0); these tumors account for approximately 19% of all newly diagnosed breast cancers in Sweden. Although the long term relapse-free survival rates among patients with such tumors is as high as ≥90%, some reports suggest that certain patient subgroups may have rates <75%. Firmly established prognostic and predictive factors for patients with T1abN0 tumors are, however, lacking. This is a nationwide, register-based cohort study investigating prognostic and predictive factors in women with centimeter or subcentimeter breast cancer. The study hypotheses are: 1) Established prognostic and/or predictive factors in overall breast cancer are prognostic and/or predictive factors also in centimeter or subcentimeter node-negative breast cancer; 2) The established relative reduction in risk of recurrence and death of adjuvant treatment for overall breast cancer are similar in centimeter or subcentimeter node-negative breast cancer. Inclusion Criteria: Female.
Operated for centimeter or subcentimeter breast cancer. Exclusion Criteria: Previous breast cancer.
Metastatic breast cancer at diagnosis. "
"[INST] Provide inclusion criteria for trial id: NCT03390608 [/INST] Female.
Operated for centimeter or subcentimeter breast cancer. "
"[INST] Provide exclusion criteria for trial id: NCT03390608 [/INST] Previous breast cancer.
Metastatic breast cancer at diagnosis. "
"[INST] Provide description for trial id: NCT03390608 [/INST] Because of mammography screening increasingly more women are diagnosed with centimeter or subcentimeter node-negative breast cancer (i.e., T1abN0); these tumors account for approximately 19% of all newly diagnosed breast cancers in Sweden. Although the long term relapse-free survival rates among patients with such tumors is as high as ≥90%, some reports suggest that certain patient subgroups may have rates <75%. Firmly established prognostic and predictive factors for patients with T1abN0 tumors are, however, lacking. This is a nationwide, register-based cohort study investigating prognostic and predictive factors in women with centimeter or subcentimeter breast cancer. The study hypotheses are: 1) Established prognostic and/or predictive factors in overall breast cancer are prognostic and/or predictive factors also in centimeter or subcentimeter node-negative breast cancer; 2) The established relative reduction in risk of recurrence and death of adjuvant treatment for overall breast cancer are similar in centimeter or subcentimeter node-negative breast cancer. "
[INST] Provide title for trial id: NCT03390608 [/INST] Prognostic and Predictive Factors for Small Breast Tumors
[INST] Provide the recruitment status for trial id: NCT03390608 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT03390608 [/INST] Breast Cancer
"Trial Id: Breast Cancer Molecular Analysis Protocol Recruitment Status: Completed Trail description: This is a molecular testing study for patients with metastatic breast cancer. The purpose of this study is to find defects in the DNA of the cancer that could potentially be treated with US Food and Drug Administration (FDA)approved or investigational drugs. For example, if your cancer has a mutation in the Epidermal Growth Factor Receptor (EGFR) gene (a mutation is a change int he DNA sequence of a gene) that makes this receptor ""superactive"" a drug that inhibits this receptor may also inhibit the growth of the cancer. If this genetic defect is not present in the cancer the same drug may not work. This EGFR gene mutation based patient selection for treatment has worked in lung cancer and we are testing its value in breast cancer. What drugs may be available against particular genetic abnormalities in the context of this clinical study will change over time. Inclusion Criteria: All patients with metastatic breast cancer who are considered for further systemic therapy are eligible regardless of number of prior therapies.
Patient must have a metastatic lesion that could be safely biopsied with or without image-guidance. The final arbiter to decide what lesion can be biopsied is the physician who will perform the biopsy.
There is no age limit for this study. However, this study will not include children because metastatic breast cancer does not occur in children.
Patients may participate in the biopsy study multiple times to repeat molecular assessment of the cancer after progression.
Patients who undergo routine clinical biopsy of metastatic breast cancer are also eligible to participate in this study. When the routine biopsies are obtained for diagnostic or other purposes, additional biopsies will be taken during the same biopsy session for molecular analysis. Exclusion Criteria: 1. Known medical contraindication for needle biopsy procedure such as bleeding disorder, low platelet count, inability to provide informed consent "
"[INST] Provide inclusion criteria for trial id: NCT01855503 [/INST] All patients with metastatic breast cancer who are considered for further systemic therapy are eligible regardless of number of prior therapies.
Patient must have a metastatic lesion that could be safely biopsied with or without image-guidance. The final arbiter to decide what lesion can be biopsied is the physician who will perform the biopsy.
There is no age limit for this study. However, this study will not include children because metastatic breast cancer does not occur in children.
Patients may participate in the biopsy study multiple times to repeat molecular assessment of the cancer after progression.
Patients who undergo routine clinical biopsy of metastatic breast cancer are also eligible to participate in this study. When the routine biopsies are obtained for diagnostic or other purposes, additional biopsies will be taken during the same biopsy session for molecular analysis. "
"[INST] Provide exclusion criteria for trial id: NCT01855503 [/INST] 1. Known medical contraindication for needle biopsy procedure such as bleeding disorder, low platelet count, inability to provide informed consent "
"[INST] Provide description for trial id: NCT01855503 [/INST] This is a molecular testing study for patients with metastatic breast cancer. The purpose of this study is to find defects in the DNA of the cancer that could potentially be treated with US Food and Drug Administration (FDA)approved or investigational drugs. For example, if your cancer has a mutation in the Epidermal Growth Factor Receptor (EGFR) gene (a mutation is a change int he DNA sequence of a gene) that makes this receptor ""superactive"" a drug that inhibits this receptor may also inhibit the growth of the cancer. If this genetic defect is not present in the cancer the same drug may not work. This EGFR gene mutation based patient selection for treatment has worked in lung cancer and we are testing its value in breast cancer. What drugs may be available against particular genetic abnormalities in the context of this clinical study will change over time. "
[INST] Provide title for trial id: NCT01855503 [/INST] Breast Cancer Molecular Analysis Protocol
[INST] Provide the recruitment status for trial id: NCT01855503 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT01855503 [/INST] Metastatic Breast Cancer
"Trial Id: Breast Cancer and Breast Self-examination Education Recruitment Status: Recruiting Trail description: According to a news published by the World Health Organization (WHO); More than 2.3 million cases of breast cancer occur each year, making it the most common cancer among adults. In 95% of all countries, breast cancer is the first or second cause of female cancer death. In 2020, 2.3 million women worldwide were diagnosed with breast cancer and 685,000 deaths occurred (WHO, 2023; https://www.who.int/news/item/03-02-2023-who-launches-new-roadmap- on-breast-cancer). In our country, breast cancer ranks first among the most common cancer types in women, and the number of breast cancer cases in women in 2020 was recorded as 74 638 (IARC, 2023). As a result of this situation, WHO (2023) published the Global Breast Cancer Initiative Framework to save 2.5 million lives from breast cancer by 2040. This published framework includes health promotion for early detection, timely diagnosis and comprehensive management of breast cancer.
One of the most effective ways to reduce breast cancer mortality and morbidity rate is early diagnosis. It is important to determine early diagnosis and signs and symptoms of cancer before they appear. Early diagnosis of breast cancer is possible with breast self-examination (BSE), clinical breast examination and mammography (Kayar, 2019). Breast self-examination is an important examination method in terms of detecting changes in breast tissue and preventing subsequent complications (Abo Al-Shiekh et al., 2021). It is also an easy-to-apply, cheap and non-invasive method. In our country, it is recommended that women regularly perform breast self-examination every month after the age of 20, women between the ages of 20 and 40 should have a clinical breast examination every two years, and women between the ages of 40 and 69 should have a clinical breast examination every year and have a mammogram every two years (Ministry of Health, 2019). .
There are studies showing that fear of breast cancer has a positive and negative impact on early diagnosis behaviors (Champion et al., 2004; Yavan et al., 2010). Champion et al. (2004) stated that women with moderate breast cancer fear had a high rate of early detection behavior, whereas low and high fear levels had a negative effect on behavior. In the study conducted by Yavan et al. (2010) on 188 women, 2% of the women. They found that 3 of them had regular BSE and 78.7% of them had never had a mammography. In addition, 85% of the women included in the study stated that they had a fear of breast cancer due to a family history of breast cancer, being diagnosed with breast cancer, and the presence of risk factors. Study results show that fear of breast cancer affects screening results. Therefore, our aim in the study is; To determine the effect of breast cancer and BSE training given to women on breast cancer fear and BSE skills. Inclusion Criteria: Able to read and write, Having no history of breast cancer, No communication barriers, Not pregnant or lactating, Those who are willing and agree to participate in the research. Exclusion Criteria: Having a mental illness, Those who wish to withdraw from any part of the research. "
"[INST] Provide inclusion criteria for trial id: NCT06371508 [/INST] Able to read and write, Having no history of breast cancer, No communication barriers, Not pregnant or lactating, Those who are willing and agree to participate in the research. "
"[INST] Provide exclusion criteria for trial id: NCT06371508 [/INST] Having a mental illness, Those who wish to withdraw from any part of the research. "
"[INST] Provide description for trial id: NCT06371508 [/INST] According to a news published by the World Health Organization (WHO); More than 2.3 million cases of breast cancer occur each year, making it the most common cancer among adults. In 95% of all countries, breast cancer is the first or second cause of female cancer death. In 2020, 2.3 million women worldwide were diagnosed with breast cancer and 685,000 deaths occurred (WHO, 2023; https://www.who.int/news/item/03-02-2023-who-launches-new-roadmap- on-breast-cancer). In our country, breast cancer ranks first among the most common cancer types in women, and the number of breast cancer cases in women in 2020 was recorded as 74 638 (IARC, 2023). As a result of this situation, WHO (2023) published the Global Breast Cancer Initiative Framework to save 2.5 million lives from breast cancer by 2040. This published framework includes health promotion for early detection, timely diagnosis and comprehensive management of breast cancer.
One of the most effective ways to reduce breast cancer mortality and morbidity rate is early diagnosis. It is important to determine early diagnosis and signs and symptoms of cancer before they appear. Early diagnosis of breast cancer is possible with breast self-examination (BSE), clinical breast examination and mammography (Kayar, 2019). Breast self-examination is an important examination method in terms of detecting changes in breast tissue and preventing subsequent complications (Abo Al-Shiekh et al., 2021). It is also an easy-to-apply, cheap and non-invasive method. In our country, it is recommended that women regularly perform breast self-examination every month after the age of 20, women between the ages of 20 and 40 should have a clinical breast examination every two years, and women between the ages of 40 and 69 should have a clinical breast examination every year and have a mammogram every two years (Ministry of Health, 2019). .
There are studies showing that fear of breast cancer has a positive and negative impact on early diagnosis behaviors (Champion et al., 2004; Yavan et al., 2010). Champion et al. (2004) stated that women with moderate breast cancer fear had a high rate of early detection behavior, whereas low and high fear levels had a negative effect on behavior. In the study conducted by Yavan et al. (2010) on 188 women, 2% of the women. They found that 3 of them had regular BSE and 78.7% of them had never had a mammography. In addition, 85% of the women included in the study stated that they had a fear of breast cancer due to a family history of breast cancer, being diagnosed with breast cancer, and the presence of risk factors. Study results show that fear of breast cancer affects screening results. Therefore, our aim in the study is; To determine the effect of breast cancer and BSE training given to women on breast cancer fear and BSE skills. "
[INST] Provide title for trial id: NCT06371508 [/INST] Breast Cancer and Breast Self-examination Education
[INST] Provide the recruitment status for trial id: NCT06371508 [/INST] Recruiting
"[INST] Provide the medical condition for trial id: NCT06371508 [/INST] Breast Cancer, Breast Self-Examination "
"Trial Id: Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer Recruitment Status: Completed Trail description: In this prospective study the investigators sought to evaluate the feasibility of using the genomic signature - Genomic Grade Index (GGI) - in routine clinical practice and its impact on treatment recommendations. Inclusion Criteria: Histologically confirmed invasive breast cancer meeting the following criteria:
T1, T2, or operable T3 disease
Zero to three positive lymph nodes and no distant metastases
Operable disease - Must have undergone breast-conserving surgery or mastectomy with either a sentinel node procedure or full axillary clearance Exclusion Criteria: No other invasive cancer within the past 5 years except for adequately treated carcinoma in situ of the cervix or non melanoma skin cancer
No psychological, familial, sociological, or geographical condition that would preclude entering into a clinical study "
"[INST] Provide inclusion criteria for trial id: NCT01916837 [/INST] Histologically confirmed invasive breast cancer meeting the following criteria:
T1, T2, or operable T3 disease
Zero to three positive lymph nodes and no distant metastases
Operable disease - Must have undergone breast-conserving surgery or mastectomy with either a sentinel node procedure or full axillary clearance "
"[INST] Provide exclusion criteria for trial id: NCT01916837 [/INST] No other invasive cancer within the past 5 years except for adequately treated carcinoma in situ of the cervix or non melanoma skin cancer
No psychological, familial, sociological, or geographical condition that would preclude entering into a clinical study "
[INST] Provide description for trial id: NCT01916837 [/INST] In this prospective study the investigators sought to evaluate the feasibility of using the genomic signature - Genomic Grade Index (GGI) - in routine clinical practice and its impact on treatment recommendations.
[INST] Provide title for trial id: NCT01916837 [/INST] Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer
[INST] Provide the recruitment status for trial id: NCT01916837 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT01916837 [/INST] Invasive Breast Cancer
"Trial Id: Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software Recruitment Status: Completed Trail description: Patients with early breast cancer were randomized at the final visit of adjuvant radiotherapy to surveillance by phone calls or by mobile Noona software. After six months the groups were crossed over to the other arm. At 12 months the patients were asked their preference which was the primary end-point. At baseline, 6 months and 12 months the patients answered the other questionnaires. Inclusion Criteria: Adult patients with early breast cancer after primary treatment including also radiotherapy (the patients were randomized at the final visit of radiotherapy) Exclusion Criteria: not able to use a computer
another malignancy "
[INST] Provide inclusion criteria for trial id: NCT04980989 [/INST] Adult patients with early breast cancer after primary treatment including also radiotherapy (the patients were randomized at the final visit of radiotherapy)
"[INST] Provide exclusion criteria for trial id: NCT04980989 [/INST] not able to use a computer
another malignancy "
"[INST] Provide description for trial id: NCT04980989 [/INST] Patients with early breast cancer were randomized at the final visit of adjuvant radiotherapy to surveillance by phone calls or by mobile Noona software. After six months the groups were crossed over to the other arm. At 12 months the patients were asked their preference which was the primary end-point. At baseline, 6 months and 12 months the patients answered the other questionnaires. "
[INST] Provide title for trial id: NCT04980989 [/INST] Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software
[INST] Provide the recruitment status for trial id: NCT04980989 [/INST] Completed
"[INST] Provide the medical condition for trial id: NCT04980989 [/INST] Breast Cancer, Early-Onset "
"Trial Id: The Development of a Personalized Decision Aid: Perspectives of Patients and Health Care Professionals on Shared Decision Making and Informational Needs on Radiotherapy for Breast Cancer Recruitment Status: Completed Trail description: Background: The Dutch guideline on breast cancer treatment shows several grey areas, where no clear recommendation is given on the radiotherapy options, but where the advice is to discuss the treatment of choice with the patient. Currently, patients are exposed to different information given by the professionals' personal styles of informing patients. The challenge for all oncological professionals is to give clear, structured, and neutral information on the pros and cons of the treatment option(s) in the context of the natural course of the disease to the patient; to elicit patients' needs and preferences. How and which information should be shared in a decision aid is up for investigation, as well as how this should best be implemented.
Research goals: Qualitative assessment of patients' and health care professionals' informational needs and perspectives on breast cancer radiotherapy and shard decision making.
Methods: Semi-structured interviews will be held with both breast cancer patients and health care professionals. To reach as heterogeneous groups as possible patients of different ages, with different education levels and who underwent different treatments or chose not to get radiotherapy at all will be selected . Data will be collected til saturation is reached. Interviews will be transcribed verbatim and analysed using thematic analysis.
Results: Results of the qualitative study are expected at the beginning of 2017.
Hypothesis: Investigating the patients' and health care professionals' perspectives on shared decision making and informational needs on radiotherapeutic options will help the development of a personalized decision aid eligible for broad implementation. Inclusion Criteria: 2-3 months after facing decision or > 1 year after decision
able to speak and understand Dutch
Written informed consent Exclusion Criteria: recurrence of breast cancer prior to interview "
"[INST] Provide inclusion criteria for trial id: NCT02934126 [/INST] 2-3 months after facing decision or > 1 year after decision
able to speak and understand Dutch
Written informed consent "
[INST] Provide exclusion criteria for trial id: NCT02934126 [/INST] recurrence of breast cancer prior to interview
"[INST] Provide description for trial id: NCT02934126 [/INST] Background: The Dutch guideline on breast cancer treatment shows several grey areas, where no clear recommendation is given on the radiotherapy options, but where the advice is to discuss the treatment of choice with the patient. Currently, patients are exposed to different information given by the professionals' personal styles of informing patients. The challenge for all oncological professionals is to give clear, structured, and neutral information on the pros and cons of the treatment option(s) in the context of the natural course of the disease to the patient; to elicit patients' needs and preferences. How and which information should be shared in a decision aid is up for investigation, as well as how this should best be implemented.
Research goals: Qualitative assessment of patients' and health care professionals' informational needs and perspectives on breast cancer radiotherapy and shard decision making.
Methods: Semi-structured interviews will be held with both breast cancer patients and health care professionals. To reach as heterogeneous groups as possible patients of different ages, with different education levels and who underwent different treatments or chose not to get radiotherapy at all will be selected . Data will be collected til saturation is reached. Interviews will be transcribed verbatim and analysed using thematic analysis.
Results: Results of the qualitative study are expected at the beginning of 2017.
Hypothesis: Investigating the patients' and health care professionals' perspectives on shared decision making and informational needs on radiotherapeutic options will help the development of a personalized decision aid eligible for broad implementation. "
[INST] Provide title for trial id: NCT02934126 [/INST] The Development of a Personalized Decision Aid: Perspectives of Patients and Health Care Professionals on Shared Decision Making and Informational Needs on Radiotherapy for Breast Cancer
[INST] Provide the recruitment status for trial id: NCT02934126 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT02934126 [/INST] Breast Cancer
"Trial Id: Individualized Risk-Based Education in Promoting Breast Cancer Screening in Healthy Women Recruitment Status: Completed Trail description: RATIONALE: Education, based on a patient's risk factors, may help promote breast cancer screening in healthy women.
PURPOSE: This randomized clinical trial is studying individualized risk-based education to see how well it promotes breast cancer screening in healthy women compared to standard education. Inclusion Criteria: None Exclusion Criteria: None "
[INST] Provide inclusion criteria for trial id: NCT00416975 [/INST] None
[INST] Provide exclusion criteria for trial id: NCT00416975 [/INST] None
"[INST] Provide description for trial id: NCT00416975 [/INST] RATIONALE: Education, based on a patient's risk factors, may help promote breast cancer screening in healthy women.
PURPOSE: This randomized clinical trial is studying individualized risk-based education to see how well it promotes breast cancer screening in healthy women compared to standard education. "
[INST] Provide title for trial id: NCT00416975 [/INST] Individualized Risk-Based Education in Promoting Breast Cancer Screening in Healthy Women
[INST] Provide the recruitment status for trial id: NCT00416975 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT00416975 [/INST] Breast Cancer
"Trial Id: Treatment Decision Impact of OncotypeDX™ in HR+, N- Breast Cancer Patients Recruitment Status: Completed Trail description: Primary objective:
Determine the impact of the Oncotype DX Recurrence Score (RS) on the treatment recommendation made (administration of chemotherapy or not, in addition to hormonotherapy) in a HR+, N- or pN1(mi), Her2- breast cancer adjuvant population.
The impact of Oncotype DX on treatment recommendations can be either a decrease in treatment intensity defined as a change in treatment recommendation from chemotherapy plus hormonal therapy to hormonal therapy alone or an increase in treatment intensity defined as a movement from hormonal therapy alone to the addition of chemotherapy to hormonal therapy.
Patients with HR+, N- breast cancer currently represent around 70% of newly diagnosed breast cancers. These are usually good prognosis tumors. However, on the basis of classical clinical and pathological prognostic parameters and markers, the international consensus guidelines recommend treatment with hormone- and chemotherapy in 85-95% of the cases. Considering the natural disease history, such as documented by the EBCTCG meta-analysis, more than 50% of these patients are overtreated, which leads to unnecessary side effects and costs to the health system and to the society.
Oncotype DX appears to be well adapted to therapeutic de-escalation as it targets HR+, N- patients and is performed on fixed paraffin embedded tissue (FPET). It is therefore best adapted to daily clinical practice as it does not necessitate any specific surgical procedure or tissue freezing.
The prognostic and predictive value of Oncotype DX in ER+, N- patients has been validated on three large adjuvant randomized trials (NASBP B-14, NSABP B-20, and the ATAC study). The test has been commercially available in the USA since 2004, and is being used for more than 50% of the HR+ N- patients in this country.
While Oncotype DX has been validated in the USA, it needs to be independently evaluated in France, in the context of the local treatment guidelines and habits, to provide data that are meaningful to the French health system and to the French medical community. Inclusion Criteria: Patients > 18 years old.
Pre- or post- menopausal women with breast adenocarcinoma, confirmed by a pathologist and who underwent surgery, with a maximum of 4 weeks between surgery and the 2nd therapeutic decision with Oncotype DX.
HR positive (at least ER+) breast cancer patients (defined by a threshold of 10% of the cells IHC + without N- or pN1(mi), Her2 - (IHC0, 1, 2+ or FISH -)
Patients must be eligible to receive adjuvant chemotherapy as defined by a good Karnofsky index, no hematological, cardiological or hepatic contraindications nor any impeding comorbidity.
Patients must have given a written informed consent. Exclusion Criteria: T3 or T4, HR-, N+ (except pN1 (mi) (sn), Her2+ (IHC 3+ or Fish+) patients.
Metastatic patients.
Patients who cannot give an informed consent.
Patients who cannot receive chemotherapy.
Patient who participated in another clinical trial and is still in the exclusion period of any other trial.
Mentally disabled patient who has no legal responsibility for herself. "
"[INST] Provide inclusion criteria for trial id: NCT01446185 [/INST] Patients > 18 years old.
Pre- or post- menopausal women with breast adenocarcinoma, confirmed by a pathologist and who underwent surgery, with a maximum of 4 weeks between surgery and the 2nd therapeutic decision with Oncotype DX.
HR positive (at least ER+) breast cancer patients (defined by a threshold of 10% of the cells IHC + without N- or pN1(mi), Her2 - (IHC0, 1, 2+ or FISH -)
Patients must be eligible to receive adjuvant chemotherapy as defined by a good Karnofsky index, no hematological, cardiological or hepatic contraindications nor any impeding comorbidity.
Patients must have given a written informed consent. "
"[INST] Provide exclusion criteria for trial id: NCT01446185 [/INST] T3 or T4, HR-, N+ (except pN1 (mi) (sn), Her2+ (IHC 3+ or Fish+) patients.
Metastatic patients.
Patients who cannot give an informed consent.
Patients who cannot receive chemotherapy.
Patient who participated in another clinical trial and is still in the exclusion period of any other trial.
Mentally disabled patient who has no legal responsibility for herself. "
"[INST] Provide description for trial id: NCT01446185 [/INST] Primary objective:
Determine the impact of the Oncotype DX Recurrence Score (RS) on the treatment recommendation made (administration of chemotherapy or not, in addition to hormonotherapy) in a HR+, N- or pN1(mi), Her2- breast cancer adjuvant population.
The impact of Oncotype DX on treatment recommendations can be either a decrease in treatment intensity defined as a change in treatment recommendation from chemotherapy plus hormonal therapy to hormonal therapy alone or an increase in treatment intensity defined as a movement from hormonal therapy alone to the addition of chemotherapy to hormonal therapy.
Patients with HR+, N- breast cancer currently represent around 70% of newly diagnosed breast cancers. These are usually good prognosis tumors. However, on the basis of classical clinical and pathological prognostic parameters and markers, the international consensus guidelines recommend treatment with hormone- and chemotherapy in 85-95% of the cases. Considering the natural disease history, such as documented by the EBCTCG meta-analysis, more than 50% of these patients are overtreated, which leads to unnecessary side effects and costs to the health system and to the society.
Oncotype DX appears to be well adapted to therapeutic de-escalation as it targets HR+, N- patients and is performed on fixed paraffin embedded tissue (FPET). It is therefore best adapted to daily clinical practice as it does not necessitate any specific surgical procedure or tissue freezing.
The prognostic and predictive value of Oncotype DX in ER+, N- patients has been validated on three large adjuvant randomized trials (NASBP B-14, NSABP B-20, and the ATAC study). The test has been commercially available in the USA since 2004, and is being used for more than 50% of the HR+ N- patients in this country.
While Oncotype DX has been validated in the USA, it needs to be independently evaluated in France, in the context of the local treatment guidelines and habits, to provide data that are meaningful to the French health system and to the French medical community. "
"[INST] Provide title for trial id: NCT01446185 [/INST] Treatment Decision Impact of OncotypeDX™ in HR+, N- Breast Cancer Patients "
[INST] Provide the recruitment status for trial id: NCT01446185 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT01446185 [/INST] Breast Cancer
"Trial Id: Know Your Risk: Assessment at Screening for Breast Cancer - Pilot Study Recruitment Status: Completed Trail description: The purpose of this pilot study is to evaluate a decision support website (RealRisks) designed to inform patients about breast cancer chemoprevention. It is coupled with a physician-centered (BNAV) decision support website as part of clinical workflow in the primary care setting. The investigator hypothesizes that improving accuracy of breast cancer risk perception and understanding of the risks/benefits of chemoprevention will enhance informed decision-making and uptake of breast cancer prevention strategies in the primary care setting. Inclusion Criteria: 5-year breast risk of 1.67% or lifetime risk of 20% according to the Gail model
The participant understands and is willing to provide informed consent in English or Spanish
Has a primary care provider at Columbia University Medical Center (CUMC) / New York-Presbyterian Hospital Exclusion Criteria: Prior use of a selective estrogen receptor modulator (SERM) or aromatase inhibitor (AI) for chemoprevention
Prior history of breast cancer "
"[INST] Provide inclusion criteria for trial id: NCT02954900 [/INST] 5-year breast risk of 1.67% or lifetime risk of 20% according to the Gail model
The participant understands and is willing to provide informed consent in English or Spanish
Has a primary care provider at Columbia University Medical Center (CUMC) / New York-Presbyterian Hospital "
"[INST] Provide exclusion criteria for trial id: NCT02954900 [/INST] Prior use of a selective estrogen receptor modulator (SERM) or aromatase inhibitor (AI) for chemoprevention
Prior history of breast cancer "
[INST] Provide description for trial id: NCT02954900 [/INST] The purpose of this pilot study is to evaluate a decision support website (RealRisks) designed to inform patients about breast cancer chemoprevention. It is coupled with a physician-centered (BNAV) decision support website as part of clinical workflow in the primary care setting. The investigator hypothesizes that improving accuracy of breast cancer risk perception and understanding of the risks/benefits of chemoprevention will enhance informed decision-making and uptake of breast cancer prevention strategies in the primary care setting.
[INST] Provide title for trial id: NCT02954900 [/INST] Know Your Risk: Assessment at Screening for Breast Cancer - Pilot Study
[INST] Provide the recruitment status for trial id: NCT02954900 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT02954900 [/INST] Breast Neoplasms
"Trial Id: Transgender and Gender-Diverse Breast Cancer Screening Pilot Recruitment Status: Recruiting Trail description: This investigation is a prospective breast cancer screening study open to all transgender and gender-diverse persons (regardless of sex assigned at birth). Using a mixed methods approach, the study will 1) gather prospective quantitative breast imaging data in conjunction with gender-affirming therapy and family cancer history and 2) investigate TGD persons perceptions and experiences in the breast cancer screening program, and 3) identify individual and systems-level barriers to breast cancer screening. Inclusion Criteria: None Exclusion Criteria: None "
[INST] Provide inclusion criteria for trial id: NCT06383026 [/INST] None
[INST] Provide exclusion criteria for trial id: NCT06383026 [/INST] None
"[INST] Provide description for trial id: NCT06383026 [/INST] This investigation is a prospective breast cancer screening study open to all transgender and gender-diverse persons (regardless of sex assigned at birth). Using a mixed methods approach, the study will 1) gather prospective quantitative breast imaging data in conjunction with gender-affirming therapy and family cancer history and 2) investigate TGD persons perceptions and experiences in the breast cancer screening program, and 3) identify individual and systems-level barriers to breast cancer screening. "
[INST] Provide title for trial id: NCT06383026 [/INST] Transgender and Gender-Diverse Breast Cancer Screening Pilot
[INST] Provide the recruitment status for trial id: NCT06383026 [/INST] Recruiting
[INST] Provide the medical condition for trial id: NCT06383026 [/INST] Breast Cancer
"Trial Id: To Enhance Breast Cancer Survivorship of Asian Americans Recruitment Status: Completed Trail description: The purpose of this randomized intervention study is to test the efficacy of the technology-based information and coaching/support program for Asian American breast cancer survivors (TICAA) in enhancing the women's breast cancer survivorship experience. Inclusion Criteria: Self-reported Asian American women aged 21 years and older who identify their sub-ethnicity as Chinese, Korean, or Japanese
Have had a breast cancer diagnosis
Can read and write English, Mandarin Chinese, Korean or Japanese
Have access to the Internet through computers or mobile devices (smart phones and tablets) Exclusion Criteria: Those under 21 years old are excluded because their cancer experience would be different from adults "
"[INST] Provide inclusion criteria for trial id: NCT02803593 [/INST] Self-reported Asian American women aged 21 years and older who identify their sub-ethnicity as Chinese, Korean, or Japanese
Have had a breast cancer diagnosis
Can read and write English, Mandarin Chinese, Korean or Japanese
Have access to the Internet through computers or mobile devices (smart phones and tablets) "
[INST] Provide exclusion criteria for trial id: NCT02803593 [/INST] Those under 21 years old are excluded because their cancer experience would be different from adults
[INST] Provide description for trial id: NCT02803593 [/INST] The purpose of this randomized intervention study is to test the efficacy of the technology-based information and coaching/support program for Asian American breast cancer survivors (TICAA) in enhancing the women's breast cancer survivorship experience.
[INST] Provide title for trial id: NCT02803593 [/INST] To Enhance Breast Cancer Survivorship of Asian Americans
[INST] Provide the recruitment status for trial id: NCT02803593 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT02803593 [/INST] Breast Cancer
"Trial Id: Exploring the Efficacy and Feasibility of the LymphaTech Scanner for Breast Cancer-Related Lymphedema Screening Recruitment Status: Recruiting Trail description: This research will compare the absolute volumes of the upper extremity using both the LymphaTech Scanner and Perometer in a cohort of patients with a history of invasive or in-situ carcinoma of the breast. Inclusion Criteria: Participants must have histologically or cytologically confirmed invasive or in-situ carcinoma of the breast and will undergo unilateral breast cancer surgery
Age >18 years.
Ability to understand and the willingness to verbally consent to the trial Exclusion Criteria: History of primary lymphedema.
Any patient with a current case of cellulitis.
Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Participants unable to abduct upper-extremity perpendicular to body or to stand comfortably without aid for several minutes, both of which are necessary to perform a LymphaTech Scan "
"[INST] Provide inclusion criteria for trial id: NCT03861975 [/INST] Participants must have histologically or cytologically confirmed invasive or in-situ carcinoma of the breast and will undergo unilateral breast cancer surgery
Age >18 years.
Ability to understand and the willingness to verbally consent to the trial "
"[INST] Provide exclusion criteria for trial id: NCT03861975 [/INST] History of primary lymphedema.
Any patient with a current case of cellulitis.
Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Participants unable to abduct upper-extremity perpendicular to body or to stand comfortably without aid for several minutes, both of which are necessary to perform a LymphaTech Scan "
[INST] Provide description for trial id: NCT03861975 [/INST] This research will compare the absolute volumes of the upper extremity using both the LymphaTech Scanner and Perometer in a cohort of patients with a history of invasive or in-situ carcinoma of the breast.
[INST] Provide title for trial id: NCT03861975 [/INST] Exploring the Efficacy and Feasibility of the LymphaTech Scanner for Breast Cancer-Related Lymphedema Screening
[INST] Provide the recruitment status for trial id: NCT03861975 [/INST] Recruiting
[INST] Provide the medical condition for trial id: NCT03861975 [/INST] Breast Cancer
"Trial Id: Clinical Evaluation of OSNA Breast Cancer System to Test Sentinel Lymph Nodes From Patients With Breast Cancer Recruitment Status: Completed Trail description: The study will determine the sensitivity, specificity, negative predictive value and positive predictive value of the OSNA Breast Cancer System by comparing its performance to permanent section Hematoxylin and Eosin (H&E) and IHC staining. Inclusion Criteria: Male or Female patients, over the age of 18, diagnosed pre-surgically with T1 or T2 breast cancer and scheduled for surgery including sentinel node dissection.
Patients who have read and understand the informed consent form and are capable and willing to provide written informed consent. Exclusion Criteria: Patients diagnosed pre-surgically with large or locally advanced (T3 and T4) breast cancers.
Patients diagnosed with inflammatory breast cancer.
Patients diagnosed with ductal carcinoma in situ (DCIS) when breast conserving is to be done.
Patients who are pregnant, as confirmed by a patient/treating physician interview.
Patients with suspicious palpable axillary lymph nodes.
Patients currently being treated for or previously diagnosed with, another type of carcinoma.
Patients who have undergone prior non-oncologic breast surgery or axillary surgery.
Patients who have received pre-operative systemic therapy.
Patients who are incapable of providing written informed consent.
Patients who have been judged to be inappropriate by a medical care provider (i.e. surgeon, oncologist, pathologists, etc.). "
"[INST] Provide inclusion criteria for trial id: NCT01136369 [/INST] Male or Female patients, over the age of 18, diagnosed pre-surgically with T1 or T2 breast cancer and scheduled for surgery including sentinel node dissection.
Patients who have read and understand the informed consent form and are capable and willing to provide written informed consent. "
"[INST] Provide exclusion criteria for trial id: NCT01136369 [/INST] Patients diagnosed pre-surgically with large or locally advanced (T3 and T4) breast cancers.
Patients diagnosed with inflammatory breast cancer.
Patients diagnosed with ductal carcinoma in situ (DCIS) when breast conserving is to be done.
Patients who are pregnant, as confirmed by a patient/treating physician interview.
Patients with suspicious palpable axillary lymph nodes.
Patients currently being treated for or previously diagnosed with, another type of carcinoma.
Patients who have undergone prior non-oncologic breast surgery or axillary surgery.
Patients who have received pre-operative systemic therapy.
Patients who are incapable of providing written informed consent.
Patients who have been judged to be inappropriate by a medical care provider (i.e. surgeon, oncologist, pathologists, etc.). "
"[INST] Provide description for trial id: NCT01136369 [/INST] The study will determine the sensitivity, specificity, negative predictive value and positive predictive value of the OSNA Breast Cancer System by comparing its performance to permanent section Hematoxylin and Eosin (H&E) and IHC staining. "
[INST] Provide title for trial id: NCT01136369 [/INST] Clinical Evaluation of OSNA Breast Cancer System to Test Sentinel Lymph Nodes From Patients With Breast Cancer
[INST] Provide the recruitment status for trial id: NCT01136369 [/INST] Completed
"[INST] Provide the medical condition for trial id: NCT01136369 [/INST] Breast Neoplasms, Breast Diseases "
"Trial Id: Catheter Guided Chemo-infusion in Breast Cancer Recruitment Status: Not yet recruiting Trail description: In the present prospective study, we will analyze the outcome of image-guided delivery of intra-arterially infused chemotherapeutic drugs for patients with breast cancer in III, IV stages. Inclusion Criteria: Adult female had stage III,IV breast cancer.
Female had received no prior chemotherapy, radiotherapy, or definitive surgical therapy for breast cancer.
Patient had adequate organ function. Exclusion Criteria: Patients known to have absolute contraindications for contrast.
Patient known to have systemic organ failure. "
"[INST] Provide inclusion criteria for trial id: NCT05661656 [/INST] Adult female had stage III,IV breast cancer.
Female had received no prior chemotherapy, radiotherapy, or definitive surgical therapy for breast cancer.
Patient had adequate organ function. "
"[INST] Provide exclusion criteria for trial id: NCT05661656 [/INST] Patients known to have absolute contraindications for contrast.
Patient known to have systemic organ failure. "
"[INST] Provide description for trial id: NCT05661656 [/INST] In the present prospective study, we will analyze the outcome of image-guided delivery of intra-arterially infused chemotherapeutic drugs for patients with breast cancer in III, IV stages. "
[INST] Provide title for trial id: NCT05661656 [/INST] Catheter Guided Chemo-infusion in Breast Cancer
[INST] Provide the recruitment status for trial id: NCT05661656 [/INST] Not yet recruiting
[INST] Provide the medical condition for trial id: NCT05661656 [/INST] Breast Cancer
"Trial Id: Reliability And Validity Study Of ""The Evaluation Tool For Myofascial Adhesions In Patients After Breast Cancer"" In Turkish Language Recruitment Status: Not yet recruiting Trail description: The aim of this observational study is to translate the MAP-BC Evaluation Tool into Turkish by adapting it to Turkish society and to conduct a validity and reliability study in women who have received breast cancer treatment.
The main questions it aims to answer are:
Are the same researcher's MAP-BC Evaluation Tool results similar at intervals to detect myofascial adhesions in breast cancer patients in Turkish population?
Are the different researchers' MAP-BC Evaluation Tool results similar to detect myofascial adhesions in breast cancer patients in Turkish population?
After comparing the results of Turkish version of both The Patient and Observer Scar Assessment Scale Observer Subscale and MAP-BC Evaluation Tool, is there a sufficient correlation between them? Inclusion Criteria: None Exclusion Criteria: None "
[INST] Provide inclusion criteria for trial id: NCT05923164 [/INST] None
[INST] Provide exclusion criteria for trial id: NCT05923164 [/INST] None
"[INST] Provide description for trial id: NCT05923164 [/INST] The aim of this observational study is to translate the MAP-BC Evaluation Tool into Turkish by adapting it to Turkish society and to conduct a validity and reliability study in women who have received breast cancer treatment.
The main questions it aims to answer are:
Are the same researcher's MAP-BC Evaluation Tool results similar at intervals to detect myofascial adhesions in breast cancer patients in Turkish population?
Are the different researchers' MAP-BC Evaluation Tool results similar to detect myofascial adhesions in breast cancer patients in Turkish population?
After comparing the results of Turkish version of both The Patient and Observer Scar Assessment Scale Observer Subscale and MAP-BC Evaluation Tool, is there a sufficient correlation between them? "
"[INST] Provide title for trial id: NCT05923164 [/INST] Reliability And Validity Study Of ""The Evaluation Tool For Myofascial Adhesions In Patients After Breast Cancer"" In Turkish Language "
[INST] Provide the recruitment status for trial id: NCT05923164 [/INST] Not yet recruiting
"[INST] Provide the medical condition for trial id: NCT05923164 [/INST] Breast Cancer, Upper Extremity Dysfunction, Tissue Adhesion "
"Trial Id: Breast Cancer Trials Education Program Recruitment Status: Completed Trail description: The purpose of this study is to test a program designed to increase African American and Hispanic American women's scientific literacy, knowledge of clinical trials, and to facilitate breast cancer clinical trial participation. Inclusion Criteria: Self-Identified as an African American or a Hispanic American female
Speak English and/or Spanish
Mentally and Physically capable of completing the consenting process Exclusion Criteria: None "
"[INST] Provide inclusion criteria for trial id: NCT02808598 [/INST] Self-Identified as an African American or a Hispanic American female
Speak English and/or Spanish
Mentally and Physically capable of completing the consenting process "
[INST] Provide exclusion criteria for trial id: NCT02808598 [/INST] None
"[INST] Provide description for trial id: NCT02808598 [/INST] The purpose of this study is to test a program designed to increase African American and Hispanic American women's scientific literacy, knowledge of clinical trials, and to facilitate breast cancer clinical trial participation. "
[INST] Provide title for trial id: NCT02808598 [/INST] Breast Cancer Trials Education Program
[INST] Provide the recruitment status for trial id: NCT02808598 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT02808598 [/INST] Breast Cancer
"Trial Id: The Characteristics, Treatment Patterns and Prognosis of Chinese Male Breast Cancer: A Real-world Study Recruitment Status: Recruiting Trail description: The goal of this observational study is to investigate the features in Chinese male breast cancer (MBC) patients. The main question it aims to answer is:
The characteristics, treatment patterns and prognosis of Chinese MBC patients. The clinicopathological characteristics, treatment information and follow-up data of participants will be extracted from a Chinese national database (Chinese Society of Clinical Oncology Breast Cancer database) and other involved Chinese centers.
Researchers will investigate the features, survival associated factors and other relevant factors of this population. Inclusion Criteria: Biological sex is male;
Microscopically diagnosed as primary breast cancer. Exclusion Criteria: Presence of skin-origin malignancy on the breast. "
"[INST] Provide inclusion criteria for trial id: NCT06220630 [/INST] Biological sex is male;
Microscopically diagnosed as primary breast cancer. "
[INST] Provide exclusion criteria for trial id: NCT06220630 [/INST] Presence of skin-origin malignancy on the breast.
"[INST] Provide description for trial id: NCT06220630 [/INST] The goal of this observational study is to investigate the features in Chinese male breast cancer (MBC) patients. The main question it aims to answer is:
The characteristics, treatment patterns and prognosis of Chinese MBC patients. The clinicopathological characteristics, treatment information and follow-up data of participants will be extracted from a Chinese national database (Chinese Society of Clinical Oncology Breast Cancer database) and other involved Chinese centers.
Researchers will investigate the features, survival associated factors and other relevant factors of this population. "
"[INST] Provide title for trial id: NCT06220630 [/INST] The Characteristics, Treatment Patterns and Prognosis of Chinese Male Breast Cancer: A Real-world Study "
[INST] Provide the recruitment status for trial id: NCT06220630 [/INST] Recruiting
[INST] Provide the medical condition for trial id: NCT06220630 [/INST] Breast Cancer
"Trial Id: Nurse Navigation Program Based On Health Belief Model In Breast Cancer Screening (NaHeB-CaS) Recruitment Status: Completed Trail description: This study, which is designed according to the experimental model with randomized pre-test and post-test control group, will be carried out with Syrian women who apply to Empowered Migrant Health Center in İstanbul province, Sultanbeyli district, where Syria citizens are immigranted. The population of the study consisted of all Syrian women aged 40-69 under temporary protection who came to the Empowered Migrant Health Center at the time of the research. The working group will be composed of 80 Syrian women who meet the selection criteria. According to the sources, the frequency of breast cancer screening in Turkey is taken as 15%; For the study at 95% confidence level, d=0,6 was taken and n=136 sample size was taken. Considering that there may be those who left during the research period, 14 women will be taken as substitutes and the sample will be completed to a total of 150 in order to increase the power of representing the universe. A personal questionnaire prepared by the researcher in line with the literature, Health Belief Model Scale, Mammography Self-Efficacy Scale, Champion Breast Cancer Fear Scale, Breast Self Examination Checklist Form, will be administered to Syrian women under temporary protection who applied to the empowered migrant health center and agreed to participate in the study.According to the sample pool formed by the women included in the study, the participants were assigned to 2 groups as experiment and control with the ""Research Randomizer"" program. Each group will be determined as 75 people. A 4-week training program will be applied to the experimental group. The women in the experimental group will be given a self-breast examination control calendar after their first training. Afterwards, motivational interviews will be held once a month for the second and third months. A ""Nurse-managed screening consultancy telephone support line"" will be established for Syrian women within the scope of the Nurse Navigation Program. Reminder phone calls will be made 4 times a week. Personal questionnaire, Health Belief Model Scale, Mammography Self-Efficacy Scale, Champion Breast Cancer Fear Scale, Breast Self Examination Checklist Form, Post-Training Screening Behavior Follow-up Form will be administered to the experimental and control groups as a post-test. Inclusion Criteria: Being between the ages of 40-69.
Being a woman.
Not having been diagnosed with breast cancer.
Not doing BSE on a regular basis every month.
Not having had CME and mammography in the last three years.
Not to be pregnant, breastfeeding or postpartum.
No history of breast cancer.
Not having received training on breast cancer.
To agree to participate in the research.
Absence of a mental illness.
Being literate, accessible and communicative.
Not having a communication barrier
Being registered with Sultanbeyli Empowered Migrant Health Center Exclusion Criteria: Having a problem with breast cancer before.
Having BSE, CBE or Mammography at regular intervals.
Having had a mastectomy for any reason. "
"[INST] Provide inclusion criteria for trial id: NCT04966377 [/INST] Being between the ages of 40-69.
Being a woman.
Not having been diagnosed with breast cancer.
Not doing BSE on a regular basis every month.
Not having had CME and mammography in the last three years.
Not to be pregnant, breastfeeding or postpartum.
No history of breast cancer.
Not having received training on breast cancer.
To agree to participate in the research.
Absence of a mental illness.
Being literate, accessible and communicative.
Not having a communication barrier
Being registered with Sultanbeyli Empowered Migrant Health Center "
"[INST] Provide exclusion criteria for trial id: NCT04966377 [/INST] Having a problem with breast cancer before.
Having BSE, CBE or Mammography at regular intervals.
Having had a mastectomy for any reason. "
"[INST] Provide description for trial id: NCT04966377 [/INST] This study, which is designed according to the experimental model with randomized pre-test and post-test control group, will be carried out with Syrian women who apply to Empowered Migrant Health Center in İstanbul province, Sultanbeyli district, where Syria citizens are immigranted. The population of the study consisted of all Syrian women aged 40-69 under temporary protection who came to the Empowered Migrant Health Center at the time of the research. The working group will be composed of 80 Syrian women who meet the selection criteria. According to the sources, the frequency of breast cancer screening in Turkey is taken as 15%; For the study at 95% confidence level, d=0,6 was taken and n=136 sample size was taken. Considering that there may be those who left during the research period, 14 women will be taken as substitutes and the sample will be completed to a total of 150 in order to increase the power of representing the universe. A personal questionnaire prepared by the researcher in line with the literature, Health Belief Model Scale, Mammography Self-Efficacy Scale, Champion Breast Cancer Fear Scale, Breast Self Examination Checklist Form, will be administered to Syrian women under temporary protection who applied to the empowered migrant health center and agreed to participate in the study.According to the sample pool formed by the women included in the study, the participants were assigned to 2 groups as experiment and control with the ""Research Randomizer"" program. Each group will be determined as 75 people. A 4-week training program will be applied to the experimental group. The women in the experimental group will be given a self-breast examination control calendar after their first training. Afterwards, motivational interviews will be held once a month for the second and third months. A ""Nurse-managed screening consultancy telephone support line"" will be established for Syrian women within the scope of the Nurse Navigation Program. Reminder phone calls will be made 4 times a week. Personal questionnaire, Health Belief Model Scale, Mammography Self-Efficacy Scale, Champion Breast Cancer Fear Scale, Breast Self Examination Checklist Form, Post-Training Screening Behavior Follow-up Form will be administered to the experimental and control groups as a post-test. "
[INST] Provide title for trial id: NCT04966377 [/INST] Nurse Navigation Program Based On Health Belief Model In Breast Cancer Screening (NaHeB-CaS)
[INST] Provide the recruitment status for trial id: NCT04966377 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT04966377 [/INST] Breast Cancer
"Trial Id: A Pilot Study of Working Women and Breast Cancer Recruitment Status: Completed Trail description: The purpose of this research is to better understand the relationship between employment and breast cancer. Research is being conducted to understand how workplace factors influence breast cancer patients' ability to adhere to recommended cancer treatment and effectively recover from cancer. Investigators hope to use the findings from the study to help working breast cancer survivors make informed decisions about treatment and employment in collaboration with their employers and healthcare providers. Inclusion Criteria: Women age 18-65
Working at least 20 hours per week
Currently patients of the University of Kentucky Markey Cancer Center
Are able to read, write, and communicate in English
Have reliable telephone or Internet/Web access in or outside the home Exclusion Criteria: Self-employed
Unemployed
Cognitively impaired "
"[INST] Provide inclusion criteria for trial id: NCT01914614 [/INST] Women age 18-65
Working at least 20 hours per week
Currently patients of the University of Kentucky Markey Cancer Center
Are able to read, write, and communicate in English
Have reliable telephone or Internet/Web access in or outside the home "
"[INST] Provide exclusion criteria for trial id: NCT01914614 [/INST] Self-employed
Unemployed
Cognitively impaired "
[INST] Provide description for trial id: NCT01914614 [/INST] The purpose of this research is to better understand the relationship between employment and breast cancer. Research is being conducted to understand how workplace factors influence breast cancer patients' ability to adhere to recommended cancer treatment and effectively recover from cancer. Investigators hope to use the findings from the study to help working breast cancer survivors make informed decisions about treatment and employment in collaboration with their employers and healthcare providers.
[INST] Provide title for trial id: NCT01914614 [/INST] A Pilot Study of Working Women and Breast Cancer
[INST] Provide the recruitment status for trial id: NCT01914614 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT01914614 [/INST] Breast Cancer
"Trial Id: A Clinical Trial of Docetaxel and Oxaliplatin in Patients With Recurrent or Metastatic Breast Cancer Recruitment Status: Unknown status Trail description: The purpose of this study is to evaluate the overall response rate, toxicity, progression free survival and quality of life of chemotherapy with docetaxel and oxaliplatin in recurrent or metastatic breast cancer. Inclusion Criteria: Women aged : 20~70 years
WHO (ECOG) performance status 0-2
Patients with measurable lesion assessed by imaging using the RECIST (Response Evaluation Criteria In Solid Tumor) guideline
patients had previously not received chemotherapy of recurrent or metastatic lesion.
Have given written informed consent and are available for prolonged follow-up Exclusion Criteria: Patients with previous chemotherapy for recurrent breast cancer
Breast cancer recurrence within 12 months after taxane treatment
Her-2/neu expression breast cancer
Patients with malignancies (other than breast cancer) within the last 5 years, except for adequately treated in situ carcinoma of the cervix or basal cell, squamous cell carcinoma of the skin.
Brain metastasis
uncontrolled infection, medically uncontrollable heart disease
other serious medical illness or prior malignancies
Pregnant or lactating women were excluded. "
"[INST] Provide inclusion criteria for trial id: NCT01351597 [/INST] Women aged : 20~70 years
WHO (ECOG) performance status 0-2
Patients with measurable lesion assessed by imaging using the RECIST (Response Evaluation Criteria In Solid Tumor) guideline
patients had previously not received chemotherapy of recurrent or metastatic lesion.
Have given written informed consent and are available for prolonged follow-up "
"[INST] Provide exclusion criteria for trial id: NCT01351597 [/INST] Patients with previous chemotherapy for recurrent breast cancer
Breast cancer recurrence within 12 months after taxane treatment
Her-2/neu expression breast cancer
Patients with malignancies (other than breast cancer) within the last 5 years, except for adequately treated in situ carcinoma of the cervix or basal cell, squamous cell carcinoma of the skin.
Brain metastasis
uncontrolled infection, medically uncontrollable heart disease
other serious medical illness or prior malignancies
Pregnant or lactating women were excluded. "
"[INST] Provide description for trial id: NCT01351597 [/INST] The purpose of this study is to evaluate the overall response rate, toxicity, progression free survival and quality of life of chemotherapy with docetaxel and oxaliplatin in recurrent or metastatic breast cancer. "
[INST] Provide title for trial id: NCT01351597 [/INST] A Clinical Trial of Docetaxel and Oxaliplatin in Patients With Recurrent or Metastatic Breast Cancer
[INST] Provide the recruitment status for trial id: NCT01351597 [/INST] Unknown status
"[INST] Provide the medical condition for trial id: NCT01351597 [/INST] Recurrent Breast Cancer, Metastatic Breast Cancer "
"Trial Id: [18F] F-GLN by PET/CT in Breast Cancer Recruitment Status: Recruiting Trail description: Patients with known or suspected primary or metastatic breast cancer with one lesion that is 1.5 cm in diameter or greater may be eligible for this study. Patients may participate in this study if they are at least 18 years of age. Up to 40 evaluable subjects will participate in a single imaging cohort. Patients will be stratified for analysis by breast cancer subtype with prioritization to recruit at least 10 estrogen-receptor-expressing (ER+) and 10 triple-negative breast cancers (TNBC).
This is an observational study; [18F]F-GLN PET/CT will not be used to direct treatment decisions. While patients and referring physicians will not be blinded to the [18F]F-GLN PET/CT results, treatment decisions are made by the treating physicians based upon clinical criteria.
[18F]F-GLN PET/CT imaging sessions will include an injection of [18F]F-GLN. Metabolism data will be collected. Pilot data will be collected to evaluate image quality and collect preliminary information on the uptake of [18F]F-GLN in breast cancer. Uptake measures will be compared to tumor markers of glutamine metabolism, when tissue is available. The safety of [18F]F-GLN will also be evaluated in all subjects. Inclusion Criteria: Participants will be ≥ 18 years of age
Known or suspected primary or metastatic breast cancer.
At least one lesion ≥ 1.5 cm that is seen on standard imaging (e.g. CT, MRI, mammogram, ultrasound, FDG-PET/CT). Only one type of imaging is required to show a lesion.
Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures. Exclusion Criteria: Females who are pregnant or breast feeding at the time of screening; a urine pregnancy test will be performed in women of child-bearing potential at screening.
Inability to tolerate imaging procedures in the opinion of an investigator or treating physician.
Any current medical condition, illness, or disorder, as assessed by medical record review and/or self-reported, that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study. "
"[INST] Provide inclusion criteria for trial id: NCT03863457 [/INST] Participants will be ≥ 18 years of age
Known or suspected primary or metastatic breast cancer.
At least one lesion ≥ 1.5 cm that is seen on standard imaging (e.g. CT, MRI, mammogram, ultrasound, FDG-PET/CT). Only one type of imaging is required to show a lesion.
Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures. "
"[INST] Provide exclusion criteria for trial id: NCT03863457 [/INST] Females who are pregnant or breast feeding at the time of screening; a urine pregnancy test will be performed in women of child-bearing potential at screening.
Inability to tolerate imaging procedures in the opinion of an investigator or treating physician.
Any current medical condition, illness, or disorder, as assessed by medical record review and/or self-reported, that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study. "
"[INST] Provide description for trial id: NCT03863457 [/INST] Patients with known or suspected primary or metastatic breast cancer with one lesion that is 1.5 cm in diameter or greater may be eligible for this study. Patients may participate in this study if they are at least 18 years of age. Up to 40 evaluable subjects will participate in a single imaging cohort. Patients will be stratified for analysis by breast cancer subtype with prioritization to recruit at least 10 estrogen-receptor-expressing (ER+) and 10 triple-negative breast cancers (TNBC).
This is an observational study; [18F]F-GLN PET/CT will not be used to direct treatment decisions. While patients and referring physicians will not be blinded to the [18F]F-GLN PET/CT results, treatment decisions are made by the treating physicians based upon clinical criteria.
[18F]F-GLN PET/CT imaging sessions will include an injection of [18F]F-GLN. Metabolism data will be collected. Pilot data will be collected to evaluate image quality and collect preliminary information on the uptake of [18F]F-GLN in breast cancer. Uptake measures will be compared to tumor markers of glutamine metabolism, when tissue is available. The safety of [18F]F-GLN will also be evaluated in all subjects. "
[INST] Provide title for trial id: NCT03863457 [/INST] [18F] F-GLN by PET/CT in Breast Cancer
[INST] Provide the recruitment status for trial id: NCT03863457 [/INST] Recruiting
[INST] Provide the medical condition for trial id: NCT03863457 [/INST] Breast Cancer
"Trial Id: Contrast Enhanced Spectral Mammography vs. MRI for Breast Cancer Screening Recruitment Status: Active, not recruiting Trail description: This research study is evaluating whether contrast enhanced mammography can be used as an alternative to breast Magnetic Resonance Imaging (MRI) for cancer screening Inclusion Criteria: Prospective Patient Recruitment
Women
Age > or equal to 30 years
Recommendation for breast biopsy has been made
Recommendation for biopsy will result from an imaging work-up originating with a screening exam (mammogram, tomosynthesis, ultrasound, or MRI) that was within 3 months of biopsy.
Reader Study Inclusion Criteria:
CESM and MRI exam performed within 3 months of one another.
CESM and breast MRI exams must be performed as part of imaging work-up based on a screening exam of any type (mammography, tomosynthesis, ultrasound, and MRI)
CESM studies will include at least four low energy and four recombined images (LCC, LMLO, RCC, RMLO).
MRI exams will include at least fluid sensitive sequence, multi-phase T1-weighted Exclusion Criteria: Prospective Patient Recruitment
Men
Women with implants
Participants who have a known allergy to contrast media.
Participants who have a known severe allergic response to one or more allergens, defined as anaphylaxis
Participants with poor asthma control using the National Heart, Lung, and Blood Institute guidelines as defined by:
Symptoms > 2 days per week Short-term beta agonist use > 2 days per week Nighttime awakenings > 2 times per month
Participants with Renal insufficiency or failure, as determined by GFR < 60 mL/min/1.73 m2 , performed for all patients within 24 hours of the imaging exams
Participants who are pregnant. Pregnant women are excluded from this study due to the radiation dose from the CT scan and its potential teratogenic effects on the fetus.
Participants who are breastfeeding are excluded because there is an unknown but potential risk for adverse events in nursing infants secondary to contrast administration in the mother.
Participants with the following underlying medical conditions: multiple myeloma, myasthenia gravis, dysproteinemias, severe cardiac disease, aortic stenosis, primary pulmonary hypertension, cardiac arrythmia, or severe cardiomyopathy. These underlying medical conditions may make the participant more likely to develop a contrast reaction. This is based on the ACR contrast manual version 10.3 and hospital policy.
Participants with a concurrent active illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, thyroid storm.
Participants with thyroid carcinoma or thyroid disease for whom systemic radioactive iodine therapy is part of planned diagnostic work-up or treatment within 2 months following the contrast mammogram study.
Participants with non-MR compatible objects or implants that would make MRI a contraindication.
Participants who have a pacemaker, pacer wires, implantable defibrillator, or implanted monitoring device.
Participants with intracranial clips, metal implants or external clips within 10 mm of the head.
Participants who have had a metal injury to the eye.
Reader Study Exclusion Criteria:
Imaging sets with implants.
Imaging sets in which a biopsy or surgical intervention was performed since the most recent screening exam, prior to acquisition of the study MRI or CESM.
Imaging sets in which a biopsy was recommended, but biopsy was not performed and 2 year imaging follow-up is not available "
"[INST] Provide inclusion criteria for trial id: NCT03482557 [/INST] Prospective Patient Recruitment
Women
Age > or equal to 30 years
Recommendation for breast biopsy has been made
Recommendation for biopsy will result from an imaging work-up originating with a screening exam (mammogram, tomosynthesis, ultrasound, or MRI) that was within 3 months of biopsy.
Reader Study Inclusion Criteria:
CESM and MRI exam performed within 3 months of one another.
CESM and breast MRI exams must be performed as part of imaging work-up based on a screening exam of any type (mammography, tomosynthesis, ultrasound, and MRI)
CESM studies will include at least four low energy and four recombined images (LCC, LMLO, RCC, RMLO).
MRI exams will include at least fluid sensitive sequence, multi-phase T1-weighted "
"[INST] Provide exclusion criteria for trial id: NCT03482557 [/INST] Prospective Patient Recruitment
Men
Women with implants
Participants who have a known allergy to contrast media.
Participants who have a known severe allergic response to one or more allergens, defined as anaphylaxis
Participants with poor asthma control using the National Heart, Lung, and Blood Institute guidelines as defined by:
Symptoms > 2 days per week Short-term beta agonist use > 2 days per week Nighttime awakenings > 2 times per month
Participants with Renal insufficiency or failure, as determined by GFR < 60 mL/min/1.73 m2 , performed for all patients within 24 hours of the imaging exams
Participants who are pregnant. Pregnant women are excluded from this study due to the radiation dose from the CT scan and its potential teratogenic effects on the fetus.
Participants who are breastfeeding are excluded because there is an unknown but potential risk for adverse events in nursing infants secondary to contrast administration in the mother.
Participants with the following underlying medical conditions: multiple myeloma, myasthenia gravis, dysproteinemias, severe cardiac disease, aortic stenosis, primary pulmonary hypertension, cardiac arrythmia, or severe cardiomyopathy. These underlying medical conditions may make the participant more likely to develop a contrast reaction. This is based on the ACR contrast manual version 10.3 and hospital policy.
Participants with a concurrent active illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, thyroid storm.
Participants with thyroid carcinoma or thyroid disease for whom systemic radioactive iodine therapy is part of planned diagnostic work-up or treatment within 2 months following the contrast mammogram study.
Participants with non-MR compatible objects or implants that would make MRI a contraindication.
Participants who have a pacemaker, pacer wires, implantable defibrillator, or implanted monitoring device.
Participants with intracranial clips, metal implants or external clips within 10 mm of the head.
Participants who have had a metal injury to the eye.
Reader Study Exclusion Criteria:
Imaging sets with implants.
Imaging sets in which a biopsy or surgical intervention was performed since the most recent screening exam, prior to acquisition of the study MRI or CESM.
Imaging sets in which a biopsy was recommended, but biopsy was not performed and 2 year imaging follow-up is not available "
[INST] Provide description for trial id: NCT03482557 [/INST] This research study is evaluating whether contrast enhanced mammography can be used as an alternative to breast Magnetic Resonance Imaging (MRI) for cancer screening
[INST] Provide title for trial id: NCT03482557 [/INST] Contrast Enhanced Spectral Mammography vs. MRI for Breast Cancer Screening
"[INST] Provide the recruitment status for trial id: NCT03482557 [/INST] Active, not recruiting "
[INST] Provide the medical condition for trial id: NCT03482557 [/INST] Breast Cancer
"Trial Id: Study for the Knowledge of Risk Factors Associated With Breast Cancer in Women Recruitment Status: Completed Trail description: Breast cancer is the most frequent tumor in Western women. In Spain about 26,000 new breast cancers are diagnosed each year. This type of tumor is increasing worldwide with an increase in aggressive neoplasms in young women. There are some risk factors responsible for this global increase: lifestyle, diet and body weight especially in postmenopausal women.
Some cell mutations, especially in the BRCA1, BRCA2 and p53 genes, are associated with a very high risk of this type of cancer. Some authors have calculated the contribution of various modifiable risk factors to the global burden of breast cancer, and they concluded that 21% of all breast cancer deaths are attributable to alcohol consumption, overweight and obesity, and lack of physical activity. Nowadays, there aren't specific studies in the Community of Madrid designed to know the risk factors related to breast cancer.
For this reason, it is proposed to carry out an observational study that collects detailed information about dietary habits, genetic factors and life quality of a group of women with recent diagnosis in pre or post-surgical phase. Inclusion Criteria: Older women than 18 years old
Newly diagnosed patients with a breast tumor (Phase I, II or III). Being in one of the following cases:
Patient who has not yet received any treatment and the committee has decided that as a first treatment will receive chemo or radiotherapy.
Patient who has just undergone surgery and is waiting to start adjuvant treatment with chemo or radiotherapy.
Sign the informed consent. Exclusion Criteria: Patients with stage IV disease.
Associated Eating Disorders.
Patients with dementia, mental illness or decreased cognitive function.
Pregnant or lactating women. "
"[INST] Provide inclusion criteria for trial id: NCT03918668 [/INST] Older women than 18 years old
Newly diagnosed patients with a breast tumor (Phase I, II or III). Being in one of the following cases:
Patient who has not yet received any treatment and the committee has decided that as a first treatment will receive chemo or radiotherapy.
Patient who has just undergone surgery and is waiting to start adjuvant treatment with chemo or radiotherapy.
Sign the informed consent. "
"[INST] Provide exclusion criteria for trial id: NCT03918668 [/INST] Patients with stage IV disease.
Associated Eating Disorders.
Patients with dementia, mental illness or decreased cognitive function.
Pregnant or lactating women. "
"[INST] Provide description for trial id: NCT03918668 [/INST] Breast cancer is the most frequent tumor in Western women. In Spain about 26,000 new breast cancers are diagnosed each year. This type of tumor is increasing worldwide with an increase in aggressive neoplasms in young women. There are some risk factors responsible for this global increase: lifestyle, diet and body weight especially in postmenopausal women.
Some cell mutations, especially in the BRCA1, BRCA2 and p53 genes, are associated with a very high risk of this type of cancer. Some authors have calculated the contribution of various modifiable risk factors to the global burden of breast cancer, and they concluded that 21% of all breast cancer deaths are attributable to alcohol consumption, overweight and obesity, and lack of physical activity. Nowadays, there aren't specific studies in the Community of Madrid designed to know the risk factors related to breast cancer.
For this reason, it is proposed to carry out an observational study that collects detailed information about dietary habits, genetic factors and life quality of a group of women with recent diagnosis in pre or post-surgical phase. "
[INST] Provide title for trial id: NCT03918668 [/INST] Study for the Knowledge of Risk Factors Associated With Breast Cancer in Women
[INST] Provide the recruitment status for trial id: NCT03918668 [/INST] Completed
"[INST] Provide the medical condition for trial id: NCT03918668 [/INST] Breast Neoplasm Female, Nutrition Related Cancer, Habits, Diet, Cancer, Breast "
"Trial Id: Breast MRI in Women With Known or Suspected Breast Cancer and in Healthy Participants Recruitment Status: Completed Trail description: RATIONALE: Diagnostic procedures, such as MRI, may help diagnose breast cancer. It may also help doctors predict a patient's response to treatment.
PURPOSE: This clinical trial is studying breast MRI in women with known or suspected breast cancer and in healthy participants. Inclusion Criteria: None Exclusion Criteria: None "
[INST] Provide inclusion criteria for trial id: NCT00474604 [/INST] None
[INST] Provide exclusion criteria for trial id: NCT00474604 [/INST] None
"[INST] Provide description for trial id: NCT00474604 [/INST] RATIONALE: Diagnostic procedures, such as MRI, may help diagnose breast cancer. It may also help doctors predict a patient's response to treatment.
PURPOSE: This clinical trial is studying breast MRI in women with known or suspected breast cancer and in healthy participants. "
[INST] Provide title for trial id: NCT00474604 [/INST] Breast MRI in Women With Known or Suspected Breast Cancer and in Healthy Participants
[INST] Provide the recruitment status for trial id: NCT00474604 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT00474604 [/INST] Breast Cancer
"Trial Id: Integrative Oncology Outcomes Study in Breast Cancer Recruitment Status: Completed Trail description: This NIH-NCCAM funded epidemiologic research is being conducted as an observational prospective case-control study of the use of Complementary and Alternative Medicine (CAM) and Integrated Oncology (IO) and their effects on breast cancer patients in community settings.
Hypothesis: IO services improve patients' quality of life and decrease cancer recurrence rates in breast cancer patients as compared to women with similar disease states and prognoses who do not receive IO care, and may or may not use CAM treatment on their own. Inclusion Criteria: None Exclusion Criteria: None "
[INST] Provide inclusion criteria for trial id: NCT01366248 [/INST] None
[INST] Provide exclusion criteria for trial id: NCT01366248 [/INST] None
"[INST] Provide description for trial id: NCT01366248 [/INST] This NIH-NCCAM funded epidemiologic research is being conducted as an observational prospective case-control study of the use of Complementary and Alternative Medicine (CAM) and Integrated Oncology (IO) and their effects on breast cancer patients in community settings.
Hypothesis: IO services improve patients' quality of life and decrease cancer recurrence rates in breast cancer patients as compared to women with similar disease states and prognoses who do not receive IO care, and may or may not use CAM treatment on their own. "
[INST] Provide title for trial id: NCT01366248 [/INST] Integrative Oncology Outcomes Study in Breast Cancer
[INST] Provide the recruitment status for trial id: NCT01366248 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT01366248 [/INST] Breast Cancer
"Trial Id: Characteristics and Treatment Trends of Young Breast Cancer in China Recruitment Status: Not yet recruiting Trail description: To describe the clinical characteristics, the diagnosis and treatment, the survival status and change trend of young breast cancer patients in China from 2000 to 2015, and to explore and discuss the main influencing factors. Inclusion Criteria: Young Breast cancer patients (≤35 years old) in China Exclusion Criteria: Breast cancer patients (>35 years old) in China "
[INST] Provide inclusion criteria for trial id: NCT05068115 [/INST] Young Breast cancer patients (≤35 years old) in China
[INST] Provide exclusion criteria for trial id: NCT05068115 [/INST] Breast cancer patients (>35 years old) in China
"[INST] Provide description for trial id: NCT05068115 [/INST] To describe the clinical characteristics, the diagnosis and treatment, the survival status and change trend of young breast cancer patients in China from 2000 to 2015, and to explore and discuss the main influencing factors. "
[INST] Provide title for trial id: NCT05068115 [/INST] Characteristics and Treatment Trends of Young Breast Cancer in China
[INST] Provide the recruitment status for trial id: NCT05068115 [/INST] Not yet recruiting
[INST] Provide the medical condition for trial id: NCT05068115 [/INST] Breast Cancer
"Trial Id: Study on SBRT for Inoperable Lung and Liver Oligometastases From Breast Cancer Recruitment Status: Unknown status Trail description: Investigators designed a phase II study to evaluate safety and efficacy of lung and liver stereotactic radiation therapy (SRT) in oligometastatic breast cancer patients unsuitable for surgery, using VMAT RapidArc approach. Inclusion Criteria: Patients aged >18 years with ECOG 0-2
Diagnosis of Breast Cancer
DFI (Disease-free interval) > 1 year
No extrapulmonary and/or extrahepatic disease or other metastatic sites stable or responding after chemotherapy
No life threatening conditions
Lung and liver lesions < 5 (with maximum diameter < 5 cm)
Chemotherapy completed at least 3 weeks before treatment
Chemotherapy started at least 2 weeks after treatment allowed
Systemic therapies other than chemotherapy allowed (i.e hormonal therapies and/or immunotherapy)
Written informed consent Exclusion Criteria: ECOG > 2
Pregnant women
Patients with inability to consent "
"[INST] Provide inclusion criteria for trial id: NCT02581670 [/INST] Patients aged >18 years with ECOG 0-2
Diagnosis of Breast Cancer
DFI (Disease-free interval) > 1 year
No extrapulmonary and/or extrahepatic disease or other metastatic sites stable or responding after chemotherapy
No life threatening conditions
Lung and liver lesions < 5 (with maximum diameter < 5 cm)
Chemotherapy completed at least 3 weeks before treatment
Chemotherapy started at least 2 weeks after treatment allowed
Systemic therapies other than chemotherapy allowed (i.e hormonal therapies and/or immunotherapy)
Written informed consent "
"[INST] Provide exclusion criteria for trial id: NCT02581670 [/INST] ECOG > 2
Pregnant women
Patients with inability to consent "
"[INST] Provide description for trial id: NCT02581670 [/INST] Investigators designed a phase II study to evaluate safety and efficacy of lung and liver stereotactic radiation therapy (SRT) in oligometastatic breast cancer patients unsuitable for surgery, using VMAT RapidArc approach. "
[INST] Provide title for trial id: NCT02581670 [/INST] Study on SBRT for Inoperable Lung and Liver Oligometastases From Breast Cancer
[INST] Provide the recruitment status for trial id: NCT02581670 [/INST] Unknown status
"[INST] Provide the medical condition for trial id: NCT02581670 [/INST] Breast Cancer, Metastasis to Liver, Metastasis to Lung "
"Trial Id: A Study to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Blood of Stage IV Breast Cancer Patients Recruitment Status: Completed Trail description: This study is designed to determine whether molecular detection of breast cancer cells in the peripheral blood of Stage IV breast cancer patients is a clinically relevant predictor of progression-free and overall survival. Stage IV breast cancer patients who have measurable breast cancer metastases and are initiating a regimen of systemic therapy are eligible for enrollment. Multi-marker real-time RT-PCR analysis will be performed on peripheral blood specimens from 92 breast cancer patients and 120 healthy volunteers. Peripheral blood specimens from breast cancer patients will be obtained at the time of study entry (prior to initiation of systemic therapy) and at serial time points during follow-up. Subjects will be followed longitudinally until death, although the study has been powered so that the primary objective can be addressed after 12 months of follow-up. Healthy volunteers will be asked to provide a blood sample at time of enrollment but will not be followed. Inclusion Criteria: Inclusion Criteria - Stage IV breast cancer patients
Patient age must be > 21 years.
Patient must have a tissue diagnosis of invasive breast cancer.
Patient must have documented evidence of metastatic disease.
Patient must have measurable lesions.
Patients must be initiating systemic therapy. Patients receiving hormonal therapy, and/or chemotherapy alone or in combination with other therapies are eligible.
Patient must have an ECOG performance status of 0, 1, or 2.
Patient must be available for follow-up.
Patient or their authorized legally acceptable representative must consent to be in the study and must have signed and dated an approved consent form which conforms to federal and institutional guidelines.
The patient with a previous history of non-breast malignancy is eligible for this study only if the patient meets the following criteria for a cancer survivor. A cancer survivor is eligible provided the following criteria are met: (1) patient has undergone potentially curative therapy for all prior malignancies, (2) patients have been considered disease free for at least 5 years (with the exception of basal cell or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix).
Inclusion Criteria - Healthy volunteers
A volunteer will be eligible for inclusion in this study only if ALL of the following criteria apply:
Volunteer age must be > 21 years.
Volunteer or their authorized legally acceptable representative must consent to be in the study and must have signed and dated an approved consent form which conforms to federal and institutional guidelines.
Patients with benign breast disease are eligible for enrollment.
The volunteer with a previous history of non-breast malignancy is eligible for this study only if the patient meets the following criteria for a cancer survivor. A cancer survivor is eligible provided both of the following criteria are met: (1) patient has undergone potentially curative therapy for all prior malignancies, (2) patient has been considered disease free for at least 5 years (with the exception of basal cell or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix). Exclusion Criteria: Exclusion Criteria - Stage IV breast cancer patients
A patient will be ineligible for inclusion in this study if ANY of the following criteria apply:
No documented metastatic disease.
No measurable lesions.
Bone only and/or brain metastasis.
Patient is not initiating a new regimen of systemic therapy. "
"[INST] Provide inclusion criteria for trial id: NCT00355316 [/INST] Inclusion Criteria - Stage IV breast cancer patients
Patient age must be > 21 years.
Patient must have a tissue diagnosis of invasive breast cancer.
Patient must have documented evidence of metastatic disease.
Patient must have measurable lesions.
Patients must be initiating systemic therapy. Patients receiving hormonal therapy, and/or chemotherapy alone or in combination with other therapies are eligible.
Patient must have an ECOG performance status of 0, 1, or 2.
Patient must be available for follow-up.
Patient or their authorized legally acceptable representative must consent to be in the study and must have signed and dated an approved consent form which conforms to federal and institutional guidelines.
The patient with a previous history of non-breast malignancy is eligible for this study only if the patient meets the following criteria for a cancer survivor. A cancer survivor is eligible provided the following criteria are met: (1) patient has undergone potentially curative therapy for all prior malignancies, (2) patients have been considered disease free for at least 5 years (with the exception of basal cell or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix).
Inclusion Criteria - Healthy volunteers
A volunteer will be eligible for inclusion in this study only if ALL of the following criteria apply:
Volunteer age must be > 21 years.
Volunteer or their authorized legally acceptable representative must consent to be in the study and must have signed and dated an approved consent form which conforms to federal and institutional guidelines.
Patients with benign breast disease are eligible for enrollment.
The volunteer with a previous history of non-breast malignancy is eligible for this study only if the patient meets the following criteria for a cancer survivor. A cancer survivor is eligible provided both of the following criteria are met: (1) patient has undergone potentially curative therapy for all prior malignancies, (2) patient has been considered disease free for at least 5 years (with the exception of basal cell or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix). "
"[INST] Provide exclusion criteria for trial id: NCT00355316 [/INST] Exclusion Criteria - Stage IV breast cancer patients
A patient will be ineligible for inclusion in this study if ANY of the following criteria apply:
No documented metastatic disease.
No measurable lesions.
Bone only and/or brain metastasis.
Patient is not initiating a new regimen of systemic therapy. "
"[INST] Provide description for trial id: NCT00355316 [/INST] This study is designed to determine whether molecular detection of breast cancer cells in the peripheral blood of Stage IV breast cancer patients is a clinically relevant predictor of progression-free and overall survival. Stage IV breast cancer patients who have measurable breast cancer metastases and are initiating a regimen of systemic therapy are eligible for enrollment. Multi-marker real-time RT-PCR analysis will be performed on peripheral blood specimens from 92 breast cancer patients and 120 healthy volunteers. Peripheral blood specimens from breast cancer patients will be obtained at the time of study entry (prior to initiation of systemic therapy) and at serial time points during follow-up. Subjects will be followed longitudinally until death, although the study has been powered so that the primary objective can be addressed after 12 months of follow-up. Healthy volunteers will be asked to provide a blood sample at time of enrollment but will not be followed. "
[INST] Provide title for trial id: NCT00355316 [/INST] A Study to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Blood of Stage IV Breast Cancer Patients
[INST] Provide the recruitment status for trial id: NCT00355316 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT00355316 [/INST] Breast Neoplasms
"Trial Id: Sodium (23Na) MRI for Tumour Characterisation and Assessment of Therapy Response in Breast Cancer Recruitment Status: Recruiting Trail description: The scope of this study is the methodological development and optimisation of sodium MRI (23Na-MRI) protocols for breast cancer imaging. The study further proposes to utilise biomarkers obtained from 23Na-imaging (cell integrity), FDG-PET (metabolism), multi-parametric MRI (perfusion, vascularity, cellularity, morphology) to generate parameter maps specific for physiological processes in breast cancer. Inclusion Criteria: None Exclusion Criteria: None "
[INST] Provide inclusion criteria for trial id: NCT03940092 [/INST] None
[INST] Provide exclusion criteria for trial id: NCT03940092 [/INST] None
"[INST] Provide description for trial id: NCT03940092 [/INST] The scope of this study is the methodological development and optimisation of sodium MRI (23Na-MRI) protocols for breast cancer imaging. The study further proposes to utilise biomarkers obtained from 23Na-imaging (cell integrity), FDG-PET (metabolism), multi-parametric MRI (perfusion, vascularity, cellularity, morphology) to generate parameter maps specific for physiological processes in breast cancer. "
[INST] Provide title for trial id: NCT03940092 [/INST] Sodium (23Na) MRI for Tumour Characterisation and Assessment of Therapy Response in Breast Cancer
[INST] Provide the recruitment status for trial id: NCT03940092 [/INST] Recruiting
[INST] Provide the medical condition for trial id: NCT03940092 [/INST] Breast Cancer
"Trial Id: Triple Negative Breast Cancer: Study of Molecular and Genetic Factors Recruitment Status: Unknown status Trail description: Breast cancer triples negatives (TN; 15 % of the cases) are characterized by a high histoprognostic grade, a strong proliferation, a strong metastatic power, and a worse prognosis than the other forms of breast cancer. It is however a heterogenous group for histological and molecular level, but also for evolution. Most of the TN is part of the basal breast cancer subcategory. Until now, the medical treatment is based on chemotherapy.
Breast cancers by constitutional mutation of BRCA1 / BRCA2 (5 % of breast cancers) are mostly of basal type and their prognostic seems better that what could be expected from high grade tumours and without hormonal receptors. They would be much more frequent in the TN group. However, at this day, no prospective study was led to estimate this incidence, or to study the intervention of other genes of predisposition, as well to analyse the links between this phenotype and their consequences at the germinal or somatic level, in terms of associated molecular changes and prognosis.
The purpose of this study is, on a prospective study, to lead a joined analysis at the germinal level, in search of mutations of the main genes of breast cancer predisposition (BRCA1/2, PALB2, PTEN, PALB2), and at the tumour level (tissue micro-array and transcriptome), by correlating these results to the main clinical parameters.
The 5 years relapse-free survival will also be estimated. Inclusion Criteria: women > 18
non metastatic breast cancer
triple negative
5 years follow-up
signed informed consent Exclusion Criteria: other cancer (except in situ)
metastases at diagnosis
impossibility of follow-up "
"[INST] Provide inclusion criteria for trial id: NCT01434420 [/INST] women > 18
non metastatic breast cancer
triple negative
5 years follow-up
signed informed consent "
"[INST] Provide exclusion criteria for trial id: NCT01434420 [/INST] other cancer (except in situ)
metastases at diagnosis
impossibility of follow-up "
"[INST] Provide description for trial id: NCT01434420 [/INST] Breast cancer triples negatives (TN; 15 % of the cases) are characterized by a high histoprognostic grade, a strong proliferation, a strong metastatic power, and a worse prognosis than the other forms of breast cancer. It is however a heterogenous group for histological and molecular level, but also for evolution. Most of the TN is part of the basal breast cancer subcategory. Until now, the medical treatment is based on chemotherapy.
Breast cancers by constitutional mutation of BRCA1 / BRCA2 (5 % of breast cancers) are mostly of basal type and their prognostic seems better that what could be expected from high grade tumours and without hormonal receptors. They would be much more frequent in the TN group. However, at this day, no prospective study was led to estimate this incidence, or to study the intervention of other genes of predisposition, as well to analyse the links between this phenotype and their consequences at the germinal or somatic level, in terms of associated molecular changes and prognosis.
The purpose of this study is, on a prospective study, to lead a joined analysis at the germinal level, in search of mutations of the main genes of breast cancer predisposition (BRCA1/2, PALB2, PTEN, PALB2), and at the tumour level (tissue micro-array and transcriptome), by correlating these results to the main clinical parameters.
The 5 years relapse-free survival will also be estimated. "
[INST] Provide title for trial id: NCT01434420 [/INST] Triple Negative Breast Cancer: Study of Molecular and Genetic Factors
[INST] Provide the recruitment status for trial id: NCT01434420 [/INST] Unknown status
[INST] Provide the medical condition for trial id: NCT01434420 [/INST] Breast Cancer
"Trial Id: Short and Long Term Effects of a Physical Therapy Program After Breast Cancer Surgery Recruitment Status: Suspended Trail description: Objectives: To evaluate the pressure pain threshold, shoulder biomechanics, cardiorespiratory function and the quality of life associated with the short and long-term physical therapy rehabilitation following breast cancer surgery. Methodology: The study presents three objectives and involves three groups of participants. Objective 1 is to develop a topographic map of pressure pain in the shoulder (using a digital pressure algometer), evaluate the biomechanics of the shoulder (using a digital inclinometer and load card), cardiorespiratory function (through frequency variability resting heart rate and distance traveled, through the six-minute walk test) and quality of life (through questionnaires of quality of life, anxiety, depression, sleep quality, upper limb functionality, fatigue and level of physical activity) between a group of women prior to the operation of breast cancer (experimental group, n = 36) and a group of asymptomatic controls for shoulder pain (control group, n = 18). Objective 2 is to evaluate the possible changes in the pain map over 24 weeks of supervised kinetic intervention (Supervised Physiotherapy experimental group, n = 18, will begin after drainage, frequency 3 times per week and duration of 60 minutes each session) compared to unsupervised kinetic intervention (Home Physiotherapy experimental group, n = 18, participants will receive an exercise booklet). Objective 3 is to evaluate the biomechanics of the shoulder, cardiorespiratory function and the quality of life with respect to the experimental group with and without kinesic supervision. To achieve objective 1, two baseline evaluations will be carried out in both experimental and control groups (considering the month prior to the surgery of the experimental group) and the average of the evaluations will be considered evaluation 1. To achieve objectives 2 and 3, evaluation 2 (after 4 weeks of intervention), 3 (after 12 weeks of intervention) and 4 (after 24 weeks of intervention) will be performed. The statistical analysis will include the examination of qualitative and quantitative variables. Statistical tests will be applied according to the normality of the data and a significance level of 5% will be adopted for all comparisons. Expected results: It is expected to identify sensory, biomechanical, cardiorespiratory and quality of life alterations in the experimental group, compared to the control group. In addition, after 24 weeks of intervention, the supervised experimental group will show improvement in all the aforementioned variables with respect to the unsupervised group. Inclusion Criteria: Surgical indication of conservative or removal breast surgery, associated with axillary lymphadenectomy or sentinel lymph node biopsy
Any type of breast cancer
Age range over 18 years Exclusion Criteria: Breast cancer recurrence;
Surgical treatment for bilateral breast cancer;
Presence of lymphedema in the upper limb, measured by means of cirtometry of the upper limb with a measuring tape 14, asymmetries of more than 1.5 cm between the limbs were considered edema;
Diagnosis of metastases;
Shoulder pain compatible with shoulder compression symptoms as determined by the positive Hawkins-Kennedy test 30;
Previous history of surgery and fractures in the upper extremities. "
"[INST] Provide inclusion criteria for trial id: NCT04116281 [/INST] Surgical indication of conservative or removal breast surgery, associated with axillary lymphadenectomy or sentinel lymph node biopsy
Any type of breast cancer
Age range over 18 years "
"[INST] Provide exclusion criteria for trial id: NCT04116281 [/INST] Breast cancer recurrence;
Surgical treatment for bilateral breast cancer;
Presence of lymphedema in the upper limb, measured by means of cirtometry of the upper limb with a measuring tape 14, asymmetries of more than 1.5 cm between the limbs were considered edema;
Diagnosis of metastases;
Shoulder pain compatible with shoulder compression symptoms as determined by the positive Hawkins-Kennedy test 30;
Previous history of surgery and fractures in the upper extremities. "
"[INST] Provide description for trial id: NCT04116281 [/INST] Objectives: To evaluate the pressure pain threshold, shoulder biomechanics, cardiorespiratory function and the quality of life associated with the short and long-term physical therapy rehabilitation following breast cancer surgery. Methodology: The study presents three objectives and involves three groups of participants. Objective 1 is to develop a topographic map of pressure pain in the shoulder (using a digital pressure algometer), evaluate the biomechanics of the shoulder (using a digital inclinometer and load card), cardiorespiratory function (through frequency variability resting heart rate and distance traveled, through the six-minute walk test) and quality of life (through questionnaires of quality of life, anxiety, depression, sleep quality, upper limb functionality, fatigue and level of physical activity) between a group of women prior to the operation of breast cancer (experimental group, n = 36) and a group of asymptomatic controls for shoulder pain (control group, n = 18). Objective 2 is to evaluate the possible changes in the pain map over 24 weeks of supervised kinetic intervention (Supervised Physiotherapy experimental group, n = 18, will begin after drainage, frequency 3 times per week and duration of 60 minutes each session) compared to unsupervised kinetic intervention (Home Physiotherapy experimental group, n = 18, participants will receive an exercise booklet). Objective 3 is to evaluate the biomechanics of the shoulder, cardiorespiratory function and the quality of life with respect to the experimental group with and without kinesic supervision. To achieve objective 1, two baseline evaluations will be carried out in both experimental and control groups (considering the month prior to the surgery of the experimental group) and the average of the evaluations will be considered evaluation 1. To achieve objectives 2 and 3, evaluation 2 (after 4 weeks of intervention), 3 (after 12 weeks of intervention) and 4 (after 24 weeks of intervention) will be performed. The statistical analysis will include the examination of qualitative and quantitative variables. Statistical tests will be applied according to the normality of the data and a significance level of 5% will be adopted for all comparisons. Expected results: It is expected to identify sensory, biomechanical, cardiorespiratory and quality of life alterations in the experimental group, compared to the control group. In addition, after 24 weeks of intervention, the supervised experimental group will show improvement in all the aforementioned variables with respect to the unsupervised group. "
[INST] Provide title for trial id: NCT04116281 [/INST] Short and Long Term Effects of a Physical Therapy Program After Breast Cancer Surgery
[INST] Provide the recruitment status for trial id: NCT04116281 [/INST] Suspended
[INST] Provide the medical condition for trial id: NCT04116281 [/INST] Breast Cancer
"Trial Id: Prospective Breast Cancer Biobanking Recruitment Status: Enrolling by invitation Trail description: Prospective Breast Cancer Biobanking study (PBCB) will apply advanced monitoring in liquid biopsies of early staged breast cancer ration in order to facilitate A. Early detection of systemic relapses B.Improve adherence and drug monitoring av tamoxifen treatment C. Tumour microenvironment in breast cancer - adipose stromal immune infiltration and interaction with tumour at the growth zone D.Monitor side effects, QoL, depression, fatigue and work life participation Inclusion Criteria: Early stage Breast Cancer
DCIS gr III Exclusion Criteria: Not able to read Norwegian
Not able to communicate in Norwegian
Previously diagnosed with cancer
Dementia "
"[INST] Provide inclusion criteria for trial id: NCT04488614 [/INST] Early stage Breast Cancer
DCIS gr III "
"[INST] Provide exclusion criteria for trial id: NCT04488614 [/INST] Not able to read Norwegian
Not able to communicate in Norwegian
Previously diagnosed with cancer
Dementia "
"[INST] Provide description for trial id: NCT04488614 [/INST] Prospective Breast Cancer Biobanking study (PBCB) will apply advanced monitoring in liquid biopsies of early staged breast cancer ration in order to facilitate A. Early detection of systemic relapses B.Improve adherence and drug monitoring av tamoxifen treatment C. Tumour microenvironment in breast cancer - adipose stromal immune infiltration and interaction with tumour at the growth zone D.Monitor side effects, QoL, depression, fatigue and work life participation "
[INST] Provide title for trial id: NCT04488614 [/INST] Prospective Breast Cancer Biobanking
[INST] Provide the recruitment status for trial id: NCT04488614 [/INST] Enrolling by invitation
[INST] Provide the medical condition for trial id: NCT04488614 [/INST] Breast Cancer
"Trial Id: The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism Recruitment Status: Not yet recruiting Trail description: breast cancer is the most common cancer in women. With more than 1 in 10 new cancer diagnoses each year, It is the second most frequent cancer-related death among women worldwide. Breast cancer develops slowly, and the majority of cases are found through routine screening.
breast cancer-causing deaths among women all over the world and increased in the last few years even though the treatment is advanced like immunotherapy chemotherapy by yet no treatment for triple-negative breast cancer zinc and competition between znt1 and zip6,10 at breast cancer cells. Is zinc ionophore like quercetin and EGCG has a role, In a novel experimental study zinc is a trace metal that has many roles in cells, enzymatic activity, and gene regulations, and also for the integrity of DNA.
Zinc transporters (zinc related -proteins such as ZIPs, and ZnTs are affected by triggers factors like cytokines and growth factors.
There are two large families of zinc transporters like ZIPs ( 14 members) and ZnTs family (10 members), ZIPS family cause an influx of zinc from the extracellular to the cytoplasm and also from intracellular organelles like endoplasmic reticulum or Golgi or mitochondria in contrast to ZnTs which cause an influx of zinc from the cytoplasm to intracellular organelles. ( lower cytoplasmic zinc) (1) Breast cancer deaths occurred from metastasis; Catalytic enzymes called proteases like cathepsin L are frequently overexpressed in aggressive cancers. Breast tumor metastatic potential is correlated with macrophage presence. These macrophages associated with tumors frequently adopt an M2-like pro-tumorigenic phenotype, which results in the production of growth hormones and proteases, notably the lysosomal protease cathepsin L. Because cathepsin L is commonly released by breast cancer cells and aids in tumor invasion, metastasis, and angiogenesis. It is expected that cathepsin L secretion by both tumor-associated macrophages and neoplastic cells would promote the metastatic phenotype because cathepsin L is widely produced by breast cancer cells and helps with tumor invasion, metastasis, and angiogenesis. (2) this study target new mechanisms and achieves the best management as some types of cancer breast like triple-negative breast cancer (TNBC) no definite treatment so we target the following pathways and epigenetic processes by these adjuvant compounds which have a promising role in the immunity like EGCG, Quercetin, Zinc, Metformin so our team will discuss novel methods to achieve the best efficacy from chemotherapy Inclusion Criteria: Age above 18
Female patients
with any type of breast cancer Ductal carcinoma in situ (DCIS) ... Invasive breast cancer (ILC or IDC) ... Triple-negative breast cancer. ... Inflammatory breast cancer. ... Paget disease of the breast. ... Angiosarcoma. ... Phyllodes tumor.
HER2-positive by ASCO CAP 2018 guidelines, confirmed by central testing
Participants must have normal organ and marrow function as defined below:
ANC ≥ 1000/mm3 hemoglobin ≥8 g/dl platelets ≥ 75,000/mm3 AST and ALT both <5x institutional ULN Total bilirubin ≤ 1.5 mg/dL. For patients with Gilbert syndrome, the direct bilirubin should be "
"[INST] Provide inclusion criteria for trial id: NCT05680662 [/INST] Age above 18
Female patients
with any type of breast cancer Ductal carcinoma in situ (DCIS) ... Invasive breast cancer (ILC or IDC) ... Triple-negative breast cancer. ... Inflammatory breast cancer. ... Paget disease of the breast. ... Angiosarcoma. ... Phyllodes tumor.
HER2-positive by ASCO CAP 2018 guidelines, confirmed by central testing
Participants must have normal organ and marrow function as defined below:
ANC ≥ 1000/mm3 hemoglobin ≥8 g/dl platelets ≥ 75,000/mm3 AST and ALT both <5x institutional ULN Total bilirubin ≤ 1.5 mg/dL. For patients with Gilbert syndrome, the direct bilirubin should be "
"[INST] Provide exclusion criteria for trial id: NCT05680662 [/INST] Neoadjuvant or adjuvant chemotherapy for this breast cancer prior to enrollment is prohibited.
Any of the following due to teratogenic potential of the study drugs:
Pregnant women Nursing women Women of childbearing potential who are unwilling to employ adequate contraception (condoms, diaphragms, IUDS, surgical sterilization, abstinence, etc). Hormonal birth control methods are not permitted.
Participants who are receiving any other investigational agents for treatment of breast cancer, unless specific approval is obtained from the Sponsor-Investigator.
- "
"[INST] Provide description for trial id: NCT05680662 [/INST] breast cancer is the most common cancer in women. With more than 1 in 10 new cancer diagnoses each year, It is the second most frequent cancer-related death among women worldwide. Breast cancer develops slowly, and the majority of cases are found through routine screening.
breast cancer-causing deaths among women all over the world and increased in the last few years even though the treatment is advanced like immunotherapy chemotherapy by yet no treatment for triple-negative breast cancer zinc and competition between znt1 and zip6,10 at breast cancer cells. Is zinc ionophore like quercetin and EGCG has a role, In a novel experimental study zinc is a trace metal that has many roles in cells, enzymatic activity, and gene regulations, and also for the integrity of DNA.
Zinc transporters (zinc related -proteins such as ZIPs, and ZnTs are affected by triggers factors like cytokines and growth factors.
There are two large families of zinc transporters like ZIPs ( 14 members) and ZnTs family (10 members), ZIPS family cause an influx of zinc from the extracellular to the cytoplasm and also from intracellular organelles like endoplasmic reticulum or Golgi or mitochondria in contrast to ZnTs which cause an influx of zinc from the cytoplasm to intracellular organelles. ( lower cytoplasmic zinc) (1) Breast cancer deaths occurred from metastasis; Catalytic enzymes called proteases like cathepsin L are frequently overexpressed in aggressive cancers. Breast tumor metastatic potential is correlated with macrophage presence. These macrophages associated with tumors frequently adopt an M2-like pro-tumorigenic phenotype, which results in the production of growth hormones and proteases, notably the lysosomal protease cathepsin L. Because cathepsin L is commonly released by breast cancer cells and aids in tumor invasion, metastasis, and angiogenesis. It is expected that cathepsin L secretion by both tumor-associated macrophages and neoplastic cells would promote the metastatic phenotype because cathepsin L is widely produced by breast cancer cells and helps with tumor invasion, metastasis, and angiogenesis. (2) this study target new mechanisms and achieves the best management as some types of cancer breast like triple-negative breast cancer (TNBC) no definite treatment so we target the following pathways and epigenetic processes by these adjuvant compounds which have a promising role in the immunity like EGCG, Quercetin, Zinc, Metformin so our team will discuss novel methods to achieve the best efficacy from chemotherapy "
"[INST] Provide title for trial id: NCT05680662 [/INST] The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism "
[INST] Provide the recruitment status for trial id: NCT05680662 [/INST] Not yet recruiting
"[INST] Provide the medical condition for trial id: NCT05680662 [/INST] Breast Cancer Female, Triple Negative Breast Cancer "
"Trial Id: Evaluation the Diagnostic Ability of the Cancer Detection Technology (CDT) to Detect Breast Cancer Among Women Population Over Age 40 Recruitment Status: Unknown status Trail description: This study aimed to validate the diagnostic ability of the CDT (cancer detection technology) software to detect breast cancer among women population. Inclusion Criteria: Inclusion Criteria for Breast Cancer Patients for Experimental Group:
Patient is over the age of 40.
Patient is willing to participate as evidenced by signing the written informed consent form.
Patient referred to the Department of Oncology/ Surgery for operative treatment of breast cancer with previously detected disease. Positive conventional tests finding can include (but not limited to) the record of screening or diagnostic mammography, blood oncomarkers, breast ultrasound, breast CT, biopsy.
Non-treated patients (w/o previous chemotherapy, hormonal drugs and radiotherapy).
Patient without other cancer locations
Inclusion Criteria for Presumably Healthy Subjects for Control Group:
Subjects over the age of 40.
Subjects who are willing to participate as evidenced by signing the written informed consent form.
Subjects who are presumably healthy and without breast pathologies' symptoms and family history of breast cancer, i.e., breast disease (except history of functional breast problems, e.g., mastitis within lactation period) has been ruled out based on physician anamnesis
Subjects with negative results of screening mammography.
Subjects without taking of any hormonal medicines Exclusion Criteria: Subjects with any known cancer in other internal organs or systems.
Subjects with high fever presentation (more than 38.5).
Subjects with known breast disease undergoing treatment for the disease.
Pregnant or lactating women "
"[INST] Provide inclusion criteria for trial id: NCT01043055 [/INST] Inclusion Criteria for Breast Cancer Patients for Experimental Group:
Patient is over the age of 40.
Patient is willing to participate as evidenced by signing the written informed consent form.
Patient referred to the Department of Oncology/ Surgery for operative treatment of breast cancer with previously detected disease. Positive conventional tests finding can include (but not limited to) the record of screening or diagnostic mammography, blood oncomarkers, breast ultrasound, breast CT, biopsy.
Non-treated patients (w/o previous chemotherapy, hormonal drugs and radiotherapy).
Patient without other cancer locations
Inclusion Criteria for Presumably Healthy Subjects for Control Group:
Subjects over the age of 40.
Subjects who are willing to participate as evidenced by signing the written informed consent form.
Subjects who are presumably healthy and without breast pathologies' symptoms and family history of breast cancer, i.e., breast disease (except history of functional breast problems, e.g., mastitis within lactation period) has been ruled out based on physician anamnesis
Subjects with negative results of screening mammography.
Subjects without taking of any hormonal medicines "
"[INST] Provide exclusion criteria for trial id: NCT01043055 [/INST] Subjects with any known cancer in other internal organs or systems.
Subjects with high fever presentation (more than 38.5).
Subjects with known breast disease undergoing treatment for the disease.
Pregnant or lactating women "
[INST] Provide description for trial id: NCT01043055 [/INST] This study aimed to validate the diagnostic ability of the CDT (cancer detection technology) software to detect breast cancer among women population.
[INST] Provide title for trial id: NCT01043055 [/INST] Evaluation the Diagnostic Ability of the Cancer Detection Technology (CDT) to Detect Breast Cancer Among Women Population Over Age 40
[INST] Provide the recruitment status for trial id: NCT01043055 [/INST] Unknown status
[INST] Provide the medical condition for trial id: NCT01043055 [/INST] Breast Cancer
"Trial Id: Oncoliq: Test for Early Breast Cancer Detection. Recruitment Status: Recruiting Trail description: Oncoliq is a novel early breast cancer detection test based on liquid biopsies and microRNAs. This innovative test will allow improving the accuracy of cancer detection which will impact on health, reducing the patient mortality and health costs.
To develop this test, it has been finished the preclinical PHASE I: in laboratory animals; PHASE II: exploratory clinical phase for the discovery of candidate biomarkers in breast cancer patients and PHASE III: clinical validation of biomarkers showing that Oncoliq has 91% of sensitivity.
Currently it is been setting up a ""pilot test"" for breast cancer to enrol 500 woman volunteers without previous cancer diagnosis that go to the annual medical control. The results of the pilot test will give the accuracy for early breast cancer detection. Inclusion Criteria: Women patients performing gynecological control
Between 50-70 years old
Without personal history of oncological disease
Informed consent signed Exclusion Criteria: Patients who don´t meet the inclusion criteria.
Active infection with SARS-CoV-2 (COVID-19). "
"[INST] Provide inclusion criteria for trial id: NCT04906330 [/INST] Women patients performing gynecological control
Between 50-70 years old
Without personal history of oncological disease
Informed consent signed "
"[INST] Provide exclusion criteria for trial id: NCT04906330 [/INST] Patients who don´t meet the inclusion criteria.
Active infection with SARS-CoV-2 (COVID-19). "
"[INST] Provide description for trial id: NCT04906330 [/INST] Oncoliq is a novel early breast cancer detection test based on liquid biopsies and microRNAs. This innovative test will allow improving the accuracy of cancer detection which will impact on health, reducing the patient mortality and health costs.
To develop this test, it has been finished the preclinical PHASE I: in laboratory animals; PHASE II: exploratory clinical phase for the discovery of candidate biomarkers in breast cancer patients and PHASE III: clinical validation of biomarkers showing that Oncoliq has 91% of sensitivity.
Currently it is been setting up a ""pilot test"" for breast cancer to enrol 500 woman volunteers without previous cancer diagnosis that go to the annual medical control. The results of the pilot test will give the accuracy for early breast cancer detection. "
[INST] Provide title for trial id: NCT04906330 [/INST] Oncoliq: Test for Early Breast Cancer Detection.
[INST] Provide the recruitment status for trial id: NCT04906330 [/INST] Recruiting
[INST] Provide the medical condition for trial id: NCT04906330 [/INST] Breast Cancer
"Trial Id: Breast Cancer Recurrence - the Accuracy of Dual-time PET/CT Recruitment Status: Completed Trail description: The purpose of this study is to elucidate the value of dual-time-point PET/CT in the recurrence of breast cancer and to determine whether the method is better than the modalities used in the standard work up.
150 patients with suspected breast cancer recurrence will be included. All patients will undergo dual-time-point PET/CT, CT of thorax and upper abdomen and bone scintigraphy. After completion of the examinations the early and the late PET/CT scan will be compared with each other, the diagnostic CT-scan and the bone scintigraphy. A verification of suspicious findings will be done by biopsy, if the area is accessible. If a biopsy cannot be obtained, the presence of recurrence will be verified with additional imaging follow-up to ensure the highest possible confidence. Sensitivity, specificity, accuracy, negative and positive predictive value (NPV/PPV) will be calculated for each modality (incl. early and late PET/CT). Inclusion Criteria: Clinical suspected recurrence of breast cancer
Blood glucose level less than 8,0 mmol/L Exclusion Criteria: Disqualified patients
Other malignancies
< 18 years
< 50 kg
> 90 kg
Pregnant or lactating
Patients with permanent address outside of the Region of Southern Denmark
Estimated inability to collaborate "
"[INST] Provide inclusion criteria for trial id: NCT01552655 [/INST] Clinical suspected recurrence of breast cancer
Blood glucose level less than 8,0 mmol/L "
"[INST] Provide exclusion criteria for trial id: NCT01552655 [/INST] Disqualified patients
Other malignancies
< 18 years
< 50 kg
> 90 kg
Pregnant or lactating
Patients with permanent address outside of the Region of Southern Denmark
Estimated inability to collaborate "
"[INST] Provide description for trial id: NCT01552655 [/INST] The purpose of this study is to elucidate the value of dual-time-point PET/CT in the recurrence of breast cancer and to determine whether the method is better than the modalities used in the standard work up.
150 patients with suspected breast cancer recurrence will be included. All patients will undergo dual-time-point PET/CT, CT of thorax and upper abdomen and bone scintigraphy. After completion of the examinations the early and the late PET/CT scan will be compared with each other, the diagnostic CT-scan and the bone scintigraphy. A verification of suspicious findings will be done by biopsy, if the area is accessible. If a biopsy cannot be obtained, the presence of recurrence will be verified with additional imaging follow-up to ensure the highest possible confidence. Sensitivity, specificity, accuracy, negative and positive predictive value (NPV/PPV) will be calculated for each modality (incl. early and late PET/CT). "
[INST] Provide title for trial id: NCT01552655 [/INST] Breast Cancer Recurrence - the Accuracy of Dual-time PET/CT
[INST] Provide the recruitment status for trial id: NCT01552655 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT01552655 [/INST] Breast Cancer Recurrent
"Trial Id: PERSONAL - Sleep In Breast Cancer Recruitment Status: Completed Trail description: Sleep is essential for human function, immunity, and well-being. In the general population, sleep disturbance and insomnia cause significant health problems and impact on the quality of life of many individuals. The incidence of insomnia in cancer patients is disproportionality higher, with breast cancer patients experiencing prevalence rates ranging from 19% to 69%. The impact of insomnia on cancer patients' lives can be significant and is associated with depression, cancer-related fatigue, increased pain, reduced quality of life, decreased immunity, disease progression, and survival. To date, breast cancer studies show large variation in reported insomnia prevalence rates, and the severity of sleep complaints in these patients have been difficult to assess. Thus, these issues require further investigation using standardised and validated measures.
In this observational study, we aim to investigate the prevalence and severity of insomnia in a cohort of breast cancer patients at the Christie Hospital using the Insomnia Severity Index (ISI), a validated measure for insomnia. This study will consist of two stages. In Stage 1, patients aged 18 and over, who provide informed consent and have a diagnosis of Stage I, II or III breast cancer in the previous 12 months will be asked to complete the validated ISI. Using the ISI, participants identified as having sleeping difficulties and/or insomnia will be invited to Stage 2 of the study. In this stage, participants will be asked to track their sleep each morning for 3 weeks using a digital sleep diary downloaded onto their own smartphone. They will also be asked to complete a series of questionnaires gathering information regarding their quality of life, well-being, and health. This research will provide a better understanding of sleeping patterns, sleeping difficulties and insomnia in patients with breast cancer, and in the long-term, help us design better treatments for patients with sleeping problems. Inclusion Criteria: None Exclusion Criteria: None "
[INST] Provide inclusion criteria for trial id: NCT05093426 [/INST] None
[INST] Provide exclusion criteria for trial id: NCT05093426 [/INST] None
"[INST] Provide description for trial id: NCT05093426 [/INST] Sleep is essential for human function, immunity, and well-being. In the general population, sleep disturbance and insomnia cause significant health problems and impact on the quality of life of many individuals. The incidence of insomnia in cancer patients is disproportionality higher, with breast cancer patients experiencing prevalence rates ranging from 19% to 69%. The impact of insomnia on cancer patients' lives can be significant and is associated with depression, cancer-related fatigue, increased pain, reduced quality of life, decreased immunity, disease progression, and survival. To date, breast cancer studies show large variation in reported insomnia prevalence rates, and the severity of sleep complaints in these patients have been difficult to assess. Thus, these issues require further investigation using standardised and validated measures.
In this observational study, we aim to investigate the prevalence and severity of insomnia in a cohort of breast cancer patients at the Christie Hospital using the Insomnia Severity Index (ISI), a validated measure for insomnia. This study will consist of two stages. In Stage 1, patients aged 18 and over, who provide informed consent and have a diagnosis of Stage I, II or III breast cancer in the previous 12 months will be asked to complete the validated ISI. Using the ISI, participants identified as having sleeping difficulties and/or insomnia will be invited to Stage 2 of the study. In this stage, participants will be asked to track their sleep each morning for 3 weeks using a digital sleep diary downloaded onto their own smartphone. They will also be asked to complete a series of questionnaires gathering information regarding their quality of life, well-being, and health. This research will provide a better understanding of sleeping patterns, sleeping difficulties and insomnia in patients with breast cancer, and in the long-term, help us design better treatments for patients with sleeping problems. "
[INST] Provide title for trial id: NCT05093426 [/INST] PERSONAL - Sleep In Breast Cancer
[INST] Provide the recruitment status for trial id: NCT05093426 [/INST] Completed
"[INST] Provide the medical condition for trial id: NCT05093426 [/INST] Insomnia, Breast Cancer "
"Trial Id: Identification of New Prognostic Markers for Breast Cancer. Recruitment Status: Recruiting Trail description: Candidate markers have been identified thanks to an original approach developed by our research team aiming at detecting ectopic gene expression using public pan-genomic breast cancer data. The same approach had already been used and validated in lung tumors, leukemias and lymphomas. The main objective of the present research is to use tumor samples from patients in a retrospective and prospective cohort to test and validate the relevance of these prognostic markers in breast cancer. Inclusion Criteria: Adult female patients with breast cancer Exclusion Criteria: Presence of another cancer, excluding basal cell cancers or pre-neoplastic lesions of the cervix.
Subject under guardianship or subject deprived of liberty
Impossibility of collecting information on exposure (subjects recently arrived in France, foreign language, etc.)
Male patients "
[INST] Provide inclusion criteria for trial id: NCT03436069 [/INST] Adult female patients with breast cancer
"[INST] Provide exclusion criteria for trial id: NCT03436069 [/INST] Presence of another cancer, excluding basal cell cancers or pre-neoplastic lesions of the cervix.
Subject under guardianship or subject deprived of liberty
Impossibility of collecting information on exposure (subjects recently arrived in France, foreign language, etc.)
Male patients "
"[INST] Provide description for trial id: NCT03436069 [/INST] Candidate markers have been identified thanks to an original approach developed by our research team aiming at detecting ectopic gene expression using public pan-genomic breast cancer data. The same approach had already been used and validated in lung tumors, leukemias and lymphomas. The main objective of the present research is to use tumor samples from patients in a retrospective and prospective cohort to test and validate the relevance of these prognostic markers in breast cancer. "
[INST] Provide title for trial id: NCT03436069 [/INST] Identification of New Prognostic Markers for Breast Cancer.
[INST] Provide the recruitment status for trial id: NCT03436069 [/INST] Recruiting
[INST] Provide the medical condition for trial id: NCT03436069 [/INST] Breast Cancer
"Trial Id: Aberrant Expression of Micro RNA for Diagnosis of Breast Cancer Recruitment Status: Unknown status Trail description: In this study we aim to:
Assess serum miRNA-373, miRNA-425-5p expression in patients with breast cancer.
Explore their correlations with breast cancer clinicopathological documented data including staging, grading and tumor receptors. Inclusion Criteria: Female age 20 years or older
documented diagnosis of breast cancer based on physical examination, imaging and histopathology
possibility of obtaining blood samples from the subject. Exclusion Criteria: All patients with prior history of exposure to chemotherapy, radiotherapy or hormonal therapy .
patients with other malignancies.
patients with chronic inflammatory diseases.
patients with missed documentation for histopathological diagnosis of breast cancer. "
"[INST] Provide inclusion criteria for trial id: NCT04720508 [/INST] Female age 20 years or older
documented diagnosis of breast cancer based on physical examination, imaging and histopathology
possibility of obtaining blood samples from the subject. "
"[INST] Provide exclusion criteria for trial id: NCT04720508 [/INST] All patients with prior history of exposure to chemotherapy, radiotherapy or hormonal therapy .
patients with other malignancies.
patients with chronic inflammatory diseases.
patients with missed documentation for histopathological diagnosis of breast cancer. "
"[INST] Provide description for trial id: NCT04720508 [/INST] In this study we aim to:
Assess serum miRNA-373, miRNA-425-5p expression in patients with breast cancer.
Explore their correlations with breast cancer clinicopathological documented data including staging, grading and tumor receptors. "
[INST] Provide title for trial id: NCT04720508 [/INST] Aberrant Expression of Micro RNA for Diagnosis of Breast Cancer
[INST] Provide the recruitment status for trial id: NCT04720508 [/INST] Unknown status
[INST] Provide the medical condition for trial id: NCT04720508 [/INST] Breast Cancer
"Trial Id: What Matters Most: Choosing the Right Breast Cancer Surgery for You Recruitment Status: Completed Trail description: What Matters Most is a study that aims to determine how best to help women of lower socioeconomic status make high-quality decisions about early stage breast cancer treatments. What Matters Most will be comparing two decision aids used in the clinic visit to usual care (what normally happens in the clinic). The first decision aid (Option Grid) presents evidence-based information about lumpectomy and mastectomy in a tabular format using text only. The second decision aid (Picture Option Grid) presents evidence-based information about lumpectomy and mastectomy using pictures, pictographs and simplified text. What Matters Most aims to show that the interventions can reduce disparities in decision-making and treatment choice between women of high and low SES. Inclusion Criteria: Assigned female at birth;
18 years and older;
Confirmed diagnosis (via biopsy) of early stage breast cancer (stages I-IIIA);
Eligible for both breast-conserving surgery and mastectomy based on medical records and clinician's opinion before surgery;
Spoken English, Spanish, or Mandarin Chinese. Exclusion Criteria: Transgender men and women;
Women who have undergone prophylactic mastectomy;
Women with visual impairment;
Women with a diagnosis of severe mental illness or severe dementia;
Women with inflammatory breast carcinoma. "
"[INST] Provide inclusion criteria for trial id: NCT03136367 [/INST] Assigned female at birth;
18 years and older;
Confirmed diagnosis (via biopsy) of early stage breast cancer (stages I-IIIA);
Eligible for both breast-conserving surgery and mastectomy based on medical records and clinician's opinion before surgery;
Spoken English, Spanish, or Mandarin Chinese. "
"[INST] Provide exclusion criteria for trial id: NCT03136367 [/INST] Transgender men and women;
Women who have undergone prophylactic mastectomy;
Women with visual impairment;
Women with a diagnosis of severe mental illness or severe dementia;
Women with inflammatory breast carcinoma. "
"[INST] Provide description for trial id: NCT03136367 [/INST] What Matters Most is a study that aims to determine how best to help women of lower socioeconomic status make high-quality decisions about early stage breast cancer treatments. What Matters Most will be comparing two decision aids used in the clinic visit to usual care (what normally happens in the clinic). The first decision aid (Option Grid) presents evidence-based information about lumpectomy and mastectomy in a tabular format using text only. The second decision aid (Picture Option Grid) presents evidence-based information about lumpectomy and mastectomy using pictures, pictographs and simplified text. What Matters Most aims to show that the interventions can reduce disparities in decision-making and treatment choice between women of high and low SES. "
[INST] Provide title for trial id: NCT03136367 [/INST] What Matters Most: Choosing the Right Breast Cancer Surgery for You
[INST] Provide the recruitment status for trial id: NCT03136367 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT03136367 [/INST] Breast Cancer
"Trial Id: Comparison of Ultrasound and Breast MRI for Breast Cancer Detection Recruitment Status: Recruiting Trail description: The goal of this randomized clinical trial is to compare diagnostic results of secondary breast cancer surveillance using breast ultrasound abbreviated MRI and full protocol MRI. Inclusion Criteria: Women aged 20-75 with a history of breast cancer (in situ carcinoma or invasive breast cancer [stage 0-3])
Women with a negative resection margin in the pathology results of the last surgical specimen from past breast cancer
Women with dense breasts with pattern C (heterogeneously dense) or D (extremely dense breasts) using AI-based Lunit INSIGHT for Mammography (version 1.1.4.3, Lunit Inc.) in the most recent mammography
Women who have not had a breast imaging test within 6 months
Women who agreed to undergo regular annual mammography, breast ultrasound, and breast MRI
If mammography, ultrasound, or breast MRI was performed within the last 1 year, the most recent test result is normal or positive (BI-RADS 1 or 2) Exclusion Criteria: Patients with symptoms related to current breast cancer or breast cancer recurrence (palpable mass, bloody or transparent nipple secretion, palpable mass in the axillary region, abnormal skin changes in the breast or nipple)
If you have been diagnosed with regional recurrence (axillary lymph nodes, supraclavicular and subclavian lymph nodes, internal mammary lymph nodes, etc.) or distant metastases
In case of bilateral total mastectomy
If women are receiving chemotherapy for cancer in other organs
Women during pregnancy or lactation
Glomerular filtration rate < 30 mL/min/1.73m2, or patients with renal insufficiency on dialysis
If women have severe claustrophobia
If women have a metal prosthesis that is not suitable for MR (e.g. breast tissue expander, etc.)
If there is a history of severe contrast agent side effects (e.g., anaphylactoid reaction, dyspnea, etc.) "
"[INST] Provide inclusion criteria for trial id: NCT05797545 [/INST] Women aged 20-75 with a history of breast cancer (in situ carcinoma or invasive breast cancer [stage 0-3])
Women with a negative resection margin in the pathology results of the last surgical specimen from past breast cancer
Women with dense breasts with pattern C (heterogeneously dense) or D (extremely dense breasts) using AI-based Lunit INSIGHT for Mammography (version 1.1.4.3, Lunit Inc.) in the most recent mammography
Women who have not had a breast imaging test within 6 months
Women who agreed to undergo regular annual mammography, breast ultrasound, and breast MRI
If mammography, ultrasound, or breast MRI was performed within the last 1 year, the most recent test result is normal or positive (BI-RADS 1 or 2) "
"[INST] Provide exclusion criteria for trial id: NCT05797545 [/INST] Patients with symptoms related to current breast cancer or breast cancer recurrence (palpable mass, bloody or transparent nipple secretion, palpable mass in the axillary region, abnormal skin changes in the breast or nipple)
If you have been diagnosed with regional recurrence (axillary lymph nodes, supraclavicular and subclavian lymph nodes, internal mammary lymph nodes, etc.) or distant metastases
In case of bilateral total mastectomy
If women are receiving chemotherapy for cancer in other organs
Women during pregnancy or lactation
Glomerular filtration rate < 30 mL/min/1.73m2, or patients with renal insufficiency on dialysis
If women have severe claustrophobia
If women have a metal prosthesis that is not suitable for MR (e.g. breast tissue expander, etc.)
If there is a history of severe contrast agent side effects (e.g., anaphylactoid reaction, dyspnea, etc.) "
[INST] Provide description for trial id: NCT05797545 [/INST] The goal of this randomized clinical trial is to compare diagnostic results of secondary breast cancer surveillance using breast ultrasound abbreviated MRI and full protocol MRI.
[INST] Provide title for trial id: NCT05797545 [/INST] Comparison of Ultrasound and Breast MRI for Breast Cancer Detection
[INST] Provide the recruitment status for trial id: NCT05797545 [/INST] Recruiting
"[INST] Provide the medical condition for trial id: NCT05797545 [/INST] Breast Neoplasms, Breast Cancer "
"Trial Id: The Effect of Breast Cancer Screening Training Recruitment Status: Active, not recruiting Trail description: The lack of knowledge of women on breast cancer and health literacy poses a major obstacle to people's breast cancer screening behaviors and beliefs. In order to increase social sensitivity and awareness on this issue; In particular, it is important to research, examine and examine how the municipalities and their employees, who are representatives of the society, evaluate breast cancer screening studies. The aim of our project is to evaluate the effect of breast cancer screening training given to women working in the municipality on health literacy, breast cancer screening belief and behavior. This study will be conducted in a randomized-controlled experimental design with women (n=120) working in a municipality in Istanbul Province between November 2022 and November 2023. Data will be obtained face-to-face using the Participant Information Form, the Health Literacy Scale and the Breast Cancer Screening Beliefs Scale. The women in the experimental group (n=60) will be given 16 hours of breast cancer screening training, two days a week, two hours a day (60 min+60 min) for four weeks, by the researchers. No application will be made to the control group (n=60). Follow-up evaluations of the research will be completed in the following six months. The Health Literacy Scale and Breast Cancer Screening Beliefs Scale will be re-administered to all women in the experimental and control groups at the first follow-up after three months and at the second follow-up after 6 months. The data will be analyzed with statistical methods and the effectiveness of the training will be evaluated.
When the project is concluded; The results will be presented as an article in a national or international journal, or as an oral presentation at a national or international congress. It will be ensured that breast cancer screening training given to women working in the municipality will increase their level of health literacy, have a positive effect on breast cancer screening belief and behavior, and increase their awareness and knowledge level on this subject. In the long term, widespread effects such as reducing the costs women spend on breast cancer, reducing mortality and morbidity rates, raising a conscious society, training undergraduate students involved in the project, and helping them learn by experiencing the research conducted at the national level are foreseen. Inclusion Criteria: Women aged 18 and over,
Volunteering to participate in the study,
Working in the municipality for at least 1 month and
Not having any communication problems Exclusion Criteria: Women who have any communication barrier and
Do not volunteer to participate in the study will be excluded from the study. "
"[INST] Provide inclusion criteria for trial id: NCT05723237 [/INST] Women aged 18 and over,
Volunteering to participate in the study,
Working in the municipality for at least 1 month and
Not having any communication problems "
"[INST] Provide exclusion criteria for trial id: NCT05723237 [/INST] Women who have any communication barrier and
Do not volunteer to participate in the study will be excluded from the study. "
"[INST] Provide description for trial id: NCT05723237 [/INST] The lack of knowledge of women on breast cancer and health literacy poses a major obstacle to people's breast cancer screening behaviors and beliefs. In order to increase social sensitivity and awareness on this issue; In particular, it is important to research, examine and examine how the municipalities and their employees, who are representatives of the society, evaluate breast cancer screening studies. The aim of our project is to evaluate the effect of breast cancer screening training given to women working in the municipality on health literacy, breast cancer screening belief and behavior. This study will be conducted in a randomized-controlled experimental design with women (n=120) working in a municipality in Istanbul Province between November 2022 and November 2023. Data will be obtained face-to-face using the Participant Information Form, the Health Literacy Scale and the Breast Cancer Screening Beliefs Scale. The women in the experimental group (n=60) will be given 16 hours of breast cancer screening training, two days a week, two hours a day (60 min+60 min) for four weeks, by the researchers. No application will be made to the control group (n=60). Follow-up evaluations of the research will be completed in the following six months. The Health Literacy Scale and Breast Cancer Screening Beliefs Scale will be re-administered to all women in the experimental and control groups at the first follow-up after three months and at the second follow-up after 6 months. The data will be analyzed with statistical methods and the effectiveness of the training will be evaluated.
When the project is concluded; The results will be presented as an article in a national or international journal, or as an oral presentation at a national or international congress. It will be ensured that breast cancer screening training given to women working in the municipality will increase their level of health literacy, have a positive effect on breast cancer screening belief and behavior, and increase their awareness and knowledge level on this subject. In the long term, widespread effects such as reducing the costs women spend on breast cancer, reducing mortality and morbidity rates, raising a conscious society, training undergraduate students involved in the project, and helping them learn by experiencing the research conducted at the national level are foreseen. "
[INST] Provide title for trial id: NCT05723237 [/INST] The Effect of Breast Cancer Screening Training
"[INST] Provide the recruitment status for trial id: NCT05723237 [/INST] Active, not recruiting "
[INST] Provide the medical condition for trial id: NCT05723237 [/INST] Women's Health: Neoplasm of Breast
"Trial Id: Evaluation of Effectiveness of Acupuncture on Quality of Life in Patients With Breast Cancer Receiving Chemotherapy Recruitment Status: Completed Trail description: The aim of this trial is to investigate the effectiveness of acupuncture on quality of life in patients with breast cancer receiving chemotherapy compared to routine care. Inclusion Criteria: diagnosed breast cancer (invasive, intraductal, hormone-sensitive and not hormone-sensitive, only locoregional metastases)
current chemotherapy at Mammazentrum Hamburg with regimen FEC/DOC or EC/DOC
willingness to receive acupuncture within the next 6 month if randomized in acupuncture group
willingness to refrain from acupuncture within the next 6 month if randomized in control group
informed consent Exclusion Criteria: distant metastases
blood coagulation disorder and/or current use of anticoagulants
serious acute or chronic mental or physical disorders
clinically relevant cardiac arrhythmia symptoms
insufficient German language ability "
"[INST] Provide inclusion criteria for trial id: NCT01727362 [/INST] diagnosed breast cancer (invasive, intraductal, hormone-sensitive and not hormone-sensitive, only locoregional metastases)
current chemotherapy at Mammazentrum Hamburg with regimen FEC/DOC or EC/DOC
willingness to receive acupuncture within the next 6 month if randomized in acupuncture group
willingness to refrain from acupuncture within the next 6 month if randomized in control group
informed consent "
"[INST] Provide exclusion criteria for trial id: NCT01727362 [/INST] distant metastases
blood coagulation disorder and/or current use of anticoagulants
serious acute or chronic mental or physical disorders
clinically relevant cardiac arrhythmia symptoms
insufficient German language ability "
[INST] Provide description for trial id: NCT01727362 [/INST] The aim of this trial is to investigate the effectiveness of acupuncture on quality of life in patients with breast cancer receiving chemotherapy compared to routine care.
[INST] Provide title for trial id: NCT01727362 [/INST] Evaluation of Effectiveness of Acupuncture on Quality of Life in Patients With Breast Cancer Receiving Chemotherapy
[INST] Provide the recruitment status for trial id: NCT01727362 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT01727362 [/INST] Breast Cancer
"Trial Id: Evaluation of a Novel Infra-red Breast Imaging System for Risk Assessment in Women at High Risk for Breast Cancer. Recruitment Status: Unknown status Trail description: Three-dimensional functional Metabolic Imaging (3D MIRA) is a new infrared imaging technology using the Real Imager 4(RI4) developed by Real Imaging. This technology generates 3D metabolic maps and based on sophisticated machine learning technology, provides objective risk assessment for the presence of malignant tumor. The procedure is non-invasive, comfortable and does not involve ionizing radiation. Moreover, Real Imaging's 3D Functional MIRA is unaffected by breast density and is therefore ideal for evaluating patients with mammographically dense breasts.
The purpose of this clinical study is to assess the ability of this novel technology to detect clinically occult breast cancer in a cohort of women that are at high risk for breast cancer.
We hypothesize that the combination of screening mammography and metabolic screening (3D MIRA) will result in significantly higher breast cancer detection rates. Inclusion Criteria: Female
Woman has read, understood and signed the inform consent form
Age: 20 years and older
Women who are asymptomatic for breast cancer
Proven carriers of deleterious BRCA1 or BRCA2 mutations Or Women that were found to have a lifetime risk of developing breast cancer greater or equal to 20% based on Tyrer-Cuzick, Gail or Clause risk models
Women scheduled to undergo routine mammography and/or US or MRI screening Exclusion Criteria: Women who have had a mammography and/or ultrasound examination performed on the day of the study prior to MIRA scan
Women who had a lumpectomy surgery
Women who had undergone mastectomy and/or reconstruction
Women who have undergone any type of breast surgery throughout the 6 months preceding the study
Women who have had a breast biopsy performed throughout the 10 weeks preceding the study.
Women who have a fever on the day of the MIRA imaging
Women who are pregnant
Women who are breast-feeding
Women who had undergone breast reduction/augmentation "
"[INST] Provide inclusion criteria for trial id: NCT02009150 [/INST] Female
Woman has read, understood and signed the inform consent form
Age: 20 years and older
Women who are asymptomatic for breast cancer
Proven carriers of deleterious BRCA1 or BRCA2 mutations Or Women that were found to have a lifetime risk of developing breast cancer greater or equal to 20% based on Tyrer-Cuzick, Gail or Clause risk models
Women scheduled to undergo routine mammography and/or US or MRI screening "
"[INST] Provide exclusion criteria for trial id: NCT02009150 [/INST] Women who have had a mammography and/or ultrasound examination performed on the day of the study prior to MIRA scan
Women who had a lumpectomy surgery
Women who had undergone mastectomy and/or reconstruction
Women who have undergone any type of breast surgery throughout the 6 months preceding the study
Women who have had a breast biopsy performed throughout the 10 weeks preceding the study.
Women who have a fever on the day of the MIRA imaging
Women who are pregnant
Women who are breast-feeding
Women who had undergone breast reduction/augmentation "
"[INST] Provide description for trial id: NCT02009150 [/INST] Three-dimensional functional Metabolic Imaging (3D MIRA) is a new infrared imaging technology using the Real Imager 4(RI4) developed by Real Imaging. This technology generates 3D metabolic maps and based on sophisticated machine learning technology, provides objective risk assessment for the presence of malignant tumor. The procedure is non-invasive, comfortable and does not involve ionizing radiation. Moreover, Real Imaging's 3D Functional MIRA is unaffected by breast density and is therefore ideal for evaluating patients with mammographically dense breasts.
The purpose of this clinical study is to assess the ability of this novel technology to detect clinically occult breast cancer in a cohort of women that are at high risk for breast cancer.
We hypothesize that the combination of screening mammography and metabolic screening (3D MIRA) will result in significantly higher breast cancer detection rates. "
[INST] Provide title for trial id: NCT02009150 [/INST] Evaluation of a Novel Infra-red Breast Imaging System for Risk Assessment in Women at High Risk for Breast Cancer.
[INST] Provide the recruitment status for trial id: NCT02009150 [/INST] Unknown status
[INST] Provide the medical condition for trial id: NCT02009150 [/INST] Breast Cancer
"Trial Id: Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer Recruitment Status: Recruiting Trail description: Breast cancer patients who undergo neoadjuvant systemic therapy and have residual breast cancer identified at the time of surgery exhibit a high (>50%) risk of future life-threatening recurrences and death. Inclusion Criteria: Age ≥18 years.
Diagnosis of invasive breast cancer treated with neoadjuvant systemic therapy.
Surgically resectable disease following neoadjuvant systemic treatment.
At least one of the following must be true:
Received at least 2 weeks of neoadjuvant endocrine therapy
Received at least 2 months of neoadjuvant chemotherapy with suggestion of residual disease on imaging
Began neoadjuvant chemotherapy or endocrine therapy but discontinued due to evidence of progressive disease by MRI, ultrasound, or physical examination
Provide written informed consent.
Willing to return to enrolling institution for breast cancer surgery.
Willingness to provide mandatory blood specimens for future research on breast cancer at Mayo Clinic.
Willingness to provide mandatory tissue specimens for future research on breast cancer at Mayo Clinic.
Willingness to provide mandatory tissue specimens for the generation of PDX and organoids to be used future research on breast cancer at Mayo Clinic. Exclusion Criteria: Ineligible for surgery.
History of prior malignancy <3 years prior to registration. Exceptions for non-melanoma skin cancer, papillary thyroid cancer, non-invasive cancer (e.g., carcinoma in situ of the cervix). "
"[INST] Provide inclusion criteria for trial id: NCT04703244 [/INST] Age ≥18 years.
Diagnosis of invasive breast cancer treated with neoadjuvant systemic therapy.
Surgically resectable disease following neoadjuvant systemic treatment.
At least one of the following must be true:
Received at least 2 weeks of neoadjuvant endocrine therapy
Received at least 2 months of neoadjuvant chemotherapy with suggestion of residual disease on imaging
Began neoadjuvant chemotherapy or endocrine therapy but discontinued due to evidence of progressive disease by MRI, ultrasound, or physical examination
Provide written informed consent.
Willing to return to enrolling institution for breast cancer surgery.
Willingness to provide mandatory blood specimens for future research on breast cancer at Mayo Clinic.
Willingness to provide mandatory tissue specimens for future research on breast cancer at Mayo Clinic.
Willingness to provide mandatory tissue specimens for the generation of PDX and organoids to be used future research on breast cancer at Mayo Clinic. "
"[INST] Provide exclusion criteria for trial id: NCT04703244 [/INST] Ineligible for surgery.
History of prior malignancy <3 years prior to registration. Exceptions for non-melanoma skin cancer, papillary thyroid cancer, non-invasive cancer (e.g., carcinoma in situ of the cervix). "
[INST] Provide description for trial id: NCT04703244 [/INST] Breast cancer patients who undergo neoadjuvant systemic therapy and have residual breast cancer identified at the time of surgery exhibit a high (>50%) risk of future life-threatening recurrences and death.
[INST] Provide title for trial id: NCT04703244 [/INST] Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer
[INST] Provide the recruitment status for trial id: NCT04703244 [/INST] Recruiting
"[INST] Provide the medical condition for trial id: NCT04703244 [/INST] Breast Cancer, Residual "
"Trial Id: Breast Cancer Risk Reduction: A Patient Doctor Intervention Recruitment Status: Completed Trail description: The proposed research combines the scientific advances in breast cancer research with health information technology (IT) to design a personalized intervention that assesses breast cancer risk for women, disseminates important breast health information, and facilitates discussion of breast cancer risk reduction practices. Our goal is to implement a tablet-PC (personal computer) based breast cancer risk education (BreastCare) intervention in the primary care setting that estimates a woman's individual risk for breast cancer and provides her and her physician with personalized breast cancer risk information and recommendations for action. Inclusion Criteria: Patient component:
Women who visit the General Internal Medicine (GIM) practices at SFGH and UCSF during the study period
Between the ages of 40 and 74
Self-identify as Asian American, Spanish- and English-speaking Latinas, African American, or White
Have no history of breast cancer are eligible to participate.
Physician component: Primary care physicians currently practicing at the GIM clinics at SFGH and UCSF Exclusion Criteria: Patient component: Women whose physicians object to their participation in the study
Physician component: No exclusion criteria for physicians "
"[INST] Provide inclusion criteria for trial id: NCT01830933 [/INST] Patient component:
Women who visit the General Internal Medicine (GIM) practices at SFGH and UCSF during the study period
Between the ages of 40 and 74
Self-identify as Asian American, Spanish- and English-speaking Latinas, African American, or White
Have no history of breast cancer are eligible to participate.
Physician component: Primary care physicians currently practicing at the GIM clinics at SFGH and UCSF "
"[INST] Provide exclusion criteria for trial id: NCT01830933 [/INST] Patient component: Women whose physicians object to their participation in the study
Physician component: No exclusion criteria for physicians "
"[INST] Provide description for trial id: NCT01830933 [/INST] The proposed research combines the scientific advances in breast cancer research with health information technology (IT) to design a personalized intervention that assesses breast cancer risk for women, disseminates important breast health information, and facilitates discussion of breast cancer risk reduction practices. Our goal is to implement a tablet-PC (personal computer) based breast cancer risk education (BreastCare) intervention in the primary care setting that estimates a woman's individual risk for breast cancer and provides her and her physician with personalized breast cancer risk information and recommendations for action. "
[INST] Provide title for trial id: NCT01830933 [/INST] Breast Cancer Risk Reduction: A Patient Doctor Intervention
[INST] Provide the recruitment status for trial id: NCT01830933 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT01830933 [/INST] Breast Cancer
"Trial Id: VEGF-targeted Fluorescent Tracer Imaging in Breast Cancer Recruitment Status: Completed Trail description: The purpose of this study is to determine the uptake, (semi-)quantification and localization of the VEGF targeting fluorescent tracer bevacizumab-IDRye800CW in breast cancer tissue, surrounding healthy tissue, tumor margins and lymph nodes. This is measured in surgical specimens after a single intravenous administration of 4,5 bevacizumab-IDRye800CW, using fluorescence microscopy and macroscopy techniques. Also the safety of bevacizumab-IDRye800CW is assessed. Another purpose is to assess the abilities of three different fluorescent signal detection systems to detect the fluorescent signal pre- and intra-operatively. Inclusion Criteria: Age ≥ 18 years.
Patients with proven breast cancer (cytology, histology) who are scheduled to receive operation intervention.
Tumor size of at least 15 mm diameter according to anatomical imaging data.
Signed written informed consent.
Able to comply with the protocol.
WHO performance score 0-2. Exclusion Criteria: Other invasive malignancy.
Serious other medical conditions.
Pregnant or lactating women. (Documentation of a negative pregnancy test must be available for pre-menopausal women with intact reproductive organs and for women less than two years after menopause).
Prior radiotherapy on the involved area.
Major surgery within 28 days before the initiation of the study.
Prior allergic reaction to immunoglobulins or immunoglobulin allergy.
Prior neo-adjuvant chemotherapy.
Breast prosthesis in target breast.
UMC Utrecht (FDOT) specific exclusion criteria
Breast is too big to fit in the biggest cup or is too small to fit in the smallest cup of the FDOT system.
Non-intact skin at time of the FDOT procedures.
Breast located skin diseases.
Piercings or tattoos located on the breast/nipple.
Contra-indication for MR procedures or claustrophobia.
Inability to lay prone positioned for the duration of the FDOT procedure (10 minutes) and MR procedure (30 minutes).
Tumor located close to the chest wall as assessed by breast imaging data. "
"[INST] Provide inclusion criteria for trial id: NCT01508572 [/INST] Age ≥ 18 years.
Patients with proven breast cancer (cytology, histology) who are scheduled to receive operation intervention.
Tumor size of at least 15 mm diameter according to anatomical imaging data.
Signed written informed consent.
Able to comply with the protocol.
WHO performance score 0-2. "
"[INST] Provide exclusion criteria for trial id: NCT01508572 [/INST] Other invasive malignancy.
Serious other medical conditions.
Pregnant or lactating women. (Documentation of a negative pregnancy test must be available for pre-menopausal women with intact reproductive organs and for women less than two years after menopause).
Prior radiotherapy on the involved area.
Major surgery within 28 days before the initiation of the study.
Prior allergic reaction to immunoglobulins or immunoglobulin allergy.
Prior neo-adjuvant chemotherapy.
Breast prosthesis in target breast.
UMC Utrecht (FDOT) specific exclusion criteria
Breast is too big to fit in the biggest cup or is too small to fit in the smallest cup of the FDOT system.
Non-intact skin at time of the FDOT procedures.
Breast located skin diseases.
Piercings or tattoos located on the breast/nipple.
Contra-indication for MR procedures or claustrophobia.
Inability to lay prone positioned for the duration of the FDOT procedure (10 minutes) and MR procedure (30 minutes).
Tumor located close to the chest wall as assessed by breast imaging data. "
"[INST] Provide description for trial id: NCT01508572 [/INST] The purpose of this study is to determine the uptake, (semi-)quantification and localization of the VEGF targeting fluorescent tracer bevacizumab-IDRye800CW in breast cancer tissue, surrounding healthy tissue, tumor margins and lymph nodes. This is measured in surgical specimens after a single intravenous administration of 4,5 bevacizumab-IDRye800CW, using fluorescence microscopy and macroscopy techniques. Also the safety of bevacizumab-IDRye800CW is assessed. Another purpose is to assess the abilities of three different fluorescent signal detection systems to detect the fluorescent signal pre- and intra-operatively. "
[INST] Provide title for trial id: NCT01508572 [/INST] VEGF-targeted Fluorescent Tracer Imaging in Breast Cancer
[INST] Provide the recruitment status for trial id: NCT01508572 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT01508572 [/INST] Breast Cancer
"Trial Id: Cyberknife for Early Stage Breast Cancer Recruitment Status: Completed Trail description: This phase II study based on the Cyberknife Society study will evaluate the technical feasibility and acute toxicity of Partial Breast Irradiation (PBI) with the Cyberknife. It will evaluate quality of life (QOL) issues as they relate to treatment-related side effects, cosmetic result and patient convenience. It will evaluate outcome in terms of local control in the treated breast.
Radiosurgery is defined as the stereotactic delivery of ionizing radiation in 5 stages or less to a designated target with sub-millimeter accuracy. Radiosurgery in the context of this protocol will be given to the region of the tumor bed with 7 weeks of the lumpectomy and sent/axillary node sampling over the period of five to ten days using the Cyberknife (CK) or within the 7 weeks of the last chemotherapy treatment if given. Inclusion Criteria: Patients with stage 0, I, or II (Tis, Ti, or T2 <=3cm & NO) histologically confirmed invasive non-lobular carcinoma or ductal carcinoma in situ of the breast with a lesion <= 3 cm, treated with wide excision.
Negative inked histologic margins of excision or reexcision and clear of invasive tumor and DClS by at least 2mm
Negative post-excision or post-reexcision mammography if cancer presented with malignancy-associated microcalcifications; no remaining suspicious microcalcifications in the breast before radiotherapy.
No involved axillary lymph nodes by routine histologic examination (H&E) of sentinel node(s) or of nodes identified from axillary dissection.
Enrollment and initiation of CyberKnife therapy within 42 days of last breast cancer surgery or last chemotherapy treatment. Exclusion Criteria: Patients with invasive lobular carcinoma or nonepithelial breast malignancies such as sarcoma or lymphoma.
Patients with multicentric carcinoma or with other clinically or radiographically suspicious areas in the ipsilateral breast unless confirmed to be negative for malignancy by biopsy.
Patients who are pregnant.
Patients who have any histologically confirmed positive axillary nodes.
Patients with collagen vascular diseases, specifically systemic lupus erythematosis, scleroderma, or dermatomyositis with a creatine phosphokinase level above normal or with an active skin rash. "
"[INST] Provide inclusion criteria for trial id: NCT03946683 [/INST] Patients with stage 0, I, or II (Tis, Ti, or T2 <=3cm & NO) histologically confirmed invasive non-lobular carcinoma or ductal carcinoma in situ of the breast with a lesion <= 3 cm, treated with wide excision.
Negative inked histologic margins of excision or reexcision and clear of invasive tumor and DClS by at least 2mm
Negative post-excision or post-reexcision mammography if cancer presented with malignancy-associated microcalcifications; no remaining suspicious microcalcifications in the breast before radiotherapy.
No involved axillary lymph nodes by routine histologic examination (H&E) of sentinel node(s) or of nodes identified from axillary dissection.
Enrollment and initiation of CyberKnife therapy within 42 days of last breast cancer surgery or last chemotherapy treatment. "
"[INST] Provide exclusion criteria for trial id: NCT03946683 [/INST] Patients with invasive lobular carcinoma or nonepithelial breast malignancies such as sarcoma or lymphoma.
Patients with multicentric carcinoma or with other clinically or radiographically suspicious areas in the ipsilateral breast unless confirmed to be negative for malignancy by biopsy.
Patients who are pregnant.
Patients who have any histologically confirmed positive axillary nodes.
Patients with collagen vascular diseases, specifically systemic lupus erythematosis, scleroderma, or dermatomyositis with a creatine phosphokinase level above normal or with an active skin rash. "
"[INST] Provide description for trial id: NCT03946683 [/INST] This phase II study based on the Cyberknife Society study will evaluate the technical feasibility and acute toxicity of Partial Breast Irradiation (PBI) with the Cyberknife. It will evaluate quality of life (QOL) issues as they relate to treatment-related side effects, cosmetic result and patient convenience. It will evaluate outcome in terms of local control in the treated breast.
Radiosurgery is defined as the stereotactic delivery of ionizing radiation in 5 stages or less to a designated target with sub-millimeter accuracy. Radiosurgery in the context of this protocol will be given to the region of the tumor bed with 7 weeks of the lumpectomy and sent/axillary node sampling over the period of five to ten days using the Cyberknife (CK) or within the 7 weeks of the last chemotherapy treatment if given. "
[INST] Provide title for trial id: NCT03946683 [/INST] Cyberknife for Early Stage Breast Cancer
[INST] Provide the recruitment status for trial id: NCT03946683 [/INST] Completed
[INST] Provide the medical condition for trial id: NCT03946683 [/INST] Early Stage Breast Cancer
"Trial Id: Clinical Validation of Radiomics Artificial Intelligence: Application to Breast Cancer Treatment Planning Recruitment Status: Recruiting Trail description: RadioVal will develop and implement interoperable solutions for clinical deployment of the radiomics tools, including information, training, and communication packages for clinicians and patients, as well as standard operating procedures for the integration of radiomics in clinical oncology. With this study, we will clinically validate these solutions, by looking at their reliability for precise breast cancer diagnosis, treatment recommendation and prognosis estimate, treatment response, evaluation of residual disease and outcome prediction. Inclusion Criteria: Females ≥ 18 years up to 85 years old
Individuals referred to hospitals for diagnosis of breast cancer
Availability of radiological images: 2D mammography or 2D synthetic digital tomosynthesis, ultrasound, or magnetic resonance
Availability of pathological report (surgical specimen)
Availability of (Neoadjuvant) treatment allocation (scheme, duration, benefit)
Availability of treatment response Exclusion Criteria: Patient with incomplete or low-quality data (radiological, pathological or clinical) "
"[INST] Provide inclusion criteria for trial id: NCT05070884 [/INST] Females ≥ 18 years up to 85 years old
Individuals referred to hospitals for diagnosis of breast cancer
Availability of radiological images: 2D mammography or 2D synthetic digital tomosynthesis, ultrasound, or magnetic resonance
Availability of pathological report (surgical specimen)
Availability of (Neoadjuvant) treatment allocation (scheme, duration, benefit)
Availability of treatment response "
"[INST] Provide exclusion criteria for trial id: NCT05070884 [/INST] Patient with incomplete or low-quality data (radiological, pathological or clinical) "
"[INST] Provide description for trial id: NCT05070884 [/INST] RadioVal will develop and implement interoperable solutions for clinical deployment of the radiomics tools, including information, training, and communication packages for clinicians and patients, as well as standard operating procedures for the integration of radiomics in clinical oncology. With this study, we will clinically validate these solutions, by looking at their reliability for precise breast cancer diagnosis, treatment recommendation and prognosis estimate, treatment response, evaluation of residual disease and outcome prediction. "
[INST] Provide title for trial id: NCT05070884 [/INST] Clinical Validation of Radiomics Artificial Intelligence: Application to Breast Cancer Treatment Planning
[INST] Provide the recruitment status for trial id: NCT05070884 [/INST] Recruiting
[INST] Provide the medical condition for trial id: NCT05070884 [/INST] Breast Cancer